SMILES,Conditions,Name,NCT_Number,Phases,Status,Gender,Age,Funded Bys,Study Designs,Locations,Patent_id,CPC,Gender_code_0,Gender_code_1,Gender_code_2,Gender_code_3,Age_code_0,Age_code_1,Age_code_2,Age_code_3,Age_code_4,Age_code_5,Allocation_Type_0,Allocation_Type_1,Allocation_Type_2,Allocation_Type_3,Intervention_Model_0,Intervention_Model_1,Intervention_Model_2,Intervention_Model_3,Intervention_Model_4,Intervention_Model_5,Country_0,Country_1,Country_2,Country_3,Country_4,Country_5,Funder_Type_0,Funder_Type_1,Funder_Type_2,Funder_Type_3,Funder_Type_4,Funder_Type_5,claims_#,Duration,Patent_#,PCT_code_0,PCT_code_1,CPC_code_0,CPC_code_2,CPC_code_3,CPC_code_4,CPC_code_5,PCT_code_2,CPC_code_1,logP,MW,PSA,HBA,HBD,Rings,Polarizability,Refractivity,Bond_#,Bioavailability_0,Bioavailability_1,Bioavailability_2,ECFP4.1,ECFP4.2,ECFP4.3,ECFP4.4,ECFP4.5,ECFP4.6,ECFP4.7,ECFP4.8,ECFP4.9,ECFP4.10,ECFP4.11,ECFP4.12,ECFP4.13,ECFP4.14,ECFP4.15,ECFP4.16,ECFP4.17,ECFP4.18,ECFP4.19,ECFP4.20,ECFP4.21,ECFP4.22,ECFP4.23,ECFP4.24,ECFP4.25,ECFP4.26,ECFP4.27,ECFP4.28,ECFP4.29,ECFP4.30,ECFP4.31,ECFP4.32,ECFP4.33,ECFP4.34,ECFP4.35,ECFP4.36,ECFP4.37,ECFP4.38,ECFP4.39,ECFP4.40,ECFP4.41,ECFP4.42,ECFP4.43,ECFP4.44,ECFP4.45,ECFP4.46,ECFP4.47,ECFP4.48,ECFP4.49,ECFP4.50,ECFP4.51,ECFP4.52,ECFP4.53,ECFP4.54,ECFP4.55,ECFP4.56,ECFP4.57,ECFP4.58,ECFP4.59,ECFP4.60,ECFP4.61,ECFP4.62,ECFP4.63,ECFP4.64,ECFP4.65,ECFP4.66,ECFP4.67,ECFP4.68,ECFP4.69,ECFP4.70,ECFP4.71,ECFP4.72,ECFP4.73,ECFP4.74,ECFP4.75,ECFP4.76,ECFP4.77,ECFP4.78,ECFP4.79,ECFP4.80,ECFP4.81,ECFP4.82,ECFP4.83,ECFP4.84,ECFP4.85,ECFP4.86,ECFP4.87,ECFP4.88,ECFP4.89,ECFP4.90,ECFP4.91,ECFP4.92,ECFP4.93,ECFP4.94,ECFP4.95,ECFP4.96,ECFP4.97,ECFP4.98,ECFP4.99,ECFP4.100,ECFP4.101,ECFP4.102,ECFP4.103,ECFP4.104,ECFP4.105,ECFP4.106,ECFP4.107,ECFP4.108,ECFP4.109,ECFP4.110,ECFP4.111,ECFP4.112,ECFP4.113,ECFP4.114,ECFP4.115,ECFP4.116,ECFP4.117,ECFP4.118,ECFP4.119,ECFP4.120,ECFP4.121,ECFP4.122,ECFP4.123,ECFP4.124,ECFP4.125,ECFP4.126,ECFP4.127,ECFP4.128
NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,HYPERTENSION,_VASOPRESSIN,NCT04170751,Not Applicable,Recruiting,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Department of Anaesthesiology and Pain Medicine, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of",9375478.0,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,13.3062280539641,14.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.4,2140.46,463.93,16.0,14.0,8.0,108.29,272.59,38.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
NC[C@H](O)c1ccc(O)c(O)c1,HYPERTENSION,_NOREPINEPHRINE,NCT04170751,Not Applicable,Recruiting,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Department of Anaesthesiology and Pain Medicine, Anaesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of",3961060.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,2922.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,169.1778,86.71,4.0,4.0,1.0,16.96,44.46,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CCN(CC)CC(=O)Nc1c(C)cccc1C,HEMORRHOID,_LIDOCAINE,NCT03797703,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","Advocate Christ Medical Center, Oak Lawn, Illinois, United States",5234957.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl,HEMORRHOID,_LIDOCAINE_HYDROCHLORIDE,NCT03797703,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","Advocate Christ Medical Center, Oak Lawn, Illinois, United States",4091090,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,17.380233680363,1165.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,ISCHEMIC HEART DISEASE,_SIROLIMUS,NCT03600961,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Observational Model: Cohort|Time Perspective: Prospective,"Hospital de Santa Cruz, Carnaxide, Portugal|Hospital da Luz, Carnaxide, Portugal|Centro Hospitaler de Leiria E.P.E., Leiria, Portugal|Hospital Espirito Santo Evora, Évora, Portugal",5212155,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,ISCHEMIC STROKE,_VERAPAMIL,NCT03347786,Phase 1,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Our Lady of Lourdes Medical Center, Camden, New Jersey, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|Crozer Keystone Health System, Upland, Pennsylvania, United States",5785994,A61K9/0004,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,75.8619273496375,982.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.23,454.6016,63.95,6.0,0.0,2.0,51.7,132.65,13.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,DIABETIC FOOT,_DEXAMETHASONE,NCT03871049,Not Applicable,Recruiting,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Assiut University Hospital, Assiut, Egypt",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,DIABETIC FOOT,_BUPIVACAINE,NCT03871049,Not Applicable,Recruiting,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Assiut University Hospital, Assiut, Egypt",8182835.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,PERIPHERAL ARTERIAL DISEASE,_DEXAMETHASONE,NCT03942601,Phase 2,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arkansas Heart Hospital, Little Rock, Arkansas, United States|St. Joseph Hospital of Orange Heart and Vascular Center, Orange, California, United States|San Francisco VA Medical Center, San Francisco, California, United States|University of Colorado, Denver, Colorado, United States|Rocky Mountain Veterans Administration Hospital, Denver, Colorado, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Columbia University Medical Center/NYPH, New York, New York, United States|North Carolina Heart and Vascular, Raleigh, North Carolina, United States|University Hospital, Cleveland, Ohio, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,PERIPHERAL ARTERIAL DISEASE,_TEMSIROLIMUS,NCT03942601,Phase 2,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arkansas Heart Hospital, Little Rock, Arkansas, United States|St. Joseph Hospital of Orange Heart and Vascular Center, Orange, California, United States|San Francisco VA Medical Center, San Francisco, California, United States|University of Colorado, Denver, Colorado, United States|Rocky Mountain Veterans Administration Hospital, Denver, Colorado, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Columbia University Medical Center/NYPH, New York, New York, United States|North Carolina Heart and Vascular, Raleigh, North Carolina, United States|University Hospital, Cleveland, Ohio, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States",5362718,C07D498/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,24.0,6.7023963531078605,63.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,1030.2871,241.96,14.0,4.0,4.0,112.71,277.07,11.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
O=P([O-])([O-])O.[Na+].[Na+],PERIPHERAL ARTERIAL DISEASE,_SODIUM_PHOSPHATE,NCT03942601,Phase 2,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arkansas Heart Hospital, Little Rock, Arkansas, United States|St. Joseph Hospital of Orange Heart and Vascular Center, Orange, California, United States|San Francisco VA Medical Center, San Francisco, California, United States|University of Colorado, Denver, Colorado, United States|Rocky Mountain Veterans Administration Hospital, Denver, Colorado, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Columbia University Medical Center/NYPH, New York, New York, United States|North Carolina Heart and Vascular, Raleigh, North Carolina, United States|University Hospital, Cleveland, Ohio, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States",7687075,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,48.0,64.3955728043697,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.0,141.9588,83.42,4.0,1.0,0.0,5.24,12.41,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])O.[Na+],PERIPHERAL ARTERIAL DISEASE,_DEXAMETHASONE_SODIUM_PHOSPHATE,NCT03942601,Phase 2,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arkansas Heart Hospital, Little Rock, Arkansas, United States|St. Joseph Hospital of Orange Heart and Vascular Center, Orange, California, United States|San Francisco VA Medical Center, San Francisco, California, United States|University of Colorado, Denver, Colorado, United States|Rocky Mountain Veterans Administration Hospital, Denver, Colorado, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Columbia University Medical Center/NYPH, New York, New York, United States|North Carolina Heart and Vascular, Raleigh, North Carolina, United States|University Hospital, Cleveland, Ohio, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,HYPERTENSION|DYSLIPIDEMIAS,_AMLODIPINE,NCT04074551,Phase 3,Recruiting,All,"19 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Seoul National University Hospital, Seoul, Seoul-si, Korea, Republic of",6162802.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,HYPERTENSION|DYSLIPIDEMIAS,_ROSUVASTATIN,NCT04074551,Phase 3,Recruiting,All,"19 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Seoul National University Hospital, Seoul, Seoul-si, Korea, Republic of",RE37314,C07D239/42 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,HYPERTENSION|DYSLIPIDEMIAS,_EZETIMIBE,NCT04074551,Phase 3,Recruiting,All,"19 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Seoul National University Hospital, Seoul, Seoul-si, Korea, Republic of",RE42461,C07D205/08 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,HYPERTENSION|DYSLIPIDEMIAS,_LOSARTAN,NCT04074551,Phase 3,Recruiting,All,"19 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Seoul National University Hospital, Seoul, Seoul-si, Korea, Republic of",5210079,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,MYOCARDIAL INFARCTION,_CALCIFEDIOL,NCT02548364,Phase 3,Recruiting,All,"40 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Rey Juan Carlos, Mostoles, Madrid, Spain|Hospital de Móstoles, Móstoles, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain",6582727.0,A61K9/4816,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,22.0,19.4829462617302,571.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.71,400.6371,40.46,2.0,2.0,3.0,50.32,125.06,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0
CN(CC(=O)O)C(=N)N,PERIPHERAL ARTERIAL DISEASE,_CREATINE,NCT04471792,Phase 2,Recruiting,All,"40 Years to 95 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Florida State University, Tallahassee, Florida, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.6,131.1332,90.41,5.0,3.0,0.0,12.17,42.01,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(CC(=O)O)C(=N)N,INTERMITTENT CLAUDICATION,_CREATINE,NCT02993874,Not Applicable,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Israel Institute of Education and Research Albert Einstein, Sao Paulo, Brazil",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.6,131.1332,90.41,5.0,3.0,0.0,12.17,42.01,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(C)C(=N)NC(=N)N,PREECLAMPSIA,_METFORMIN,NCT03717701,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aswan University, Aswan, Egypt",6288095.0,4,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,PREECLAMPSIA,_ESOMEPRAZOLE,NCT03717701,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aswan University, Aswan, Egypt",5900424,4,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,DYSLIPIDEMIA|ATHEROSCLEROSIS,_ATORVASTATIN,NCT02726555,Phase 3,Recruiting,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","The Second Hispital of Wenzhou Medical University, Wenzhou, Zhejiang, China",4681893,C07D405/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,PERIPHERAL ARTERIAL DISEASE,_ANGIOTENSIN,NCT03240068,Early Phase 1,Recruiting,All,"21 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O,PERIPHERAL ARTERIAL DISEASE,_ANGIOTENSIN_1-7,NCT03240068,Early Phase 1,Recruiting,All,"21 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.4,899.02,377.24,16.0,13.0,3.0,92.45,238.19,25.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,OBESITY|HYPERTENSION,_ANGIOTENSIN,NCT03604289,Early Phase 1,Recruiting,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Penn State College of Medicine, Hershey, Pennsylvania, United States",,,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0
O=C(O)CCCC[C@@H]1CCSS1,"STROKE, ISCHEMIC",_LIPOIC_ACID,NCT04041167,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chonnam National University Hospital, Gwangju, Korea, Republic of",4100150.0,C07K14/565,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,19.022977884556106,2457.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.75,206.326,37.3,2.0,1.0,1.0,21.74,54.37,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,PREECLAMPSIA,_PRAVASTATIN,NCT03648970,Phase 2,Recruiting,Female,"15 Years to 45 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Sanglah General Hospital, Denpasar, Bali, Indonesia|Dr. Moewardi Hospital, Surakarta, Central Java, Indonesia|Ramelan Naval Hospital, Surabaya, East Java, Indonesia|Dr. Soetomo Hospital, Surabaya, East Java, Indonesia|Adam Malik General Hospital, Medan, North Sumatra, Indonesia|Dr. Wahidin Sudirohusodo General Hospital, Makasar, South Sulawesi, Indonesia|Hasan Sadikin General Hospital, Bandung, West Java, Indonesia",5622985.0,4,0.0,1.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,MYOCARDIAL INFARCTION,_RAMIPRIL,NCT03715998,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Groupe Hospitalier Pitie-Salpêtrière - Institut de Cardiologie, Paris, France",5403856.0,A61K38/556,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,DIABETIC FOOT ULCER,_ESMOLOL,NCT03998436,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M.S. Ramaiah Medical College and Hospital, Bangalore, Karnataka, India|Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India|Chellaram Diabetes Institute, Pune, Maharashtra, India|M.V. Hospital for Diabetes Pvt Ltd, Chennai, Tamilnadu, India|Madras Diabetes Research Foundation, Chennai, Tamilnadu, India|Sri Ramachandra Hospital, Chennai, Tamilnadu, India|Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Maharaja Agrasen Hospital, New Delhi, India",6310094.0,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,9.56077126840386,564.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.02,295.374,67.79,4.0,2.0,1.0,33.68,81.05,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl,DIABETIC FOOT ULCER,_ESMOLOL_HYDROCHLORIDE,NCT03998436,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M.S. Ramaiah Medical College and Hospital, Bangalore, Karnataka, India|Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India|Chellaram Diabetes Institute, Pune, Maharashtra, India|M.V. Hospital for Diabetes Pvt Ltd, Chennai, Tamilnadu, India|Madras Diabetes Research Foundation, Chennai, Tamilnadu, India|Sri Ramachandra Hospital, Chennai, Tamilnadu, India|Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Maharaja Agrasen Hospital, New Delhi, India",6310094,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,9.56077126840386,155.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
CN(C)C(=N)N=C(N)N.Cl,HEART FAILURE,_METFORMIN_HYDROCHLORIDE,NCT03331861,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","New York Hospital - Columbia University Irving Medical Center, New York, New York, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,HEART FAILURE,_METFORMIN,NCT03331861,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","New York Hospital - Columbia University Irving Medical Center, New York, New York, United States",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,CHRONIC HEART FAILURE,_CODEINE,NCT04332536,Not Applicable,Recruiting,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom",6383471.0,A61K47/02,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,114.0,37.0274543625125,1579.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.2,299.3642,41.93,4.0,1.0,5.0,31.95,84.6,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,PREECLAMPSIA,_SILDENAFIL,NCT03724838,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aswan University, Aswan, Egypt",5250534.0,C07D487/04,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,PREECLAMPSIA,_SILDENAFIL_CITRATE,NCT03724838,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aswan University, Aswan, Egypt",WO-1999030688-A1,A61K9/19,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,45.0,32.7488,208.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,ATRIAL FIBRILLATION,_CHLOROQUINE,NCT02932007,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of South Florida, Tampa, Florida, United States",4181725,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O,ATRIAL FIBRILLATION,_CHLOROQUINE_PHOSPHATE,NCT02932007,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of South Florida, Tampa, Florida, United States",5021426,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,15.2118113308281,90.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,BARIATRIC SURGERY,_RIVAROXABAN,NCT03522259,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Kantonsspital Baden, Baden, Switzerland|University Hospital, Inselspital Berne, Berne, Switzerland|Clinic Beau-Site, Bern, Switzerland",7157456,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,HYPERTENSION,_MINOCYCLINE,NCT02133872,Phase 1,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UF Health Cardiovascular Clinic, Gainesville, Florida, United States",5908838,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,"STROKE, ISCHEMIC",_MINOCYCLINE,NCT03320018,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Stony Brook University Hospital, Stony Brook, New York, United States",5908838,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,BREAST CANCER,_CARVEDILOL,NCT03879629,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",6022562,A61K9/5026,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,HEART FAILURE,_FENTANYL,NCT02421341,Not Applicable,Recruiting,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,"Mayo Clinic - Saint Marys Hospital, Rochester, Minnesota, United States",6169920,A61N1/303,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,ADVERSE REACTION TO OTHER DRUGS AND MEDICINES,_ONDANSETRON,NCT02436798,,Recruiting,All,"6 Months to 45 Years   (Child, Adult)",Other,Observational Model: Other|Time Perspective: Prospective,"Children's and Women's Health Centre of British Columbia, Vancouver, British Columbia, Canada",5344658,C07D403/06,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,10.0,19.5486560298979,384.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.56,293.363,39.82,2.0,0.0,4.0,33.16,86.78,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
FCOC(C(F)(F)F)C(F)(F)F,ATRIAL FIBRILLATION,_SEVOFLURANE,NCT02697448,Not Applicable,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medical University of South Carolina, Charleston, South Carolina, United States",5990176,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)c1cccc(C(C)C)c1O,ATRIAL FIBRILLATION,_PROPOFOL,NCT02697448,Not Applicable,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medical University of South Carolina, Charleston, South Carolina, United States",5714520,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,PROLIFERATIVE DIABETIC RETINOPATHY,_TRIAMCINOLONE,NCT02447185,Phase 3,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"The First People Hospital of Xuzhou, Xuzhou, Jiangsu, China",5976573,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,PROLIFERATIVE DIABETIC RETINOPATHY,_TRIAMCINOLONE_ACETONIDE,NCT02447185,Phase 3,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"The First People Hospital of Xuzhou, Xuzhou, Jiangsu, China",3962430,A61L2/0023,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,PREECLAMPSIA,_OXYTOCIN,NCT02221830,Early Phase 1,Recruiting,Female,"13 Years to 45 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Colorado Clinical and Translational Research Center, Aurora, Colorado, United States",3943246,A61K38/095,0.0,1.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,18.3658802028789,1710.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
COc1cc(CC(C)N)c(OC)cc1C,STROKE,_DOM,NCT03828851,Not Applicable,Recruiting,All,"20 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"National Taiwan University Hospital, Taipei, Zhongzheng District, Taiwan",WO-1998042331-A1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,32.7488,13.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.02,209.2848,44.48,3.0,1.0,1.0,24.09,61.67,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
[Cl-].[K+],HEART FAILURE,_POTASSIUM_CHLORIDE,NCT02840799,Phase 2,Recruiting,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Northwestern Medical Center, Evanston, Illinois, United States|Corporal Michael J Crescenz Veterans Affairs Medical Center (VA), Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",7084130,A61K9/0048,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,55.6561736380623,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.2,74.551,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=[N+]([O-])[O-],HEART FAILURE,_NITRATE,NCT02840799,Phase 2,Recruiting,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Northwestern Medical Center, Evanston, Illinois, United States|Corporal Michael J Crescenz Veterans Affairs Medical Center (VA), Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.84,62.0049,66.2,3.0,0.0,0.0,3.28,8.35,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,ACUTE DECOMPENSATED HEART FAILURE,_EMPAGLIFLOZIN,NCT04049045,Phase 2,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Internal Medicine I, Jena University Hospital, Jena, Germany",6303661,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,STROKE,_MARAVIROC,NCT03172026,Phase 2|Phase 3,Recruiting,All,"30 Years to 86 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","California Rehabilitation Institute, Los Angeles, California, United States|Yale University, New Haven, Connecticut, United States|Burke Neurological Research Institute, White Plains, New York, United States",6586430,C07D401/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
NCCCC[C@H](N)C(=O)O,HEART FAILURE,_LYSINE,NCT03446651,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Yale University, New Haven, Connecticut, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.8,146.1876,89.34,4.0,3.0,0.0,15.84,37.81,5.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC1(C)CCc2cc(O)ccc2O1,ATRIAL FIBRILLATION,_TOCOTRIENOL,NCT03807037,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Institut Jantung Negara, Kuala Lumpur, Malaysia",US-20070293449-A1,A61K9/1272 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,32.7488,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.68,382.5787,29.46,2.0,1.0,2.0,48.12,122.8,9.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,MYOCARDIAL INFARCTION,_DOBUTAMINE,NCT03289728,Not Applicable,Recruiting,All,80 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinique Mutualiste, Grenoble, France|University Hospital Grenoble, Grenoble, France",4425336,7,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,19.5815109139818,420.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.97,301.3801,72.72,4.0,4.0,2.0,34.44,88.39,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,HIV INFECTION,_EPLERENONE,NCT02740179,Not Applicable,Recruiting,All,"40 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Massachusetts General Hospital, Boston, Massachusetts, United States",6410524,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,105.0,31.639253372759104,243.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.67,414.4914,82.2,4.0,0.0,6.0,43.79,106.68,2.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,DIABETIC FOOT ULCER,_CHLORHEXIDINE,NCT03503370,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, United States",5538353,A45D34/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,LIVER CIRRHOSIS|PORTAL VEIN THROMBOSIS,_DABIGATRAN,NCT04433481,Not Applicable,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Institute of Liver & Biliary Sciences, New Delhi, Delhi, India",6087380,C07D277/64,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,28.715168689295396,108.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.37,471.52099999999996,150.22,8.0,4.0,4.0,50.96,143.26,9.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0
Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C,ACUTE HEART FAILURE,_METOLAZONE,NCT04163588,Phase 3,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Policlinico Casilino, Rome, Lazio, Italy",4472380,C07K5/022,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,23.7212263085484,333.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.21,365.835,92.5,4.0,2.0,3.0,36.38,94.59,2.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],CORONARY ARTERY DISEASE,_FERUMOXYTOL,NCT02954510,Phase 3,Enrolling by invitation,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Brigham and Women's Hospital, Boston, Massachusetts, United States",6599498,B82Y5/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],HYPERTENSION,_NITROGLYCERIN,NCT02425566,Phase 1,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Autonomic Dysfunction Center, Nashville, Tennessee, United States",5186938,A61K9/7061,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,18.3658802028789,5.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.25,227.0865,157.11,9.0,0.0,0.0,15.68,37.59,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],ACUTE HEART FAILURE,_NITROGLYCERIN,NCT03302910,Phase 2|Phase 3,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"University of Alabama - Birmingham, Birmingham, Alabama, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Beaumont Health System, Royal Oak, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University, Saint Louis, Missouri, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States",5186938,A61K9/7061,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,19.0,18.3658802028789,5.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.25,227.0865,157.11,9.0,0.0,0.0,15.68,37.59,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,ACUTE DECOMPENSATED HEART FAILURE,_LEVOSIMENDAN,NCT04158674,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CHU Dijon Bourgogne, Dijon, France",6340764,G01N30/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,11.039241052177598,104.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,280.2847,113.43,6.0,2.0,2.0,28.67,77.63,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,PREECLAMPSIA,_SALSALATE,NCT03482440,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","University of Iowa, Iowa City, Iowa, United States|Pennsylvania State University, University Park, Pennsylvania, United States",3954533,C06B23/007,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,78.1617692355079,627.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.44,258.2262,83.83,4.0,2.0,2.0,24.92,67.1,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
O=[O+][O-],ISCHEMIC HEART DISEASE,_OZONE,NCT03660657,Phase 2|Phase 3,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Dr. Negrin University Hospital, Las Palmas De Gran Canaria, Las Palmas, Spain",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.21,47.997,74.27,3.0,0.0,0.0,2.31,4.24,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,HEART FAILURE,_CANAGLIFLOZIN,NCT04252287,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Mercy Clinic Cardiology - Fort Smith, Fort Smith, Arkansas, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Scripps Clinic/Prebys Cardiovascular Institute, San Diego, California, United States|University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States|Clearwater Cardiovascular Consultants, Clearwater, Florida, United States|Emory University, Atlanta, Georgia, United States|St Lukes Regional Medical, Boise, Idaho, United States|Central Dupage Hospital, Winfield, Illinois, United States|Parkview Cancer Institute, Fort Wayne, Indiana, United States|University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States|MedStar Health Research Institute, Hyattsville, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|St. Luke's Hospital Kansas City, Kansas City, Missouri, United States|Mercy Health Research, Washington, Missouri, United States|Robert Wood Johnson Medical School Dept. of Medicine, Piscataway, New Jersey, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Thomas Spann Clinic, Corpus Christi, Texas, United States|Texas Heart Institute, Houston, Texas, United States",6723340,A61K9/2031,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
O=N[O-],HEART FAILURE,_NITRITE,NCT02713126,Phase 2,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Mayo Clinic, Rochester, Minnesota, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.17,46.0055,52.49,3.0,0.0,0.0,2.44,7.6,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=N[O-].[Na+],HEART FAILURE,_SODIUM_NITRITE,NCT02713126,Phase 2,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Mayo Clinic, Rochester, Minnesota, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCCCCC1=CC(=O)C=C(OC)C1=O,STROKE,_PRIMIN,NCT03517657,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Northwestern University and Shirley Ryan Ability Lab, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States",7381433,A61K36/185,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,16.8217006509373,3.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,STAPHYLOCOCCUS AUREUS BACTEREMIA,_DAPTOMYCIN,NCT03138733,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6701 Airport Boulevard, Mobile, Alabama, United States|eStudy Site - Chula Vista - PPDS, Chula Vista, California, United States|eStudy Site - La Mesa - PPDS, La Mesa, California, United States|Yaneicy, Coral Gables, Florida, United States|Triple O Medical Services Inc, West Palm Beach, Florida, United States|Allina Health System DBA Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Mercury Street Medical Group, Butte, Montana, United States|eStudy Site - Las Vegas - PPDS, Las Vegas, Nevada, United States|Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States|3820 Olentangy River Road, Columbus, Ohio, United States|Hospital Nuestra Senora de la Misericordia, Córdoba, Argentina|Rawson Hospital, Córdoba, Argentina|Mayo Private Sanatorium, Córdoba, Argentina|Hospital Cordoba, Córdoba, Argentina|Medical Institute Platense SA, La Plata, Argentina|Zonal General Hospital for Acute Diseases ""Dr. Carlos Bocalandro"", Loma Hermosa, Argentina|British Sanatorium SA, Rosario, Argentina|Provincial Hospital ""Dr. Jose Maria Cullen"", Santa Fe, Argentina|Santa Casa of Belo Horizonte, Clinical Research Center/Critical Care Medicine/Internal Medicine, Belo Horizonte, Brazil|Hospital do Trabalhador, Curitiba, Brazil|Hospital Ernesto Dornelles, Porto Alegre, Brazil|Base Hospital of Sao Jose do Rio Preto, São José Do Rio Preto, Brazil|Multiprofile Hospital for Active Treatment ""Puls"", Intensive Care Unit, Blagoevgrad, Bulgaria|University Multiprofile Hospital for Active Treatment ""Eurohospital Plovdiv"", Plovdiv, Intensive Care Clinic, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment 'Kanev', Ruse, Department of General, Purulent-Septic, Pediatric and One Day Surgery, Ruse, Bulgaria|Multiprofile Hospital for Active Treatment ""Dr. Ivan Seliminski"", Sliven, Anesthesiology and Intensive Care Department, Sliven, Bulgaria|University Multiprofile Hospital for Active Treatment and Emergency Medicine ""N.I. Pirogov"", Sofia, Clinic of Purulent-Septic Surgery, Sofia, Bulgaria|JSC Rustavi Central Hospital, Rustavi, Georgia|LTD High Technology Medical Center University Clinic, Tbilisi, Georgia|LTD Acad. O. Gudushauri National Medical Center, Tbilisi, Georgia|LTD Academician G. Chapidze Emergency Cardiology Center, Tbilisi, Georgia|LTD Institute of Clinical Cardiology, Tbilisi, Georgia|LTD Academician Vakhtang Bochorishvili Clinic, Tbilisi, Georgia|LTD Central University Clinic After Academic N. Kipshidze, Tbilisi, Georgia|LTD N 5 Clinikal Hospital, Tbilisi, Georgia|Greifswald University Hospital, Anaesthesiology; Emergency Medicine, Greifswald, Germany|University Hospital Schleswig-Holstein, Clinic of Anesthesiology and Operative Intensive Care Medicine, Kiel, Germany|University Hospital Regensburg, Department of Infectious Diseases, Regensburg, Germany|Bnai Zion Medical Center, Haifa, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Meir Medical Center, Kfar Saba, Israel|The Baruch Padeh Medical Center, Poriyya 'Illit, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Sieff Medical Center, Safed, Israel|Sourasky Medical Center, Tel Aviv, Israel|Local Healthcare Company Papa Giovanni XXIII (ASST Papa Giovanni XXIII), Department of Infectious Diseases, Bergamo, Italy|Polyclinic S. Orsola-Malpighi, Department of Organ Impairment and Transplants, Operative Unit of Infectious Diseases, Bologna, Italy|University Polyclinic Hospital of Modena, Department of Infectious Diseases, Modena, Italy|University of Milan-Bicocca- S.Gerardo Hospital, Monza, Italy|Integrated University Health Authority of Trieste, Trieste, Italy|St. Joseph Belgorod Regional Clinical Hospital, Belgorod, Russian Federation|Territorial Clinical Hospital #2, Krasnodar, Russian Federation|O.M. Filatov City Clinical Hospital #15, Moscow, Russian Federation|Vinogradov Moscow Municipal Hospital, Department of Surgery #14, Moscow, Russian Federation|N.I. Pirogov City Clinical Hospital #1, Moscow, Russian Federation|Federal State Budget Institution ""Central Clinical Hospital with Polyclinic"" under the Presidential Executive Office of Russian Federation, Moscow, Russian Federation|L.A. Vorokhobov City Clinical Hospital #67, Moscow, Russian Federation|City Hospital #33, Nizhny Novgorod, Russian Federation|Pyatigorsk City Clinical Hospital, Pyatigorsk, Russian Federation|Railway Clinical Hospital under OAO Russian Railways, Saint Petersburg, Russian Federation|Regional Clinical Hospital, Yaroslavl, Russian Federation|Worthwhile Clinical Trials, Lakeview Hospital, Benoni, South Africa|Hospital del Mar, Department of Intensive Care, Barcelona, Spain|University Hospital de Elche, Infectious Diseases Unit, Elche, Spain|General University Hospital Gregorio Maranon, Infectious Diseases / Internal Medicine, Madrid, Spain|University Hospital Ramon y Cajal, Department of Infectious Diseases, Madrid, Spain|La Paz University Hospital, Infectious Diseases / Internal Medicine, Madrid, Spain|University Hospital Mutua de Terrassa, Unit of Infectious Diseases, Terrassa, Spain|Dnipropetrovsk I.I. Mechnykov Regional Clinical Hospital, Dnipro, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dnipro, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivs'k, Ukraine|V.T. Zaitsev Institute of General and Emergency Surgery, Kharkiv, Ukraine|Public Non-Profit Enterprise: O.O. Shalimov City Clinical Hospital #2 under Kharkiv City Council, Kharkiv, Ukraine|City Clinical Hospital #3, Zaporizhzhya, Ukraine",6468967.0,A61K38/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,45.0,36.9288897102609,8.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.47,1620.693,702.02,27.0,22.0,4.0,158.96,393.57,35.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
Nc1nc(/C(=N/O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(/C=C4\CCN([C@@H]5CCNC5)C4=O)CS[C@H]23)ns1,STAPHYLOCOCCUS AUREUS BACTEREMIA,_CEFTOBIPROLE,NCT03138733,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6701 Airport Boulevard, Mobile, Alabama, United States|eStudy Site - Chula Vista - PPDS, Chula Vista, California, United States|eStudy Site - La Mesa - PPDS, La Mesa, California, United States|Yaneicy, Coral Gables, Florida, United States|Triple O Medical Services Inc, West Palm Beach, Florida, United States|Allina Health System DBA Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Mercury Street Medical Group, Butte, Montana, United States|eStudy Site - Las Vegas - PPDS, Las Vegas, Nevada, United States|Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States|3820 Olentangy River Road, Columbus, Ohio, United States|Hospital Nuestra Senora de la Misericordia, Córdoba, Argentina|Rawson Hospital, Córdoba, Argentina|Mayo Private Sanatorium, Córdoba, Argentina|Hospital Cordoba, Córdoba, Argentina|Medical Institute Platense SA, La Plata, Argentina|Zonal General Hospital for Acute Diseases ""Dr. Carlos Bocalandro"", Loma Hermosa, Argentina|British Sanatorium SA, Rosario, Argentina|Provincial Hospital ""Dr. Jose Maria Cullen"", Santa Fe, Argentina|Santa Casa of Belo Horizonte, Clinical Research Center/Critical Care Medicine/Internal Medicine, Belo Horizonte, Brazil|Hospital do Trabalhador, Curitiba, Brazil|Hospital Ernesto Dornelles, Porto Alegre, Brazil|Base Hospital of Sao Jose do Rio Preto, São José Do Rio Preto, Brazil|Multiprofile Hospital for Active Treatment ""Puls"", Intensive Care Unit, Blagoevgrad, Bulgaria|University Multiprofile Hospital for Active Treatment ""Eurohospital Plovdiv"", Plovdiv, Intensive Care Clinic, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment 'Kanev', Ruse, Department of General, Purulent-Septic, Pediatric and One Day Surgery, Ruse, Bulgaria|Multiprofile Hospital for Active Treatment ""Dr. Ivan Seliminski"", Sliven, Anesthesiology and Intensive Care Department, Sliven, Bulgaria|University Multiprofile Hospital for Active Treatment and Emergency Medicine ""N.I. Pirogov"", Sofia, Clinic of Purulent-Septic Surgery, Sofia, Bulgaria|JSC Rustavi Central Hospital, Rustavi, Georgia|LTD High Technology Medical Center University Clinic, Tbilisi, Georgia|LTD Acad. O. Gudushauri National Medical Center, Tbilisi, Georgia|LTD Academician G. Chapidze Emergency Cardiology Center, Tbilisi, Georgia|LTD Institute of Clinical Cardiology, Tbilisi, Georgia|LTD Academician Vakhtang Bochorishvili Clinic, Tbilisi, Georgia|LTD Central University Clinic After Academic N. Kipshidze, Tbilisi, Georgia|LTD N 5 Clinikal Hospital, Tbilisi, Georgia|Greifswald University Hospital, Anaesthesiology; Emergency Medicine, Greifswald, Germany|University Hospital Schleswig-Holstein, Clinic of Anesthesiology and Operative Intensive Care Medicine, Kiel, Germany|University Hospital Regensburg, Department of Infectious Diseases, Regensburg, Germany|Bnai Zion Medical Center, Haifa, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Meir Medical Center, Kfar Saba, Israel|The Baruch Padeh Medical Center, Poriyya 'Illit, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Sieff Medical Center, Safed, Israel|Sourasky Medical Center, Tel Aviv, Israel|Local Healthcare Company Papa Giovanni XXIII (ASST Papa Giovanni XXIII), Department of Infectious Diseases, Bergamo, Italy|Polyclinic S. Orsola-Malpighi, Department of Organ Impairment and Transplants, Operative Unit of Infectious Diseases, Bologna, Italy|University Polyclinic Hospital of Modena, Department of Infectious Diseases, Modena, Italy|University of Milan-Bicocca- S.Gerardo Hospital, Monza, Italy|Integrated University Health Authority of Trieste, Trieste, Italy|St. Joseph Belgorod Regional Clinical Hospital, Belgorod, Russian Federation|Territorial Clinical Hospital #2, Krasnodar, Russian Federation|O.M. Filatov City Clinical Hospital #15, Moscow, Russian Federation|Vinogradov Moscow Municipal Hospital, Department of Surgery #14, Moscow, Russian Federation|N.I. Pirogov City Clinical Hospital #1, Moscow, Russian Federation|Federal State Budget Institution ""Central Clinical Hospital with Polyclinic"" under the Presidential Executive Office of Russian Federation, Moscow, Russian Federation|L.A. Vorokhobov City Clinical Hospital #67, Moscow, Russian Federation|City Hospital #33, Nizhny Novgorod, Russian Federation|Pyatigorsk City Clinical Hospital, Pyatigorsk, Russian Federation|Railway Clinical Hospital under OAO Russian Railways, Saint Petersburg, Russian Federation|Regional Clinical Hospital, Yaroslavl, Russian Federation|Worthwhile Clinical Trials, Lakeview Hospital, Benoni, South Africa|Hospital del Mar, Department of Intensive Care, Barcelona, Spain|University Hospital de Elche, Infectious Diseases Unit, Elche, Spain|General University Hospital Gregorio Maranon, Infectious Diseases / Internal Medicine, Madrid, Spain|University Hospital Ramon y Cajal, Department of Infectious Diseases, Madrid, Spain|La Paz University Hospital, Infectious Diseases / Internal Medicine, Madrid, Spain|University Hospital Mutua de Terrassa, Unit of Infectious Diseases, Terrassa, Spain|Dnipropetrovsk I.I. Mechnykov Regional Clinical Hospital, Dnipro, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dnipro, Ukraine|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivs'k, Ukraine|V.T. Zaitsev Institute of General and Emergency Surgery, Kharkiv, Ukraine|Public Non-Profit Enterprise: O.O. Shalimov City Clinical Hospital #2 under Kharkiv City Council, Kharkiv, Ukraine|City Clinical Hospital #3, Zaporizhzhya, Ukraine",5981519,C07F9/572,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,65.0,23.0312737427873,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.3,534.57,203.44,11.0,5.0,5.0,51.22,131.04,6.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CC(C)NCC(O)COc1cccc2ccccc12,PORTAL HYPERTENSION,_PROPRANOLOL,NCT03094234,Not Applicable,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"West china hospital, Chengdu, China",6500454,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
NC(=O)c1cccnc1,PREECLAMPSIA,_NICOTINAMIDE,NCT03419364,Phase 2,Recruiting,Female,18 Years to 55 Years   (Adult),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC at Chapel Hill, Chapel Hill, North Carolina, United States",3931207,C07D207/44,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,7.0,24.7397277151481,6368.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.39,122.1246,55.98,2.0,1.0,1.0,11.71,32.98,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,CORONAVIRUS INFECTION,_RUXOLITINIB,NCT04348695,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Madrid Sanchinarro, Madrid, Spain",7598257,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,CORONAVIRUS INFECTION,_SIMVASTATIN,NCT04348695,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Madrid Sanchinarro, Madrid, Spain",RE42461,C07D205/08 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
CC(=O)Oc1ccccc1C(=O)O,COVID-19,_ASPIRIN,NCT04333407,Not Applicable,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Charing Cross Hospital, London, United Kingdom",6015577,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,COVID-19,_ATORVASTATIN,NCT04333407,Not Applicable,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Charing Cross Hospital, London, United Kingdom",4681893,C07D405/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,COVID-19,_OMEPRAZOLE,NCT04333407,Not Applicable,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Charing Cross Hospital, London, United Kingdom",5690960.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,COVID-19,_RIVAROXABAN,NCT04333407,Not Applicable,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Charing Cross Hospital, London, United Kingdom",7157456,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,INFECTIVE ENDOCARDITIS,_DEXMEDETOMIDINE,NCT02698930,Not Applicable,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Department of Anaesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",5344840,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,CIRRHOSIS,_CARVEDILOL,NCT01212250,Not Applicable,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India",6022562,A61K9/5026,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1cc(CC(C)N)c(OC)cc1C,HEMOPHILIA A,_DOM,NCT03818763,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",WO-1998042331-A1,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,32.7488,13.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.02,209.2848,44.48,3.0,1.0,1.0,24.09,61.67,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
O=[N+]([O-])[O-],HEART FAILURE|ARRHYTHMIA,_NITRATE,NCT03658174,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.84,62.0049,66.2,3.0,0.0,0.0,3.28,8.35,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,NEWLY DIAGNOSED MULTIPLE MYELOMA,_PREDNISONE,NCT03742297,Phase 3,Recruiting,All,65 Years to 80 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Germans Trias i Pujol (ICO Badalona), Badalona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d´Hebron, Barcelona, Spain|ICO L´Hospitalet, Barcelona, Spain|Hospital Universitario de Cruces, Bilbao, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain|Hospital de Cabueñes, Gijón, Spain|Hospital Universitari Dr. Josep Trueta (ICO Girona), Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Especialidades de Jerez de la Frontera, Jerez De La Frontera, Spain|Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Complejo Hospitalario Lucus Augusti, Lugo, Spain|Hospital 12 de octubre, MAdrid, Spain|Hospital clínico San Carlos, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital San Joan de Deu (Althaia), Manresa, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital General Universitario Santa Lucía, Murcia, Spain|Hospital Costa del Sol, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Hospitalario Universitario de Ourense, Ourense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital de Sabadell (Parc Taulí), Sabadell, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Donostia, San Sebastián, Spain|Complejo Hospitalario Universitario Nuestra Señora de la Candelaria, Santa Cruz De Tenerife, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Hospital General de Segovia, Segovia, Spain|H. Universitario Virgen de Rocío, Sevilla, Spain|Hospital Nuestra Señona de Valme, Sevilla, Spain|Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Complejo Hospitalario de Toledo (Virgen de la Salud), Toledo, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario Morales Meseguer, Valencia, Spain|Hospital Universitari i Politecnic la Fe, Valencia, Spain|Hospital Universitario Dr. Peset Aleixandre, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",6488960,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,NEWLY DIAGNOSED MULTIPLE MYELOMA,_MELPHALAN,NCT03742297,Phase 3,Recruiting,All,65 Years to 80 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Germans Trias i Pujol (ICO Badalona), Badalona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d´Hebron, Barcelona, Spain|ICO L´Hospitalet, Barcelona, Spain|Hospital Universitario de Cruces, Bilbao, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain|Hospital de Cabueñes, Gijón, Spain|Hospital Universitari Dr. Josep Trueta (ICO Girona), Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Especialidades de Jerez de la Frontera, Jerez De La Frontera, Spain|Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Complejo Hospitalario Lucus Augusti, Lugo, Spain|Hospital 12 de octubre, MAdrid, Spain|Hospital clínico San Carlos, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital San Joan de Deu (Althaia), Manresa, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital General Universitario Santa Lucía, Murcia, Spain|Hospital Costa del Sol, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Hospitalario Universitario de Ourense, Ourense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital de Sabadell (Parc Taulí), Sabadell, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Donostia, San Sebastián, Spain|Complejo Hospitalario Universitario Nuestra Señora de la Candelaria, Santa Cruz De Tenerife, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Hospital General de Segovia, Segovia, Spain|H. Universitario Virgen de Rocío, Sevilla, Spain|Hospital Nuestra Señona de Valme, Sevilla, Spain|Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Complejo Hospitalario de Toledo (Virgen de la Salud), Toledo, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario Morales Meseguer, Valencia, Spain|Hospital Universitari i Politecnic la Fe, Valencia, Spain|Hospital Universitario Dr. Peset Aleixandre, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",8410077,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,NEWLY DIAGNOSED MULTIPLE MYELOMA,_CARFILZOMIB,NCT03742297,Phase 3,Recruiting,All,65 Years to 80 Years   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitari Germans Trias i Pujol (ICO Badalona), Badalona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d´Hebron, Barcelona, Spain|ICO L´Hospitalet, Barcelona, Spain|Hospital Universitario de Cruces, Bilbao, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain|Hospital de Cabueñes, Gijón, Spain|Hospital Universitari Dr. Josep Trueta (ICO Girona), Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Especialidades de Jerez de la Frontera, Jerez De La Frontera, Spain|Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Complejo Hospitalario Lucus Augusti, Lugo, Spain|Hospital 12 de octubre, MAdrid, Spain|Hospital clínico San Carlos, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario de Fuenlabrada, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital San Joan de Deu (Althaia), Manresa, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital General Universitario Santa Lucía, Murcia, Spain|Hospital Costa del Sol, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Hospitalario Universitario de Ourense, Ourense, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital de Sabadell (Parc Taulí), Sabadell, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Donostia, San Sebastián, Spain|Complejo Hospitalario Universitario Nuestra Señora de la Candelaria, Santa Cruz De Tenerife, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Hospital General de Segovia, Segovia, Spain|H. Universitario Virgen de Rocío, Sevilla, Spain|Hospital Nuestra Señona de Valme, Sevilla, Spain|Hospital Universitari Joan XXIII de Tarragona, Tarragona, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Complejo Hospitalario de Toledo (Virgen de la Salud), Toledo, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario Morales Meseguer, Valencia, Spain|Hospital Universitari i Politecnic la Fe, Valencia, Spain|Hospital Universitario Dr. Peset Aleixandre, Valencia, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",8129346,C07K5/0812,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,MULTIPLE MYELOMA,_VINORELBINE,NCT03442673,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department for Medical Oncology University Hospital/Inselspital, Berne, Switzerland",4307100.0,C07D519/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,MULTIPLE MYELOMA,_GEMCITABINE,NCT03442673,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department for Medical Oncology University Hospital/Inselspital, Berne, Switzerland",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,MULTIPLE MYELOMA,_METHYLPREDNISOLONE,NCT03110822,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Global Oncology, Inc., Alhambra, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States|Compassionate Care Research Group, Inc., Fountain Valley, California, United States|Robert A. Moss, M.D., F.A.C.P., Inc., Fountain Valley, California, United States|Pacific Cancer Care, Monterey, California, United States|Sansum Clinic- Ridley-Tree Cancer Center, Santa Barbara, California, United States|James R. Berenson M.D. Inc., West Hollywood, California, United States|Millennium Oncology Research Clinic, Pembroke Pines, Florida, United States|Regional Cancer Care Associates (RCCA) MD, LLC, Bethesda, Maryland, United States",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,MULTIPLE MYELOMA,_RUXOLITINIB,NCT03110822,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Global Oncology, Inc., Alhambra, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States|Compassionate Care Research Group, Inc., Fountain Valley, California, United States|Robert A. Moss, M.D., F.A.C.P., Inc., Fountain Valley, California, United States|Pacific Cancer Care, Monterey, California, United States|Sansum Clinic- Ridley-Tree Cancer Center, Santa Barbara, California, United States|James R. Berenson M.D. Inc., West Hollywood, California, United States|Millennium Oncology Research Clinic, Pembroke Pines, Florida, United States|Regional Cancer Care Associates (RCCA) MD, LLC, Bethesda, Maryland, United States",7598257,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,MULTIPLE MYELOMA,_HYDROXYCHLOROQUINE,NCT04163107,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oslo University Hospital, Department of Hematology, Oslo Myeloma Center, Oslo, Norway|St. Olavs Hospital, Department of Hematology, Trondheim, Norway",4181725,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(=O)Nc1ccc(O)cc1,MULTIPLE MYELOMA,_ACETAMINOPHEN,NCT04268498,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Hospital & Clinics - Data Collection Only, Iowa City, Iowa, United States|Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States|Roswell Park Cancer Institute - Data Collection Only, Buffalo, New York, United States|Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States|Huntsman Cancer Institue, Salt Lake City, Utah, United States|Skåne University Hospital, Malmö, Sweden",5972916.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(C)CCOC(c1ccccc1)c1ccccc1,MULTIPLE MYELOMA,_DIPHENHYDRAMINE,NCT04268498,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Hospital & Clinics - Data Collection Only, Iowa City, Iowa, United States|Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States|Roswell Park Cancer Institute - Data Collection Only, Buffalo, New York, United States|Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States|Huntsman Cancer Institue, Salt Lake City, Utah, United States|Skåne University Hospital, Malmö, Sweden",8263647,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,MULTIPLE MYELOMA,_MONTELUKAST,NCT04268498,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Hospital & Clinics - Data Collection Only, Iowa City, Iowa, United States|Memoral Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States|Roswell Park Cancer Institute - Data Collection Only, Buffalo, New York, United States|Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States|Huntsman Cancer Institue, Salt Lake City, Utah, United States|Skåne University Hospital, Malmö, Sweden",8007830.0,A61K9/1623,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,WALDENSTRÖM MACROGLOBULINEMIA,_DEXAMETHASONE,NCT04463953,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China",6284804,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,WALDENSTRÖM MACROGLOBULINEMIA,_ZANUBRUTINIB,NCT04463953,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,15.836054128421528,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.27,471.561,102.48,4.0,2.0,5.0,51.75,146.25,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,_POMALIDOMIDE,NCT04191616,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Cincinnati, Ohio, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Hamburg, Germany|Research Site, Tubingen, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Ancona, Italy|Research Site, Brescia, Italy|Research Site, Lecce, Italy|Research Site, Roma, Italy",5635517,C07D401/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,MULTIPLE MYELOMA,_TRAMETINIB,NCT03091257,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States",7378423,C07C275/50,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,MULTIPLE MYELOMA,_DABRAFENIB,NCT03091257,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States",7994185,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,MULTIPLE MYELOMA,_CARFILZOMIB,NCT03989414,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Colorado Blood Cancer Institute, Denver, Colorado, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago Medicine, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Tom Baker Cancer Center, Calgary, Alberta, Canada|University of Alberta - Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Maisonneuve Rosemont dba CIUSSS de lEst de lIle de Montreal, Montreal, Quebec, Canada|Fakultni Nemocnice Brno, Brno, Czechia|Fakultni Nemocnice Ostrava, Ostrava-Poruba, Czechia|Charles University General Hospital, Praha 2, Czechia|Rigshospitalet University Hospital, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark|Hopital Claude Huriez CHRU Lille, Lille cedex, France|Institut Paoli Calmette Hematologie, Marseille cedex, France|Hotel Dieu CHU Nantes, Nantes Cedex 01, France|Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole, Toulouse Cedex 9, France|CHRU Hopital Bretonneau, Tours cedex, France|Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik, Freiburg, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Klinikum rechts der Isar der Technischen Universitaet Muenchen, Munchen, Germany|Universitaets-klinikum Wuerzburg, Wuerzburg, Germany|Alexandra General Hospital of Athens, Athens, Greece|ASST Spedali Civili P.O. di Brescia, Brescia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy|Hopsital Germans Trias I Pujol, Badalona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Universitario de Salamanca - Hospital Clinico, Salamanca, Spain|Hospital Universtario Marques de Valdecilla, Santander, Spain",8129346,C07K5/0812,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1,MULTIPLE MYELOMA,_CC-220,NCT02773030,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Scottsdale, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Robert H Lurie Comprehensive Cancer Center NW Univ, Chicago, Illinois, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|University of Maryland School of Med, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|NYU Winthrop Hospital, Mineola, New York, United States|New York University School of Medicine, New York, New York, United States|Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, United States|New York Presbyterian Hospital Weil Cornell Medical College, New York, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Prisma Health Cancer Institute, Greenville, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|McGill University Health Center - Royal Victoria Hospital, Montreal, Quebec, Canada|CHRU Hopital Claude Huriez, Lile Cedax, France|CHU Bordeaux, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Benite cedex, France|CHU La Miletrie, Poitiers Cedex, France|Medizinische Kinik und Poliklinik I, Dresden, Germany|Universitaetsklinikum Duesseldorf, Dusseldorf, Germany|Universitaetsklinik Hamburg - Eppendorf, Hamburg, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|UKT Universitaetsklinikum Tuebingen, Tuebingen, Germany|Universitaets-klinikum Wuerzburg, Wuerzburg, Germany|I.R.C.C.S. Policlinico San Matteo - Universita di Pavia, Pavia, Italy|Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Universita degli Studi di Roma La Sapienza - Umberto I Policlinico di Roma - Centro di Ematologia, Rome, Italy|Osp. S.Giovanni Battista Le Molinette, Torino, Italy|University Hospital, Kyoto Prefectural University of Medicine, Kyoto-city, Japan|Nagoya City University Hospital, Nagoya, Japan|Tohoku University Hospital, Sendai, Japan|VU University Medical Center, Amsterdam, Netherlands|Maastricht University Medical Center, Maastrich, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona), Spain|Hospital Val d'Hebron, Barcelona, Spain|Instituto Catalan de Oncologia-Hospital Duran i Reynals, Barcelona, Spain|Hospital Gregorio Maranon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Dr. Pesset, Valencia, Spain|University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital, Birmingham, United Kingdom|Saint James University Hospital, Leeds, United Kingdom|Genesis Care, Oxford, United Kingdom|The Institut of Cancer Research, Sutton, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",WO-2014025958-A2,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,29.0,32.7488,13.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,449.50699999999995,88.18,6.0,1.0,5.0,47.73,122.29,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,MULTIPLE MYELOMA,_BENDAMUSTINE,NCT04083898,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",8436190,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,87.78825027207952,515.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.07,358.26300000000015,58.36,4.0,1.0,2.0,38.19,92.92,9.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,MULTIPLE MYELOMA,_PLERIXAFOR,NCT03406091,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Case-Only|Time Perspective: Prospective,"A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy",RE42152,C07D401/14 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,43.0,217.99215589642398,89.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.62,502.782,78.66,8.0,6.0,3.0,60.51,155.01,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,BLOOD COAGULATION DISORDER,_ONDANSETRON,NCT04499274,Not Applicable,Not yet recruiting,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Seoul National Univ. Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",5344658,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,19.5486560298979,384.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.56,293.363,39.82,2.0,0.0,4.0,33.16,86.78,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,BLOOD COAGULATION DISORDER,_PALONOSETRON,NCT04507711,Not Applicable,Not yet recruiting,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Seoul National Univ. Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of",5202333.0,C07D471/08,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,50.0,22.7355797860325,147.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.72,296.414,23.55,2.0,0.0,5.0,33.9,88.52,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,MULTIPLE MYELOMA,_RIMIDUCID,NCT03288493,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|University of California Davis, Davis, California, United States|University of California San Diego, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|University of Chicago, Chicago, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Wayne State - Karmanos Cancer Institute, Detroit, Michigan, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,6.88,1411.65,262.18,18.0,2.0,8.0,153.98,379.49,39.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,IMMUNE THROMBOCYTOPENIA,_DANAZOL,NCT04481282,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China",4055562,C07J71/0063,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,16.920265303188902,611.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.62,337.4553,46.26,2.0,1.0,5.0,38.56,98.54,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(C)(C)NCC(O)c1cc(O)cc(O)c1,IMMUNE THROMBOCYTOPENIA,_TERBUTALINE,NCT04481282,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China",3937838,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,31.672108256843,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.55,225.2842,72.72,4.0,4.0,1.0,24.78,63.04,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,RELAPSED REFRACTORY MULTIPLE MYELOMA,_ERDAFITINIB,NCT03732703,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic - Arizona, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Mayo Clinic - Minnesota, Rochester, Minnesota, United States|Washington University School of Medicine Division of Medical Oncology, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Ohio State University College of Medicine, Columbus, Ohio, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,45.0,24.31261422205795,3.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,446.555,77.33,7.0,1.0,4.0,51.0,139.32,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,RELAPSED REFRACTORY MULTIPLE MYELOMA,_ENASIDENIB,NCT03732703,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic - Arizona, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Mayo Clinic - Minnesota, Rochester, Minnesota, United States|Washington University School of Medicine Division of Medical Oncology, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Ohio State University College of Medicine, Columbus, Ohio, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,9.0,6.111008439598348,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,473.38300000000004,108.74,8.0,3.0,3.0,41.41,118.37,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,CARDIOGENIC SHOCK,_HYDROCORTISONE,NCT03773822,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hôpital Henri Mondor, Paris, Ile De France, France|Hôpital Parly II, Le Chesnay, Le Chasnay, France|CH Intercommunal de Villeneuve Saint Georges, Villeneuve-Saint-Georges, Villeneuve Saint Georges, France|Hôpital Ambroise Paré, Boulogne-Billancourt, France|CH de Marne la Vallée - Site Jossigny, Jossigny, France|CHU Lille - Institut Cœur Poumon, Lille, France|Centre Hospitalier Saint Joseph Saint Luc, Lyon, France|Hôpital Privé Jacques Cartier, Massy, France|Hôpital Arnaud-de-Villeneuve, Montpellier, France|CMC Ambroise Paré, Neuilly sur seine, France|CHU de Nîmes, Nîmes, France|Hôpitaux Universitaires Pitié Salpêtrière, Paris, France|Groupe Hospitalier Paris Saint Joseph, Paris, France|Hôpital Cochin, Paris, France|Hôpital européen Georges-Pompidou, Paris, France|Hôpital Bichat, Paris, France|CH Pontoise, Pontoise, France|Centre cardiologique du nord saint denis, Saint-Denis, France|CHU de Strasbourg, Strasbourg, France|Hopital Rangueil, Toulouse, France|CHRU Hôpitaux de Tours, Tours, France",5635497,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC1=C[C@H](O)CC(C)(C)[C@H]1/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,GLAUCOMA,_LUTEIN,NCT03959592,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","Duke University Eye Center, Durham, North Carolina, United States",3932546.0,C07C11/21,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,23.1298383950389,1374.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.29,568.886,40.46,2.0,2.0,2.0,73.81,195.06,10.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,DILATED CARDIOMYOPATHY,_SIMVASTATIN,NCT03775070,Phase 2,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Taiwan University Hospital, Taipei, Taiwan",RE42461,C07D205/08 ,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,GLAUCOMA,_SILDENAFIL,NCT04052269,Phase 3,Recruiting,Male,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Western Eye Hospital, London, United Kingdom",5250534.0,C07D487/04,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CNC1(c2ccccc2Cl)CCCCC1=O,SUBARACHNOID HEMORRHAGE,_KETAMINE,NCT02636218,Phase 2|Phase 3,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","St Michael's Hospital, Toronto, Ontario, Canada",3966793,C07D307/52,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[C@@H](O[C@H]1OCCN(Cc2nc(=O)n(P(=O)(O)O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,MULTIPLE MYELOMA,_FOSAPREPITANT,NCT02780609,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",5691336,C07D413/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,25.0,26.5796012238444,22.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.89,614.4066,123.93,9.0,3.0,4.0,49.92,138.63,9.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,SUBARACHNOID HEMORRHAGE,_MANNITOL,NCT04135456,Not Applicable,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Capital Medical University Affiliated Beijing Tiantan Hospital, Beijing, Beijing, China",3932678,A23L27/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,18.628719275549802,9603.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.7,182.1718,121.38,6.0,6.0,0.0,17.04,38.4,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,DILATED CARDIOMYOPATHY,_RESVERATROL,NCT01914081,Phase 3,Recruiting,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","St. Boniface General Hospital, Winnipeg, Manitoba, Canada",5747536,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,20.0,19.05583276864,5538.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.57,228.2433,60.69,3.0,3.0,2.0,24.55,67.46,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1cccc2c1c(O)c(C(=O)N(C)c1ccc(C(F)(F)F)cc1)c(=O)n2C,MULTIPLE MYELOMA,_TASQUINIMOD,NCT04405167,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",6133285,C07D215/56,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,41.0,15.146101562660403,16.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.26,406.361,70.08,4.0,1.0,3.0,36.89,100.19,4.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,VASCULITIS,_PREDNISONE,NCT03692416,Phase 3,Recruiting,All,1 Month to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut University Pediatric Hospital, Assiut, Upper Egypt, Egypt",6488960,5,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,VASCULITIS,_METHOTREXATE,NCT03692416,Phase 3,Recruiting,All,1 Month to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut University Pediatric Hospital, Assiut, Upper Egypt, Egypt",6746429,A61M5/2425,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,VASCULITIS,_IBUPROFEN,NCT03692416,Phase 3,Recruiting,All,1 Month to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut University Pediatric Hospital, Assiut, Upper Egypt, Egypt",5215755,A61K9/0056,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,PULMONARY ARTERIAL HYPERTENSION,_ANASTROZOLE,NCT03229499,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stanford University, Stanford, California, United States|University of Colorado - Denver, Aurora, Colorado, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington University, Saint Louis, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, East Providence, Rhode Island, United States|Vanderbilt University, Nashville, Tennessee, United States",RE36617,C07D239/26,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,10.0,47.3438879648452,907.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.31,293.3663,78.29,4.0,0.0,2.0,31.97,97.47,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,PULMONARY ARTERIAL HYPERTENSION,_OLAPARIB,NCT03782818,Phase 1|Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alberta Hospital, Edmonton, Alberta, Canada|UHN-Toronto General Hospital, Toronto, Ontario, Canada|IUCPQ-UL, Quebec City, Quebec, Canada",7151102,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,POLYMYALGIA RHEUMATICA,_PREDNISOLONE,NCT03576794,Phase 3,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","ZGT Almelo, Almelo, Netherlands|University Medical Center Groningen, Groningen, Netherlands",5178878,A61K9/0056,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,POLYMYALGIA RHEUMATICA,_LEFLUNOMIDE,NCT03576794,Phase 3,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","ZGT Almelo, Almelo, Netherlands|University Medical Center Groningen, Groningen, Netherlands",5504084,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,_TARTRATE,NCT03450629,Phase 3,Recruiting,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"SPARC Site 4, Chandler, Arizona, United States|SPARC Site 5, Prescott, Arizona, United States|SPARC Site 3, Sun City, Arizona, United States|SPARC Site 38, Burbank, California, United States|SPARC Site 44, Glendale, California, United States|SPARC Site 45, Glendale, California, United States|SPARC Site 43, Mission Hills, California, United States|SPARC Site 1, Newport Beach, California, United States|SPARC Site 14, Santa Barbara, California, United States|SPARC Site 47, Torrance, California, United States|SPARC Site 7, Colorado Springs, Colorado, United States|SPARC Site 11, Coral Springs, Florida, United States|SPARC Site 29, Deerfield Beach, Florida, United States|SPARC Site 34, Fort Myers, Florida, United States|SPARC Site 46, Hollywood, Florida, United States|SPARC Site 21, Jacksonville, Florida, United States|SPARC Site 35, Miami, Florida, United States|SPARC Site 27, Miami, Florida, United States|SPARC Site 10, Miami, Florida, United States|SPARC Site 16, Miami, Florida, United States|SPARC Site 19, Miami, Florida, United States|SPARC Site 25, Miami, Florida, United States|SPARC Site 41, Pompano Beach, Florida, United States|SPARC Site 18, Tampa, Florida, United States|SPARC Site 42, Atlanta, Georgia, United States|SPARC Site 2, Morrow, Georgia, United States|SPARC Site 22, Roswell, Georgia, United States|SPARC Site 12, Chicago, Illinois, United States|SPARC Site 23, Paducah, Kentucky, United States|SPARC Site 40, Bowie, Maryland, United States|SPARC Site 28, Kansas City, Missouri, United States|SPARC Site 48, Kansas City, Missouri, United States|SPARC Site 31, Saint Louis, Missouri, United States|SPARC Site 6, Henderson, Nevada, United States|SPARC Site 15, Poughkeepsie, New York, United States|SPARC Site 36, Rochester, New York, United States|SPARC Site 30, Gastonia, North Carolina, United States|SPARC Site 9, High Point, North Carolina, United States|SPARC Site 17, Winston-Salem, North Carolina, United States|SPARC Site 33, Fargo, North Dakota, United States|SPARC Site 37, Cincinnati, Ohio, United States|SPARC Site 8, Cleveland, Ohio, United States|SPARC Site 24, Cranberry Township, Pennsylvania, United States|SPARC Site 32, Memphis, Tennessee, United States|SPARC Site 39, Houston, Texas, United States|SPARC Site 13, Mission, Texas, United States|SPARC Site 20, San Antonio, Texas, United States|SPARC Site 26, Saint Albans, Vermont, United States",,,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
Brc1c(NC2=NCCN2)ccc2nccnc12,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,_BRIMONIDINE,NCT03450629,Phase 3,Recruiting,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"SPARC Site 4, Chandler, Arizona, United States|SPARC Site 5, Prescott, Arizona, United States|SPARC Site 3, Sun City, Arizona, United States|SPARC Site 38, Burbank, California, United States|SPARC Site 44, Glendale, California, United States|SPARC Site 45, Glendale, California, United States|SPARC Site 43, Mission Hills, California, United States|SPARC Site 1, Newport Beach, California, United States|SPARC Site 14, Santa Barbara, California, United States|SPARC Site 47, Torrance, California, United States|SPARC Site 7, Colorado Springs, Colorado, United States|SPARC Site 11, Coral Springs, Florida, United States|SPARC Site 29, Deerfield Beach, Florida, United States|SPARC Site 34, Fort Myers, Florida, United States|SPARC Site 46, Hollywood, Florida, United States|SPARC Site 21, Jacksonville, Florida, United States|SPARC Site 35, Miami, Florida, United States|SPARC Site 27, Miami, Florida, United States|SPARC Site 10, Miami, Florida, United States|SPARC Site 16, Miami, Florida, United States|SPARC Site 19, Miami, Florida, United States|SPARC Site 25, Miami, Florida, United States|SPARC Site 41, Pompano Beach, Florida, United States|SPARC Site 18, Tampa, Florida, United States|SPARC Site 42, Atlanta, Georgia, United States|SPARC Site 2, Morrow, Georgia, United States|SPARC Site 22, Roswell, Georgia, United States|SPARC Site 12, Chicago, Illinois, United States|SPARC Site 23, Paducah, Kentucky, United States|SPARC Site 40, Bowie, Maryland, United States|SPARC Site 28, Kansas City, Missouri, United States|SPARC Site 48, Kansas City, Missouri, United States|SPARC Site 31, Saint Louis, Missouri, United States|SPARC Site 6, Henderson, Nevada, United States|SPARC Site 15, Poughkeepsie, New York, United States|SPARC Site 36, Rochester, New York, United States|SPARC Site 30, Gastonia, North Carolina, United States|SPARC Site 9, High Point, North Carolina, United States|SPARC Site 17, Winston-Salem, North Carolina, United States|SPARC Site 33, Fargo, North Dakota, United States|SPARC Site 37, Cincinnati, Ohio, United States|SPARC Site 8, Cleveland, Ohio, United States|SPARC Site 24, Cranberry Township, Pennsylvania, United States|SPARC Site 32, Memphis, Tennessee, United States|SPARC Site 39, Houston, Texas, United States|SPARC Site 13, Mission, Texas, United States|SPARC Site 20, San Antonio, Texas, United States|SPARC Site 26, Saint Albans, Vermont, United States",5424078.0,A61K47/02,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,_BRIMONIDINE_TARTRATE,NCT03450629,Phase 3,Recruiting,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"SPARC Site 4, Chandler, Arizona, United States|SPARC Site 5, Prescott, Arizona, United States|SPARC Site 3, Sun City, Arizona, United States|SPARC Site 38, Burbank, California, United States|SPARC Site 44, Glendale, California, United States|SPARC Site 45, Glendale, California, United States|SPARC Site 43, Mission Hills, California, United States|SPARC Site 1, Newport Beach, California, United States|SPARC Site 14, Santa Barbara, California, United States|SPARC Site 47, Torrance, California, United States|SPARC Site 7, Colorado Springs, Colorado, United States|SPARC Site 11, Coral Springs, Florida, United States|SPARC Site 29, Deerfield Beach, Florida, United States|SPARC Site 34, Fort Myers, Florida, United States|SPARC Site 46, Hollywood, Florida, United States|SPARC Site 21, Jacksonville, Florida, United States|SPARC Site 35, Miami, Florida, United States|SPARC Site 27, Miami, Florida, United States|SPARC Site 10, Miami, Florida, United States|SPARC Site 16, Miami, Florida, United States|SPARC Site 19, Miami, Florida, United States|SPARC Site 25, Miami, Florida, United States|SPARC Site 41, Pompano Beach, Florida, United States|SPARC Site 18, Tampa, Florida, United States|SPARC Site 42, Atlanta, Georgia, United States|SPARC Site 2, Morrow, Georgia, United States|SPARC Site 22, Roswell, Georgia, United States|SPARC Site 12, Chicago, Illinois, United States|SPARC Site 23, Paducah, Kentucky, United States|SPARC Site 40, Bowie, Maryland, United States|SPARC Site 28, Kansas City, Missouri, United States|SPARC Site 48, Kansas City, Missouri, United States|SPARC Site 31, Saint Louis, Missouri, United States|SPARC Site 6, Henderson, Nevada, United States|SPARC Site 15, Poughkeepsie, New York, United States|SPARC Site 36, Rochester, New York, United States|SPARC Site 30, Gastonia, North Carolina, United States|SPARC Site 9, High Point, North Carolina, United States|SPARC Site 17, Winston-Salem, North Carolina, United States|SPARC Site 33, Fargo, North Dakota, United States|SPARC Site 37, Cincinnati, Ohio, United States|SPARC Site 8, Cleveland, Ohio, United States|SPARC Site 24, Cranberry Township, Pennsylvania, United States|SPARC Site 32, Memphis, Tennessee, United States|SPARC Site 39, Houston, Texas, United States|SPARC Site 13, Mission, Texas, United States|SPARC Site 20, San Antonio, Texas, United States|SPARC Site 26, Saint Albans, Vermont, United States",WO-1995003798-A2,4,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,11.0,32.7488,19.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,"HYPERTENSION, PULMONARY",_ACETAZOLAMIDE,NCT02755298,Phase 2|Phase 3,Recruiting,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University Hospital Zurich, Zurich, Switzerland",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
N[C@@H](Cc1c[nH]cn1)C(=O)O,"RENAL INSUFFICIENCY, CHRONIC",_HISTIDINE,NCT02947750,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Atlanta VA Health Care System, Decatur, Georgia, United States",3943038.0,C12N1/38,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,9.0,18.858703464136802,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.7,155.1546,92.0,4.0,3.0,1.0,14.67,38.06,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,"RENAL INSUFFICIENCY, CHRONIC",_FOLIC_ACID,NCT02947750,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Atlanta VA Health Care System, Decatur, Georgia, United States",3960757.0,A61K9/1694,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CN(C)C(=N)NC(=N)N,PRIMARY OPEN ANGLE GLAUCOMA,_METFORMIN,NCT04155164,Not Applicable,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,ABDOMINAL AORTIC ANEURYSM,_METFORMIN,NCT03507413,Phase 2|Phase 3,Enrolling by invitation,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical University of Vienna, Department of Surgery, Division of Vascular Surgery, Vienna, Austria",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(=O)Oc1ccccc1C(=O)O,AORTIC STENOSIS,_ASPIRIN,NCT03557242,Not Applicable,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Foundation for Cardiovascular Medicine, San Diego, California, United States|Washington Hospital Center, Washington, District of Columbia, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Stony Brook Hospital, Stony Brook, New York, United States|St. John Health System, Tulsa, Oklahoma, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Henrico Doctors' Hospital, Richmond, Virginia, United States",6015577,6,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,AORTIC STENOSIS,_WARFARIN,NCT03557242,Not Applicable,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Foundation for Cardiovascular Medicine, San Diego, California, United States|Washington Hospital Center, Washington, District of Columbia, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Stony Brook Hospital, Stony Brook, New York, United States|St. John Health System, Tulsa, Oklahoma, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Henrico Doctors' Hospital, Richmond, Virginia, United States",3932656,7,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,HYPERTROPHIC CARDIOMYOPATHY,_SACUBITRIL,NCT03832660,Phase 2,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Regensburg, Regensburg, Germany|Azienda Ospedaliero Universitaria Careggi Florence, Florence, Italy|University of Belgrade Faculty of Medicine, Belgrade, Serbia|Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia|Newcastle University, Faculty of Medical Sciences, Clinical Research Facility, Royal Victoria Infirmary; Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, England, United Kingdom",7468390,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,PERSISTENT ATRIAL FIBRILLATION,_APIXABAN,NCT02633774,Not Applicable,Recruiting,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea, Republic of",6413980,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1,PERSISTENT ATRIAL FIBRILLATION,_PROPAFENONE,NCT02633774,Not Applicable,Recruiting,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea, Republic of",5681588,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,24.838292367399696,160.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.1,341.444,58.56,4.0,2.0,2.0,39.75,100.21,11.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,INFECTIVE ENDOCARDITIS,_RIFAMPIN,NCT02701608,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Service des Maladies infectieuses, Centre Hospitalier du Pays d'Aix, Aix en Provence, France|Service de court séjour gériatrique - EMG, Centre hospitalier d'Alès, Alès, France|Service de Pathologies infectieuses et tropicales, Hôpital Nord, CHU d'Amiens, Amiens, France|CHU ANGERS - Service des maladies infectieuses et tropicales, Angers, France|Service des Maladies infectieuses et Tropicales, Hôpital Jean Minjoz, CHU de Besançon, Besançon, France|Service de Maladies infectieuses et tropicales, Hôpital Avicenne, APHP, Bobigny, France|Service de Réanimation médicale, Hôpital St André, CHU de Bordeaux, Bordeaux, France|Service de Médecine interne, Hôpital Ambroise Paré, APHP, Boulogne Billancourt, France|Service de Maladies infectieuses, Hôpital de la Cavale Blanche, Brest, France|Service de Cardiologie, Hôpitall Louis Pradel, Hôpitaux Est, Hospices Civils de Lyon, Bron, France|Service Maladies Infectieuses et tropicales, Hôpital Côte de Nacre, CHU de Caen, Caen, France|Service de Maladies infectieuses et tropicales, médecine interne, CH de Chambéry, Chambéry, France|Service des maladies infectieuses et tropicales, Hôpital G. Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand, France|APHP Henri-Mondor - Service des maladies infectieuses et tropicales, Créteil, France|Département d'infectiologie, Complexe Bocage, Hôpital d'enfants, CHU de Dijon, Dijon, France|Service de Médecine interne polyvalente et neurologique CH de Douai, Douai, France|Service de Médecine aigue spécifique, Hôpital Raymond Poincaré, APHP, Garches, France|Service de Médecine post-urgence, infectiologie, Site de la Roche sur Yon, CHD Vendée, La Roche sur Yon, France|Service de Médecine infectieuse, Hôpital Nord Michallon, CHU de Grenoble, La Tronche, France|Service de Maladies infectieuses et tropicales, et pathologie VIH, Le Chesnay, France|APHP BICETRE - Service des maladies infectieuses et tropicales, Le Kremlin-Bicêtre, France|Service des Maladies infectieuses et tropicales, CH Le Mans, Le Mans, France|Unité médicale d'infectiologie, Hôpital Huriez, CHU de Lille, Lille, France|Service de Maladies Infectieuses et tropicales, Hôpital Dupuytren, CHU de Limoges, Limoges, France|Clinique de la Sauvegarde, Lyon, France|Service de Maladies infectieuses, Hôpital Gui de CHauliac, CHU de Montpellier, Montpellier, France|Service de Maladies infectieuses et tropicales, Hôpital Hôtel Dieu, CHU Nantes, Nantes, France|Service d'Infectiologie, Hôpital de l'Archet, CHU de Nice, Nice, France|Service des Maladies infectieuses, CH de Niort, Niort, France|Service des Maladies Infectieuses et Tropicales, Hôpital Carémeau, CHU de Nîmes, Nîmes, France|Service de Maladies infectieuses et tropicales, Hôpital de la Source, CHR Orléans, Orléans, France|APHP St Antoine, Paris, France|Service de Microbiologie, Hôpital Européen Georges Pompidou, APHP, Paris, France|Service de Maladies infectieuses et tropicales, Hôpital Necker, APHP, Paris, France|Service de Maladies infectieuses, parasitaires et tropicales, Hôpital Bichat, APHP, Paris, France|Institut Mutualiste Montsouris - Service de médecine interne, Paris, France|CH PAU - Service de Médecine interne et Maladies infectieuses, Pau, France|Service des Maladies infectieuses et tropicales, CH de Perpignan, Perpignan, France|Service de Médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France|Infectiologie, médecine interne et médecine des voyages, CH d'Annecy, Pringy, France|CH QUIMPER - Service d'infectiologie, Quimper, France|Service de Médecine interne, maladies infectieuses, immunologie clinique, Hôpital R. Debré, CHU de Reims, Reims, France|Service des maladies infectieuses et réanimation médicale, Hôpital Pontchaillou, CHU de Rennes, Rennes, France|Service des Maladies infectieuses et tropicales, Hôpital Charles Nicolle, CHU de Rouen, Rouen, France|Service des maladies respiratoires et infectieuses, CH de St Malo, Saint Malo, France|Service des Maladie infectieuses et tropicales, Hôpital d'instruction des armées Bégin, Saint-Mande, France|CHU St Etienne - Service des maladies infectieuses et tropicales, Saint-Priest-en-Jarez, France|Service des Maladies infectieuses et tropicales, Hôpital de Purpan, CHU de Toulouse, Toulouse, France|CHU Toulouse (Rangueil) Service de Cardiologie, Toulouse, France|Service Universitaire des Maladies Infectieuses et du voyageur, CH de Tourcoing, Tourcoing, France|Service de Médecine interne et maladies infectieuses, Hôpital Bretonneau, CHU de Tours, Tours, France|Service de Maladies infectieuses et tropicales, Hôpitaux de Brabois, CHU de Nancy, Vandoeuvre les Nancy, France|Consultation de Médecine Interne, maladies infectieuses et tropicales, CH intercommunal de Villeneuve St Georges, Villeneuve St Georges, France|Médipôle Lyon Villeurbanne, Villeurbanne, France",3963705,C07D498/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,INFECTIVE ENDOCARDITIS,_LEVOFLOXACIN,NCT02701608,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Service des Maladies infectieuses, Centre Hospitalier du Pays d'Aix, Aix en Provence, France|Service de court séjour gériatrique - EMG, Centre hospitalier d'Alès, Alès, France|Service de Pathologies infectieuses et tropicales, Hôpital Nord, CHU d'Amiens, Amiens, France|CHU ANGERS - Service des maladies infectieuses et tropicales, Angers, France|Service des Maladies infectieuses et Tropicales, Hôpital Jean Minjoz, CHU de Besançon, Besançon, France|Service de Maladies infectieuses et tropicales, Hôpital Avicenne, APHP, Bobigny, France|Service de Réanimation médicale, Hôpital St André, CHU de Bordeaux, Bordeaux, France|Service de Médecine interne, Hôpital Ambroise Paré, APHP, Boulogne Billancourt, France|Service de Maladies infectieuses, Hôpital de la Cavale Blanche, Brest, France|Service de Cardiologie, Hôpitall Louis Pradel, Hôpitaux Est, Hospices Civils de Lyon, Bron, France|Service Maladies Infectieuses et tropicales, Hôpital Côte de Nacre, CHU de Caen, Caen, France|Service de Maladies infectieuses et tropicales, médecine interne, CH de Chambéry, Chambéry, France|Service des maladies infectieuses et tropicales, Hôpital G. Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand, France|APHP Henri-Mondor - Service des maladies infectieuses et tropicales, Créteil, France|Département d'infectiologie, Complexe Bocage, Hôpital d'enfants, CHU de Dijon, Dijon, France|Service de Médecine interne polyvalente et neurologique CH de Douai, Douai, France|Service de Médecine aigue spécifique, Hôpital Raymond Poincaré, APHP, Garches, France|Service de Médecine post-urgence, infectiologie, Site de la Roche sur Yon, CHD Vendée, La Roche sur Yon, France|Service de Médecine infectieuse, Hôpital Nord Michallon, CHU de Grenoble, La Tronche, France|Service de Maladies infectieuses et tropicales, et pathologie VIH, Le Chesnay, France|APHP BICETRE - Service des maladies infectieuses et tropicales, Le Kremlin-Bicêtre, France|Service des Maladies infectieuses et tropicales, CH Le Mans, Le Mans, France|Unité médicale d'infectiologie, Hôpital Huriez, CHU de Lille, Lille, France|Service de Maladies Infectieuses et tropicales, Hôpital Dupuytren, CHU de Limoges, Limoges, France|Clinique de la Sauvegarde, Lyon, France|Service de Maladies infectieuses, Hôpital Gui de CHauliac, CHU de Montpellier, Montpellier, France|Service de Maladies infectieuses et tropicales, Hôpital Hôtel Dieu, CHU Nantes, Nantes, France|Service d'Infectiologie, Hôpital de l'Archet, CHU de Nice, Nice, France|Service des Maladies infectieuses, CH de Niort, Niort, France|Service des Maladies Infectieuses et Tropicales, Hôpital Carémeau, CHU de Nîmes, Nîmes, France|Service de Maladies infectieuses et tropicales, Hôpital de la Source, CHR Orléans, Orléans, France|APHP St Antoine, Paris, France|Service de Microbiologie, Hôpital Européen Georges Pompidou, APHP, Paris, France|Service de Maladies infectieuses et tropicales, Hôpital Necker, APHP, Paris, France|Service de Maladies infectieuses, parasitaires et tropicales, Hôpital Bichat, APHP, Paris, France|Institut Mutualiste Montsouris - Service de médecine interne, Paris, France|CH PAU - Service de Médecine interne et Maladies infectieuses, Pau, France|Service des Maladies infectieuses et tropicales, CH de Perpignan, Perpignan, France|Service de Médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France|Infectiologie, médecine interne et médecine des voyages, CH d'Annecy, Pringy, France|CH QUIMPER - Service d'infectiologie, Quimper, France|Service de Médecine interne, maladies infectieuses, immunologie clinique, Hôpital R. Debré, CHU de Reims, Reims, France|Service des maladies infectieuses et réanimation médicale, Hôpital Pontchaillou, CHU de Rennes, Rennes, France|Service des Maladies infectieuses et tropicales, Hôpital Charles Nicolle, CHU de Rouen, Rouen, France|Service des maladies respiratoires et infectieuses, CH de St Malo, Saint Malo, France|Service des Maladie infectieuses et tropicales, Hôpital d'instruction des armées Bégin, Saint-Mande, France|CHU St Etienne - Service des maladies infectieuses et tropicales, Saint-Priest-en-Jarez, France|Service des Maladies infectieuses et tropicales, Hôpital de Purpan, CHU de Toulouse, Toulouse, France|CHU Toulouse (Rangueil) Service de Cardiologie, Toulouse, France|Service Universitaire des Maladies Infectieuses et du voyageur, CH de Tourcoing, Tourcoing, France|Service de Médecine interne et maladies infectieuses, Hôpital Bretonneau, CHU de Tours, Tours, France|Service de Maladies infectieuses et tropicales, Hôpitaux de Brabois, CHU de Nancy, Vandoeuvre les Nancy, France|Consultation de Médecine Interne, maladies infectieuses et tropicales, CH intercommunal de Villeneuve St Georges, Villeneuve St Georges, France|Médipôle Lyon Villeurbanne, Villeurbanne, France",5053407,C07D413/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
Cc1onc(-c2ccccc2)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,INFECTIVE ENDOCARDITIS,_OXACILLIN,NCT02701608,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Service des Maladies infectieuses, Centre Hospitalier du Pays d'Aix, Aix en Provence, France|Service de court séjour gériatrique - EMG, Centre hospitalier d'Alès, Alès, France|Service de Pathologies infectieuses et tropicales, Hôpital Nord, CHU d'Amiens, Amiens, France|CHU ANGERS - Service des maladies infectieuses et tropicales, Angers, France|Service des Maladies infectieuses et Tropicales, Hôpital Jean Minjoz, CHU de Besançon, Besançon, France|Service de Maladies infectieuses et tropicales, Hôpital Avicenne, APHP, Bobigny, France|Service de Réanimation médicale, Hôpital St André, CHU de Bordeaux, Bordeaux, France|Service de Médecine interne, Hôpital Ambroise Paré, APHP, Boulogne Billancourt, France|Service de Maladies infectieuses, Hôpital de la Cavale Blanche, Brest, France|Service de Cardiologie, Hôpitall Louis Pradel, Hôpitaux Est, Hospices Civils de Lyon, Bron, France|Service Maladies Infectieuses et tropicales, Hôpital Côte de Nacre, CHU de Caen, Caen, France|Service de Maladies infectieuses et tropicales, médecine interne, CH de Chambéry, Chambéry, France|Service des maladies infectieuses et tropicales, Hôpital G. Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand, France|APHP Henri-Mondor - Service des maladies infectieuses et tropicales, Créteil, France|Département d'infectiologie, Complexe Bocage, Hôpital d'enfants, CHU de Dijon, Dijon, France|Service de Médecine interne polyvalente et neurologique CH de Douai, Douai, France|Service de Médecine aigue spécifique, Hôpital Raymond Poincaré, APHP, Garches, France|Service de Médecine post-urgence, infectiologie, Site de la Roche sur Yon, CHD Vendée, La Roche sur Yon, France|Service de Médecine infectieuse, Hôpital Nord Michallon, CHU de Grenoble, La Tronche, France|Service de Maladies infectieuses et tropicales, et pathologie VIH, Le Chesnay, France|APHP BICETRE - Service des maladies infectieuses et tropicales, Le Kremlin-Bicêtre, France|Service des Maladies infectieuses et tropicales, CH Le Mans, Le Mans, France|Unité médicale d'infectiologie, Hôpital Huriez, CHU de Lille, Lille, France|Service de Maladies Infectieuses et tropicales, Hôpital Dupuytren, CHU de Limoges, Limoges, France|Clinique de la Sauvegarde, Lyon, France|Service de Maladies infectieuses, Hôpital Gui de CHauliac, CHU de Montpellier, Montpellier, France|Service de Maladies infectieuses et tropicales, Hôpital Hôtel Dieu, CHU Nantes, Nantes, France|Service d'Infectiologie, Hôpital de l'Archet, CHU de Nice, Nice, France|Service des Maladies infectieuses, CH de Niort, Niort, France|Service des Maladies Infectieuses et Tropicales, Hôpital Carémeau, CHU de Nîmes, Nîmes, France|Service de Maladies infectieuses et tropicales, Hôpital de la Source, CHR Orléans, Orléans, France|APHP St Antoine, Paris, France|Service de Microbiologie, Hôpital Européen Georges Pompidou, APHP, Paris, France|Service de Maladies infectieuses et tropicales, Hôpital Necker, APHP, Paris, France|Service de Maladies infectieuses, parasitaires et tropicales, Hôpital Bichat, APHP, Paris, France|Institut Mutualiste Montsouris - Service de médecine interne, Paris, France|CH PAU - Service de Médecine interne et Maladies infectieuses, Pau, France|Service des Maladies infectieuses et tropicales, CH de Perpignan, Perpignan, France|Service de Médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France|Infectiologie, médecine interne et médecine des voyages, CH d'Annecy, Pringy, France|CH QUIMPER - Service d'infectiologie, Quimper, France|Service de Médecine interne, maladies infectieuses, immunologie clinique, Hôpital R. Debré, CHU de Reims, Reims, France|Service des maladies infectieuses et réanimation médicale, Hôpital Pontchaillou, CHU de Rennes, Rennes, France|Service des Maladies infectieuses et tropicales, Hôpital Charles Nicolle, CHU de Rouen, Rouen, France|Service des maladies respiratoires et infectieuses, CH de St Malo, Saint Malo, France|Service des Maladie infectieuses et tropicales, Hôpital d'instruction des armées Bégin, Saint-Mande, France|CHU St Etienne - Service des maladies infectieuses et tropicales, Saint-Priest-en-Jarez, France|Service des Maladies infectieuses et tropicales, Hôpital de Purpan, CHU de Toulouse, Toulouse, France|CHU Toulouse (Rangueil) Service de Cardiologie, Toulouse, France|Service Universitaire des Maladies Infectieuses et du voyageur, CH de Tourcoing, Tourcoing, France|Service de Médecine interne et maladies infectieuses, Hôpital Bretonneau, CHU de Tours, Tours, France|Service de Maladies infectieuses et tropicales, Hôpitaux de Brabois, CHU de Nancy, Vandoeuvre les Nancy, France|Consultation de Médecine Interne, maladies infectieuses et tropicales, CH intercommunal de Villeneuve St Georges, Villeneuve St Georges, France|Médipôle Lyon Villeurbanne, Villeurbanne, France",4199566,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,22.538450481529303,1121.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.05,401.436,112.74,5.0,2.0,4.0,39.61,101.83,4.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,ESOPHAGEAL VARICES,_CARVEDILOL,NCT04499898,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sherief Abd-Elsalam, Tanta, Egypt",6022562,A61K9/5026,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,PRIMARY OPEN ANGLE GLAUCOMA,_TIMOLOL,NCT03193333,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MD. Sandra Belalcazar Rey, Bogotá, Bogotá D.C., Colombia|MD. Victoria Eugenia Sanchez Castellanos, Zapopan, Jalisco, Mexico",5231095.0,C07D285/10,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,PRIMARY OPEN ANGLE GLAUCOMA,_DORZOLAMIDE,NCT03193333,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MD. Sandra Belalcazar Rey, Bogotá, Bogotá D.C., Colombia|MD. Victoria Eugenia Sanchez Castellanos, Zapopan, Jalisco, Mexico",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.5,324.44,106.33,5.0,2.0,2.0,31.55,72.46,3.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
Brc1c(NC2=NCCN2)ccc2nccnc12,PRIMARY OPEN ANGLE GLAUCOMA,_BRIMONIDINE,NCT03193333,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MD. Sandra Belalcazar Rey, Bogotá, Bogotá D.C., Colombia|MD. Victoria Eugenia Sanchez Castellanos, Zapopan, Jalisco, Mexico",5424078.0,A61K47/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,"GLAUCOMA, PRIMARY OPEN ANGLE|OCULAR HYPERTENSION",_TIMOLOL,NCT04149899,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Eye Research Foundation, Newport Beach, California, United States",5231095.0,C07D285/10,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,OPEN ANGLE GLAUCOMA,_LATANOPROST,NCT04060758,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bendigo Eye Clinic, Bendigo, Victoria, Australia|Essendon Eye Clinic, Essendon, Victoria, Australia|Melbourne Eye Specialists, Fitzroy, Victoria, Australia|PersonalEYES, Parramatta, Victoria, Australia|Eyes First, Springvale, Victoria, Australia",5296504,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,16.0,15.408940635331302,173.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.16,432.5928,86.99,4.0,3.0,2.0,50.71,124.34,14.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,_BIMATOPROST,NCT04285580,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Eye Center South, Dothan, Alabama, United States|Eye Research Foundation, Newport Beach, California, United States|Scott & Christie and Associates, Cranberry Township, Pennsylvania, United States|Keystone Research LTD, Austin, Texas, United States",6403649,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,PERIPARTUM CARDIOMYOPATHY,_BROMOCRIPTINE,NCT02590601,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Heart Institute, Monteal, Quebec, Canada",5468755,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,39.0,23.8855007289677,1010.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.2,654.595,118.21,6.0,3.0,7.0,66.44,165.51,5.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,PULMONARY HYPERTENSION,_ALBUTEROL,NCT03270332,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pulmonary Human Research Laboratory, University of Miami, Miller School of Medicine, Miami, Florida, United States",5775321,B65D83/54,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,GLAUCOMA,_HYALURONATE,NCT03758859,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Western Eye Hospital, London, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,ACUTE CORONARY SYNDROME,_TREHALOSE,NCT03700424,Phase 2,Recruiting,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ghaem Educational, Research and Treatment Center, Mashhad, Razavi Khorasan, Iran, Islamic Republic of",4010078,C12M41/46,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,12.222016879196598,9047.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.2,68.34,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,"HYPERTENSION, PULMONARY",_SELEXIPAG,NCT04175600,Phase 3,Recruiting,All,2 Years to 17 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UCLA Medical Center, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Congenital Heart Center of the University of Florida, Gainesville, Florida, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Detroit Medical Center, Detroit, Michigan, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Virginia Division of Pediatric Cardiology, Charlottesville, Virginia, United States|Queensland CHILDREN'S HOSPITAL, South Brisbane, Australia|State Institution Republican Scientific And Practical Center For Pediatric Surgery, Minsk, Belarus|Health Institution 4Th City Children'S Clinical Hospital, Minsk, Belarus|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|Complexo de Prevencao,Diagnostico,Terapia e Reabilitacao Respiratoria LTDA Hospital Dia do Pulmao, Blumenau, Brazil|Hospital Pequeno Principe, Curitiba, Brazil|Hospital de Messejana dr. Carlos Alberto Studart Gomes, Fortaleza, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Irmandade Da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil|Hospital São Paulo-UNIFESP, Sao Paulo, Brazil|Multiprofile Hospital For Active Treatment National Cardiology Hospital, Ead, Sofia, Bulgaria|Hospital For Sick Children, Toronto, Ontario, Canada|Stollery Children's Hospital, Edmonton, Canada|Centre Hospitalier Sainte Justine, Montreal, Canada|Beijing Anzhen Hospital, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, China|Guangzhou Women And Children's Medical Center, Guangzhou, China|Shanghai Children's Medical Center, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Children's Hospital of Fudan University, Shanghai, China|The General Hospital of Northern Theater Command, Shenyang, China|Wuhan Asia Heart Hospital, Wuhan, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'An, China|Clinica San Rafael, Bogota, Colombia|Fundacion Neumologica Colombiana, Bogota, Colombia|Fundacion Santa Fe de Bogota, Bogota, Colombia|Centro Medico Imbanaco de Cali S.A., Cali, Colombia|Fundacion Cardiovascular de Colombia, Floridablanca, Colombia|Clinica Vascular las Americas, Medellin, Colombia|Hospital Universidad del Norte, Soledad, Colombia|Rigshospitalet, Copenhagen Ø, Denmark|New Children's Hospital of the Helsinki University Hospital (HUS), Helsinki, Finland|Hôpital Cardiologique - Chru Lille, Lille Cedex, France|Hopital de la Timone, Marseille Cedex 5, France|CHU Arnaud de Villeneuve, Montpellier Cedex 5, France|Hôpital Necker - Enfants Malades, Paris, France|Hôpital Cardiologique Du Haut-Lévêque, Pessac, France|Chu Hopital Des Enfants, Toulouse Cedex 9, France|Universitätsklinikum Freiburg Zentrum, Freiburg, Germany|Universitäres Herzzentrum Hamburg, Hamburg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Herzzentrum Leipzig GmbH, Leipzig, Germany|Gottsegen György Országos Kardiológiai Intézet, Budapest, Hungary|Rambam Medical Center, Haifa, Israel|Sheba Medical Center, Ramat Gan, Israel|Azienda Ospedaliera Policlinico S. Orsola-Malpighi, Bologna, Italy|Universtà Degli Studi Di Padova, Padova, Italy|Ospedale Pediatrico Bambin Gesù, Roma, Italy|AOU Città della Salute e della Scienza di Torino, Presidio Ospedale Infantile Regina Margherita, Torino, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of|Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania|National Heart Institute, Kuala Lumpur, Malaysia|CICUM San Miguel, Guadalajara, Mexico|Operadora de Hospitales Angeles SA de CV Hospital Angeles Lomas, Mexico, Mexico|Unidad de Investigacion Clinica en Medicina S.C. (UDICEM), Monterrey, Mexico|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Uniwersytecki Szpital Dzieciecy w Krakowie, Kraków, Poland|Wojewodzki Szpital Specjalistyczny we Wroclawiu, Wroclaw, Poland|Slaskie Centrum Chorob Serca, Zabrze, Poland|Hospital De Santa Marta, Lisboa, Portugal|Centro Hospitalar de São João, EPE, Porto, Portugal|Kazan State Medical University, Kazan, Russian Federation|Cardiovascular Pathology Research Institute of Siberian Branch of RAMS, Kemerovo, Russian Federation|Children's City Clinical Hospital n.a. Baslyaeva, Moscow, Russian Federation|Veltischev Research and Clinical Institute for Pediatrics of the Pirogov RNRMU, Moscow, Russian Federation|National medical Research Center n.a. V.A.Almazov of MoH of Russian Federation, Saint-Petersburg, Russian Federation|Samara Regional Clinical Cardiological Dispensary, Samara, Russian Federation|Tyumen Regional Hospital #1, Tyumen, Russian Federation|Univerzitetska Dečja Klinika, Belgrade, Serbia|Hosp. Univ. A Coruña, A Coruña, Spain|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Sant Joan de Deu, Esplugues de Llobregat, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Virgen Del Rocio, Sevilla, Spain|Drottning Silvias barn- och ungdomssjukhus, Gothenburg, Sweden|Skanes universitetssjukhus, Lund, Sweden|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chiang Mai University Hospital, Chiang Mai, Thailand|Cukurova Balcali Hospital Application and Research Center, Adana, Turkey|Hacettepe University Medical Faculty, Ankara, Turkey|CAPA Istanbul University Medical Faculty, Istanbul, Turkey|Mehmet Akif Ersoy Training and Research Hospital, Istanbul, Turkey|Behcet Uz Pediatric Diseases and Surgery Training and Research Hospital, Izmir, Turkey|Izmir Tepecik Training and Research Hospital, Izmir, Turkey|Dnipropetrovsk clinical medical center of Mother and Child after prof. Rudnev, Dnipro, Ukraine|MI 'Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiac Surgery', Dnipro, Ukraine|Scientific Practical Medical Center for Pediatric Cardiology and Cardio Surgery of the MOH, Kyiv, Ukraine|Communal Non-commercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital', Lviv, Ukraine|MI Zaporizhzhia Regional Clinical Children's Hospital of Zaporizhzhia Regional Council, Zaporizhzhya, Ukraine|Hanoi Medical University Hospital, Hanoi, Vietnam|Tam Duc Cardiology Hospital, Ho Chi Minh, Vietnam|Children's Hospital 1, Ho Chi Minh, Vietnam",7205302,5,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,59.7301792644612,38.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.4,496.63,101.49,7.0,1.0,3.0,54.98,136.81,11.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1,"GLAUCOMA, OPEN-ANGLE",_NETARSUDIL,NCT04234932,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of the Incarnate Word, San Antonio, Texas, United States",8450344,3,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,37.0,58.0874350602681,2.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.77,453.542,94.31,4.0,2.0,4.0,51.09,134.66,8.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O,ST ELEVATION MYOCARDIAL INFARCTION,_BIVALIRUDIN,NCT03822975,Not Applicable,Recruiting,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"General Hospital of Northern Theater Command, Shenyang, China",5196404.0,C07K14/815,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,37.0,32.5591901271073,396.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.76,2180.2853,901.57,37.0,28.0,6.0,215.46,543.33,66.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
NC(=O)c1cccnc1,HYPERTENSION,_NICOTINAMIDE,NCT04112043,Phase 1,Recruiting,All,65 Years to 105 Years   (Older Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","UF Institute on Aging, Gainesville, Florida, United States",3931207,C07D207/44,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,7.0,24.7397277151481,6368.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.39,122.1246,55.98,2.0,1.0,1.0,11.71,32.98,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,ACUTE HEART FAILURE,_DIGOXIN,NCT02544815,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Sahloul University Hospital, Hammam sousse, Sousse, Tunisia|Fattouma Bourguiba University Hospital, Monastir, Tunisia",3933997.0,G01N31/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,22.6698700178648,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.04,780.9385,203.06,13.0,6.0,8.0,84.8,193.23,7.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,RENAL INSUFFICIENCY,_APIXABAN,NCT02664155,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CH ARRAS, Arras, Boulevard Georges Besnier, France|Chu Tours, Tours, Hôpital Trousseau, France|CH d'Agen-Nérac, Agen, France|Chu Amiens, Amiens 1, France|Chu Angers, Angers 9, France|CH Besançon, Besancon, France|CHU de Bordeaux, Bordeaux, France|CHU La Cavale Blanche Brest, Brest, France|HIA de Brest, Brest, France|CHU Castelnau-le-Lez, Castelnau Le Lez, France|CH Louis Pasteur - Chartres, Chartres, France|Chu Clermont-Ferrand, Clermont-Ferrand, France|CHU Dijon, Dijon, France|Hôpital La Tronche Grenoble, Grenoble 9, France|Hôpital Charles Foix - APHP Ivry sur Seine, Ivry sur Seine, France|Chu Limoges, Limoges, France|CHU Lyon, Lyon, France|HCL - Hôpital Edouard Herriot, Lyon, France|Chu Montpellier, Montpellier 5, France|CHU de Nantes - Hôpital Bellier, Nantes, France|CHU de Nantes - Hôpital Hôtel Dieu, Nantes, France|CHU Nice, Nice, France|HEGP - APHP Paris, Paris, France|Hôpital Louis Mourier- APHP Paris, Paris, France|CHU de Rouen, Rouen, France|Chu Saint Etienne, Saint Etienne, France|Chu Strasbourg, Strasbourg, France|CH Toulon, Toulon, France|HIA de Toulon, Toulon, France|CHU Toulouse, Toulouse 9, France|CH de Valenciennes, Valenciennes, France",6413980,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,RENAL INSUFFICIENCY,_RIVAROXABAN,NCT02664155,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CH ARRAS, Arras, Boulevard Georges Besnier, France|Chu Tours, Tours, Hôpital Trousseau, France|CH d'Agen-Nérac, Agen, France|Chu Amiens, Amiens 1, France|Chu Angers, Angers 9, France|CH Besançon, Besancon, France|CHU de Bordeaux, Bordeaux, France|CHU La Cavale Blanche Brest, Brest, France|HIA de Brest, Brest, France|CHU Castelnau-le-Lez, Castelnau Le Lez, France|CH Louis Pasteur - Chartres, Chartres, France|Chu Clermont-Ferrand, Clermont-Ferrand, France|CHU Dijon, Dijon, France|Hôpital La Tronche Grenoble, Grenoble 9, France|Hôpital Charles Foix - APHP Ivry sur Seine, Ivry sur Seine, France|Chu Limoges, Limoges, France|CHU Lyon, Lyon, France|HCL - Hôpital Edouard Herriot, Lyon, France|Chu Montpellier, Montpellier 5, France|CHU de Nantes - Hôpital Bellier, Nantes, France|CHU de Nantes - Hôpital Hôtel Dieu, Nantes, France|CHU Nice, Nice, France|HEGP - APHP Paris, Paris, France|Hôpital Louis Mourier- APHP Paris, Paris, France|CHU de Rouen, Rouen, France|Chu Saint Etienne, Saint Etienne, France|Chu Strasbourg, Strasbourg, France|CH Toulon, Toulon, France|HIA de Toulon, Toulon, France|CHU Toulouse, Toulouse 9, France|CH de Valenciennes, Valenciennes, France",7157456,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
NCCc1c[nH]c2ccc(O)cc12,STROKE,_SEROTONIN,NCT02865642,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Neurology Department Kantonsspital St. Gallen, St. Gallen, Saint Gallen, Switzerland|Support Center of Advanced Neuroimaging Institute for Diagnostic and Interventional Neuroradiology Inselspital, University Hospital Bern, Bern, Switzerland",3930948,C12N9/88,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,17.281669028111402,4461.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.56,176.2151,62.04,2.0,3.0,2.0,19.31,52.35,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,ST ELEVATION MYOCARDIAL INFARCTION,_LEVOSIMENDAN,NCT03699215,Phase 3,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UICEC, La Laguna, S/C De Tenerife, Spain",6340764,G01N30/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,11.039241052177598,104.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,280.2847,113.43,6.0,2.0,2.0,28.67,77.63,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,"CARDIAC OUTPUT, LOW",_LEVOSIMENDAN,NCT04179604,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GERMANS TRIAS I PUJOL DE BADALONA university Hospital, Badalona, Barcelona, Spain|Doctor Josep Trueta university Hospital, Girona, Gerona, Spain|Doctor Negrin University Hospital, Las Palmas De Gran Canaria, Gran Canarias, Spain|Puerta del Hierro University Hospital, Majadahonda, Madrid, Spain|Virgen de la Victoria University Hospital, Málaga, Malaga, Spain|A coruña UNIVERSITY HOSPITAL COMPLEX A CORUÑA, La Coruña, Spain|12 de Octubre University Hospital, Madrid, Spain|Virgen Macarena University Hospital, Sevilla, Spain|Valladolid universitary Hospital, Valladolid, Spain",6340764,G01N30/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,12.0,11.039241052177598,104.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,280.2847,113.43,6.0,2.0,2.0,28.67,77.63,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,DIABETIC RETINOPATHY,_METFORMIN,NCT02587741,Early Phase 1,Recruiting,All,"30 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"the third affiliated hospital of Sun yet-san university, Guangzhou, Guangdong, China",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,"GLAUCOMA, ANGLE-CLOSURE",_PILOCARPINE,NCT02613013,Not Applicable,Recruiting,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China",3947573,C08L71/02,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,17.380233680363,24.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.15,208.2569,44.12,2.0,0.0,2.0,22.34,56.53,3.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N,"GLAUCOMA, ANGLE-CLOSURE",_PROPARACAINE,NCT02613013,Not Applicable,Recruiting,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China",4022899,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,16.9859750713566,522.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.97,294.3892,64.79,4.0,1.0,1.0,34.0,86.04,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,PERIPHERAL ARTERY DISEASE,_PACLITAXEL,NCT04393389,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Observational Model: Cohort|Time Perspective: Prospective,"Department of Angiology, University Hospital Leipzig,, Leipzig, Germany|Elblandklinikum Radebeul, Radebeul, Germany|Elblandklinikum Radebeul, Riesa, Germany|REGIOMED Klinikum Sonneberg, Sonneberg, Germany|KKH Torgau, Torgau, Germany",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,"STROKE, ACUTE",_DESMOPRESSIN,NCT03696121,Phase 2,Recruiting,All,"18 Years to 110 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nottingham City Hospital, Nottingham, Notts, United Kingdom",5500413.0,C07K7/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.65775477935889,17.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,1069.22,435.41,15.0,14.0,4.0,104.78,279.78,19.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0
NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,HEART ARREST,_VASOPRESSIN,NCT03640949,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark|Copenhagen University Hospital - Gentofte, Hellerup, Denmark|Copenhagen University Hospital - Herlev, Herlev, Denmark|Horsens Regional Hospital, Horsens, Denmark|Zealand University Hospital - Køge, Køge, Denmark|Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Viborg Regional Hospital, Viborg, Denmark",9375478.0,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,13.3062280539641,14.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.4,2140.46,463.93,16.0,14.0,8.0,108.29,272.59,38.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
N=C(N)NCCC[C@H](N)C(=O)O,HEART ARREST,_ARGININE,NCT03640949,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark|Copenhagen University Hospital - Gentofte, Hellerup, Denmark|Copenhagen University Hospital - Herlev, Herlev, Denmark|Horsens Regional Hospital, Horsens, Denmark|Zealand University Hospital - Køge, Køge, Denmark|Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Viborg Regional Hospital, Viborg, Denmark",4271152.0,C07K14/672,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,HEART ARREST,_METHYLPREDNISOLONE,NCT03640949,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark|Copenhagen University Hospital - Gentofte, Hellerup, Denmark|Copenhagen University Hospital - Herlev, Herlev, Denmark|Horsens Regional Hospital, Horsens, Denmark|Zealand University Hospital - Køge, Køge, Denmark|Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Viborg Regional Hospital, Viborg, Denmark",3962414,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
NC[C@H](O)c1ccc(O)c(O)c1,HYPOTENSION DRUG-INDUCED,_NOREPINEPHRINE,NCT03626454,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Fayoum University hospital, Madīnat al Fayyūm, Faiyum Governorate, Egypt",3961060.0,5,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,2922.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,169.1778,86.71,4.0,4.0,1.0,16.96,44.46,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,ANGINA PECTORIS,_SIROLIMUS,NCT02901353,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Observational Model: Other|Time Perspective: Prospective,"University of Semmelweis, Budapest, Europe, Hungary|University of Debrecen, Debrecen, Europe, Hungary|Jordan Hospital, Amman, Jordan|University Malaya Medical Centre (UMMC), Kuala Lumpur, Selangor, Malaysia|St. Antonius Hospital, Nieuwegein, Germany, Netherlands",5212155,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,HEART FAILURE WITH REDUCED EJECTION FRACTION,_MELATONIN,NCT03894683,Phase 2,Recruiting,All,"30 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cardiac rehabilitation research center, Isfahan, Iran, Islamic Republic of",4309415,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,37.0,32.854884083862,1835.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.42,232.2783,54.12,2.0,2.0,2.0,25.65,66.28,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,CEREBRAL SMALL VESSEL DISEASE,_AMLODIPINE,NCT03082014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Insitute for Stroke and Dementia Research, Munich, Germany|Maastricht University Medical Center, Maastricht, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Nuffield Department of Clinical Neurosciences, Oxford, England, United Kingdom|Centre for Clinical Brain Sciences, Edinburgh, Scotland, United Kingdom",6162802.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,CEREBRAL SMALL VESSEL DISEASE,_LOSARTAN,NCT03082014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Insitute for Stroke and Dementia Research, Munich, Germany|Maastricht University Medical Center, Maastricht, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Nuffield Department of Clinical Neurosciences, Oxford, England, United Kingdom|Centre for Clinical Brain Sciences, Edinburgh, Scotland, United Kingdom",5210079,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,CEREBRAL SMALL VESSEL DISEASE,_ATENOLOL,NCT03082014,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Insitute for Stroke and Dementia Research, Munich, Germany|Maastricht University Medical Center, Maastricht, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Nuffield Department of Clinical Neurosciences, Oxford, England, United Kingdom|Centre for Clinical Brain Sciences, Edinburgh, Scotland, United Kingdom",4256108.0,A61F9/0017,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
[F-].[Na+],CAROTID ARTERY STENOSIS,_SODIUM_FLUORIDE,NCT03353103,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Diagnostic","Caen University Hospital, Caen, France",8323683,A61K9/0058,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,90.58091541920773,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.15,41.9882,0.0,0.0,0.0,0.0,0.44,0.87,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,CARDIAC ARREST,_THIAMINE,NCT03509662,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VU Medical Center, Amsterdam, Noord-Holland, Netherlands",3946115.0,A23K20/158,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,20.4357379001622,3121.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.1,265.355,75.91,4.0,2.0,2.0,28.14,73.4,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,"HEMATOMA, SUBDURAL, CHRONIC",_CURCUMIN,NCT03845322,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of New Mexico Health Sciences center, Albuquerque, New Mexico, United States",4138212,C09B61/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
CC(=O)Oc1ccccc1C(=O)O,CAROTID ARTERY STENOSIS,_ASPIRIN,NCT02677545,Phase 2,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"AZ Groeninge VZW, Kortrijk, Belgium|University Hospital Aachen, Klinik für Diagnostische und Interventionelle Neuroradiologie, Aachen, Germany|Asklepios Kliniken Hamburg GmbH, Hamburg, Germany|Universitätsklinikum Heidelberg, Neurologische Klinik, Heidelberg, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Ospedale Civile di Mirano, Department of Cardiology, Mirano, Italy|UOC Neuroradiologia, Ospedale dell'Angelo, Venezia, Italy|AMC Medical Research BV on behalf of Academisch Medisch Centrum, Amsterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Kantonsspital Aarau Klinik für Neurologie, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|Insel Gruppe AG, Department of Neurology, Bern, Switzerland|Stadtspital Triemli Zürich/Department of Cardiology, Zurich, Switzerland|Sheffield Clinical Research Facility, Northern General Hospital, Sheffield, United Kingdom",6015577,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,CAROTID ARTERY STENOSIS,_CLOPIDOGREL,NCT02677545,Phase 2,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"AZ Groeninge VZW, Kortrijk, Belgium|University Hospital Aachen, Klinik für Diagnostische und Interventionelle Neuroradiologie, Aachen, Germany|Asklepios Kliniken Hamburg GmbH, Hamburg, Germany|Universitätsklinikum Heidelberg, Neurologische Klinik, Heidelberg, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Ospedale Civile di Mirano, Department of Cardiology, Mirano, Italy|UOC Neuroradiologia, Ospedale dell'Angelo, Venezia, Italy|AMC Medical Research BV on behalf of Academisch Medisch Centrum, Amsterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Kantonsspital Aarau Klinik für Neurologie, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|Insel Gruppe AG, Department of Neurology, Bern, Switzerland|Stadtspital Triemli Zürich/Department of Cardiology, Zurich, Switzerland|Sheffield Clinical Research Facility, Northern General Hospital, Sheffield, United Kingdom",4847265,C07D495/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,CAROTID ARTERY STENOSIS,_TICAGRELOR,NCT02677545,Phase 2,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"AZ Groeninge VZW, Kortrijk, Belgium|University Hospital Aachen, Klinik für Diagnostische und Interventionelle Neuroradiologie, Aachen, Germany|Asklepios Kliniken Hamburg GmbH, Hamburg, Germany|Universitätsklinikum Heidelberg, Neurologische Klinik, Heidelberg, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Ospedale Civile di Mirano, Department of Cardiology, Mirano, Italy|UOC Neuroradiologia, Ospedale dell'Angelo, Venezia, Italy|AMC Medical Research BV on behalf of Academisch Medisch Centrum, Amsterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Kantonsspital Aarau Klinik für Neurologie, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|Insel Gruppe AG, Department of Neurology, Bern, Switzerland|Stadtspital Triemli Zürich/Department of Cardiology, Zurich, Switzerland|Sheffield Clinical Research Facility, Northern General Hospital, Sheffield, United Kingdom",6251910,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF),_SACUBITRIL,NCT03988634,Phase 3,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Long Beach, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Littleton, Colorado, United States|Novartis Investigative Site, West Hartford, Connecticut, United States|Novartis Investigative Site, West Haven, Connecticut, United States|Novartis Investigative Site, Newark, Delaware, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Sarasota, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Macon, Georgia, United States|Novartis Investigative Site, Boise, Idaho, United States|Novartis Investigative Site, Aurora, Illinois, United States|Novartis Investigative Site, Oakbrook Terrace, Illinois, United States|Novartis Investigative Site, Park Ridge, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Winfield, Illinois, United States|Novartis Investigative Site, Elkhart, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Muncie, Indiana, United States|Novartis Investigative Site, Richmond, Indiana, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Kansas City, Kansas, United States|Novartis Investigative Site, Lexington, Kentucky, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Slidell, Louisiana, United States|Novartis Investigative Site, Bangor, Maine, United States|Novartis Investigative Site, Annapolis, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Petoskey, Michigan, United States|Novartis Investigative Site, Ypsilanti, Michigan, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Reno, Nevada, United States|Novartis Investigative Site, Camden, New Jersey, United States|Novartis Investigative Site, Elmer, New Jersey, United States|Novartis Investigative Site, Haddon Heights, New Jersey, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Johnson City, New York, United States|Novartis Investigative Site, Poughkeepsie, New York, United States|Novartis Investigative Site, Staten Island, New York, United States|Novartis Investigative Site, Stony Brook, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Greenville, North Carolina, United States|Novartis Investigative Site, Grand Forks, North Dakota, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Abington, Pennsylvania, United States|Novartis Investigative Site, Camp Hill, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Rapid City, South Dakota, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Burlington, Vermont, United States|Novartis Investigative Site, White River Junction, Vermont, United States|Novartis Investigative Site, Fairfax, Virginia, United States|Novartis Investigative Site, Lynchburg, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States",7468390,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,ACUTE MYOCARDIAL INFARCTION,_RAMIPRIL,NCT02924727,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Gilbert, Arizona, United States|Novartis Investigative Site, Bakersfield, California, United States|Novartis Investigative Site, Beverly Hills, California, United States|Novartis Investigative Site, Carmichael, California, United States|Novartis Investigative Site, Huntington Beach, California, United States|Novartis Investigative Site, Los Alamitos, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Northridge, California, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Santa Rosa, California, United States|Novartis Investigative Site, Sylmar, California, United States|Novartis Investigative Site, Brandon, Florida, United States|Novartis Investigative Site, Clearwater, Florida, United States|Novartis Investigative Site, Daytona Beach, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Jacksonville Beach, Florida, United States|Novartis Investigative Site, Jacksonville Beach, Florida, United States|Novartis Investigative Site, Ocala, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Cumming, Georgia, United States|Novartis Investigative Site, Johns Creek, Georgia, United States|Novartis Investigative Site, Thomasville, Georgia, United States|Novartis Investigative Site, Boise, Idaho, United States|Novartis Investigative Site, Coeur d'Alene, Idaho, United States|Novartis Investigative Site, Springfield, Illinois, United States|Novartis Investigative Site, Merrillville, Indiana, United States|Novartis Investigative Site, Muncie, Indiana, United States|Novartis Investigative Site, Munster, Indiana, United States|Novartis Investigative Site, Richmond, Indiana, United States|Novartis Investigative Site, Davenport, Iowa, United States|Novartis Investigative Site, Iowa City, Iowa, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Covington, Louisiana, United States|Novartis Investigative Site, Hammond, Louisiana, United States|Novartis Investigative Site, Slidell, Louisiana, United States|Novartis Investigative Site, Bangor, Maine, United States|Novartis Investigative Site, Annapolis, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Columbia, Maryland, United States|Novartis Investigative Site, Frederick, Maryland, United States|Novartis Investigative Site, Rockville, Maryland, United States|Novartis Investigative Site, Springfield, Massachusetts, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Grand Blanc, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Lansing, Michigan, United States|Novartis Investigative Site, Midland, Michigan, United States|Novartis Investigative Site, Petoskey, Michigan, United States|Novartis Investigative Site, Saginaw, Michigan, United States|Novartis Investigative Site, Southfield, Michigan, United States|Novartis Investigative Site, Duluth, Minnesota, United States|Novartis Investigative Site, Robbinsdale, Minnesota, United States|Novartis Investigative Site, Saint Cloud, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Hattiesburg, Mississippi, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Lee's Summit, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Lebanon, New Hampshire, United States|Novartis Investigative Site, Hackensack, New Jersey, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Flushing, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Poughkeepsie, New York, United States|Novartis Investigative Site, Stony Brook, New York, United States|Novartis Investigative Site, Valhalla, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Greenville, North Carolina, United States|Novartis Investigative Site, Grand Forks, North Dakota, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Clackamas, Oregon, United States|Novartis Investigative Site, Medford, Oregon, United States|Novartis Investigative Site, Camp Hill, Pennsylvania, United States|Novartis Investigative Site, Erie, Pennsylvania, United States|Novartis Investigative Site, Hershey, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, York, Pennsylvania, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Columbia, South Carolina, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Rapid City, South Dakota, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Webster, Texas, United States|Novartis Investigative Site, Charlottesville, Virginia, United States|Novartis Investigative Site, Danville, Virginia, United States|Novartis Investigative Site, Falls Church, Virginia, United States|Novartis Investigative Site, Lynchburg, Virginia, United States|Novartis Investigative Site, Manassas, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Roanoke, Virginia, United States|Novartis Investigative Site, Bellevue, Washington, United States|Novartis Investigative Site, Everett, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Manitowoc, Wisconsin, United States|Novartis Investigative Site, Waukesha, Wisconsin, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Caba, Argentina|Novartis Investigative Site, Buenos Aires, Caba, Argentina|Novartis Investigative Site, Ciudad de Salta, Provincia De Salta, Argentina|Novartis Investigative Site, Tucuman, San Miguel De Tucuman, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Formosa, Argentina|Novartis Investigative Site, San Luis, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Chemside, Queensland, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Hobart, Tasmania, Australia|Novartis Investigative Site, Geelong, Victoria, Australia|Novartis Investigative Site, Murdoch, Western Australia, Australia|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Braunau, Austria|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, St Poelten, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Turnhout, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Uberlandia, Minas Gerais, Brazil|Novartis Investigative Site, Curitiba, Parana, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Blumenau, SC, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Campina Grande do Sul, Brazil|Novartis Investigative Site, Sao Jose, Brazil|Novartis Investigative Site, Burgas, BGR, Bulgaria|Novartis Investigative Site, Sofia, BGR, Bulgaria|Novartis Investigative Site, Blagoevgrad, Bulgaria|Novartis Investigative Site, Burgas, Bulgaria|Novartis Investigative Site, Gabrovo, Bulgaria|Novartis Investigative Site, Kardzhali, Bulgaria|Novartis Investigative Site, Pernik, Bulgaria|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Ruse, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Victoria, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sainte Foy, Quebec, Canada|Novartis Investigative Site, Terrebonne, Quebec, Canada|Novartis Investigative Site, Trois Rivieres, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Xicheng, Beijing, China|Novartis Investigative Site, Lanzhou, Gansu, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Shijiazhuang, Hebei, China|Novartis Investigative Site, Harbin, Heilongjiang, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Changsha, Hunan, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Chang Chun, Jilin, China|Novartis Investigative Site, Yanji, Jilin, China|Novartis Investigative Site, Shengyang, Liaoning, China|Novartis Investigative Site, Jinan, Shandong, China|Novartis Investigative Site, Jinshan, Shanghai, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Xian, Shanxi, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Wenzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Wuhan, China|Novartis Investigative Site, Medellin, Antioquia, Colombia|Novartis Investigative Site, Medellin, Antioquia, Colombia|Novartis Investigative Site, Bucaramanga, Santander, Colombia|Novartis Investigative Site, Cali, Valle Del Cauca, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Zagreb, HRV, Croatia|Novartis Investigative Site, Cakovec, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Kladno, Czech Republic, Czechia|Novartis Investigative Site, Liberec, Czech Republic, Czechia|Novartis Investigative Site, Ostrava, Czech Republic, Czechia|Novartis Investigative Site, Zlin, Czech Republic, Czechia|Novartis Investigative Site, Brno Bohunice, Czechia|Novartis Investigative Site, Kolin, Czechia|Novartis Investigative Site, Plzen-Bory, Czechia|Novartis Investigative Site, Prague 4, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Slany, Czechia|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Glostrup, Denmark|Novartis Investigative Site, Hellerup, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Hvidovre, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Svendborg, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Viborg, Denmark|Novartis Investigative Site, HUS, Finland|Novartis Investigative Site, Jyvaskyla, Finland|Novartis Investigative Site, Kaupio, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Bron, France|Novartis Investigative Site, Chambray les Tours, France|Novartis Investigative Site, Corbeil Essonnes, France|Novartis Investigative Site, Grenoble Cedex 9, France|Novartis Investigative Site, Marseille Cedex 8, France|Novartis Investigative Site, Paris cedex 18, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Toulouse Cedex, France|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bad Krozingen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Coburg, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erfurt, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Esslingen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Guetersloh, Germany|Novartis Investigative Site, Halle Saale, Germany|Novartis Investigative Site, Hennigsdorf, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln-Nippes, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Langen, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leverkusen, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Moenchengladbach, Germany|Novartis Investigative Site, Neuss, Germany|Novartis Investigative Site, Neuwied, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Riesa, Germany|Novartis Investigative Site, Ruesselsheim, Germany|Novartis Investigative Site, Stadtlohn, Germany|Novartis Investigative Site, Vechta, Germany|Novartis Investigative Site, Villingen-Schwenningen, Germany|Novartis Investigative Site, Witten, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Alexandroupolis, Evros, Greece|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Larissa, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Pecs, Baranya, Hungary|Novartis Investigative Site, Zalaegerszeg, Zala, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szekesfehervar, Hungary|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Vadodara, Gujarat, India|Novartis Investigative Site, Karamsad, Gujrat, India|Novartis Investigative Site, Gurgaon, Haryana, India|Novartis Investigative Site, Kochi, Kerala, India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Bikaner, Rajasthan, India|Novartis Investigative Site, Madurai, Tamil NADU, India|Novartis Investigative Site, Hyderabad, Telangana, India|Novartis Investigative Site, Secunderabad, Telangana, India|Novartis Investigative Site, DehraDun, Uttarakhand, India|Novartis Investigative Site, Ashkelon, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Lower Galilee, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Sefad, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Catanzaro, CZ, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Sanremo, IM, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Rimini, RN, Italy|Novartis Investigative Site, Trieste, TS, Italy|Novartis Investigative Site, Saronno, VA, Italy|Novartis Investigative Site, Grosseto, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Pavia, Italy|Novartis Investigative Site, Cheongju si, Chungcheongbuk Do, Korea, Republic of|Novartis Investigative Site, Wonju, Gangwon-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Gwangju, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Torreon, Coahulia, Mexico|Novartis Investigative Site, Culiacan Sinaloa, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Ciudad de Mexico, Mexico|Novartis Investigative Site, Queretaro, Mexico|Novartis Investigative Site, San Luis Potosi, Mexico|Novartis Investigative Site, Sneek, The Netherlands, Netherlands|Novartis Investigative Site, Alkmaar, Netherlands|Novartis Investigative Site, Almelo, Netherlands|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Beverwijk, Netherlands|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Ede, Netherlands|Novartis Investigative Site, Gouda, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Heemstede, Netherlands|Novartis Investigative Site, Leeuwarden, Netherlands|Novartis Investigative Site, Leiderdorp, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Schiedam, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Uden, Netherlands|Novartis Investigative Site, Veldhoven, Netherlands|Novartis Investigative Site, Venlo, Netherlands|Novartis Investigative Site, Zutphen, Netherlands|Novartis Investigative Site, Zwolle, Netherlands|Novartis Investigative Site, Gralum, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Stavanger, Norway|Novartis Investigative Site, Bellavista, Lima, Peru|Novartis Investigative Site, Cercado De Lima, Lima, Peru|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Iloilo city, Iloilo, Philippines|Novartis Investigative Site, Quezon City, Manila, Philippines|Novartis Investigative Site, Manila, Metro Manila, Philippines|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Lubin, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Carnaxide, Lisboa, Portugal|Novartis Investigative Site, Almada, Portugal|Novartis Investigative Site, Braga, Portugal|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Covilha, Portugal|Novartis Investigative Site, Faro, Portugal|Novartis Investigative Site, Guimaraes, Portugal|Novartis Investigative Site, Leiria, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Vila Real, Portugal|Novartis Investigative Site, Pitesti, Arges, Romania|Novartis Investigative Site, Bucuresti, District 4, Romania|Novartis Investigative Site, Oradea, Jud Bihor, Romania|Novartis Investigative Site, Cluj Napoca, Jud Cluj, Romania|Novartis Investigative Site, Iasi, Jud Iasi, Romania|Novartis Investigative Site, Targu Mures, Mures, Romania|Novartis Investigative Site, Braila, ROM, Romania|Novartis Investigative Site, Suceava, ROM, Romania|Novartis Investigative Site, Timisoara, Timis, Romania|Novartis Investigative Site, Arad, Romania|Novartis Investigative Site, Baia Mare, Romania|Novartis Investigative Site, Brasov, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Craiova, Romania|Novartis Investigative Site, Sibiu, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Krasnodar, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Murmansk, Russian Federation|Novartis Investigative Site, N.Novgorod, Russian Federation|Novartis Investigative Site, Nizhnii Novgorod, Russian Federation|Novartis Investigative Site, Rostov on Don, Russian Federation|Novartis Investigative Site, S.-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, Sochy, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Tomsk, Russian Federation|Novartis Investigative Site, Yekaterinburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovak Republic, Slovakia|Novartis Investigative Site, Liptovsky Mikulas, Slovak Republic, Slovakia|Novartis Investigative Site, Nitra, Slovak Republic, Slovakia|Novartis Investigative Site, Rimavska Sobota, Slovak Republic, Slovakia|Novartis Investigative Site, Banska Bystrica, SVK, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Trnava, Slovakia|Novartis Investigative Site, Pinelands, Cape Town, South Africa|Novartis Investigative Site, Bloemfontein, Free State, South Africa|Novartis Investigative Site, Cape Town, Western Cape, South Africa|Novartis Investigative Site, George, Western Cape, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Western Cape, South Africa|Novartis Investigative Site, Worcester, South Africa|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Badalona, Barcelona, Spain|Novartis Investigative Site, Villamartin, Cadiz, Spain|Novartis Investigative Site, Leon, Castilla Y Leon, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, El Palmar (Murcia), Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Stockholm, SE, Sweden|Novartis Investigative Site, Falun, Sweden|Novartis Investigative Site, Goethenburg, Sweden|Novartis Investigative Site, Helsingborg, Sweden|Novartis Investigative Site, Helsingborg, Sweden|Novartis Investigative Site, Malmo, Sweden|Novartis Investigative Site, Malmo, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Vasteras, Sweden|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Lugano, Switzerland|Novartis Investigative Site, Luzern 16, Switzerland|Novartis Investigative Site, St Gallen, Switzerland|Novartis Investigative Site, New Taipei, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Yilan, Taiwan|Novartis Investigative Site, Bangkok, THA, Thailand|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Eskisehir, Meselik, Turkey|Novartis Investigative Site, Ankara-Cankaya, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Kucukcekmece/Istanbul, Turkey|Novartis Investigative Site, Mersin, Turkey|Novartis Investigative Site, Sivas, Turkey|Novartis Investigative Site, Trabzon, Turkey|Novartis Investigative Site, Basingstoke, Hampshire, United Kingdom|Novartis Investigative Site, Blackburn, Lancashire, United Kingdom|Novartis Investigative Site, Lincoln, Lincolnshire, United Kingdom|Novartis Investigative Site, Craigavon, Northern Ireland, United Kingdom|Novartis Investigative Site, Paisley, Renfrewshire, United Kingdom|Novartis Investigative Site, Sunderland, Tyne And Wear, United Kingdom|Novartis Investigative Site, Clydebank, West Dumbartonshire, United Kingdom|Novartis Investigative Site, Belfast, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, Middlesborough, United Kingdom|Novartis Investigative Site, Middlesex, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom|Novartis Investigative Site, Norwich, United Kingdom|Novartis Investigative Site, Worcester, United Kingdom",5403856.0,A61K38/556,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,HEART FAILURE WITH REDUCED EJECTION FRACTION,_BISOPROLOL,NCT03644446,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Alexandre Joachim, Caen, Basse Normandie, France",4258062,C07D303/24,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,21.8156430316844,141.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.3,325.443,59.95,5.0,2.0,1.0,38.5,92.15,12.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,PERIPHERAL ARTERY DISEASE,_TELMISARTAN,NCT02593110,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Northwestern University, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States",5591762,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,8.0,19.252962073143106,181.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.66,514.6169,72.94,4.0,1.0,6.0,58.61,164.49,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,ESSENTIAL HYPERTENSION,_IRBESARTAN,NCT04488978,Phase 2,Recruiting,All,"19 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of",5270317,C07D231/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,24.805437483315806,334.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,428.5294,87.13,5.0,1.0,5.0,47.59,136.72,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,BLOOD COAGULATION DISORDER,_DEXMEDETOMIDINE,NCT04269278,,Recruiting,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,Observational Model: Case-Control|Time Perspective: Cross-Sectional,"Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",5344840,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0
N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1,ORTHOSTATIC HYPOTENSION,_DROXIDOPA,NCT01370512,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mayo Clinic in Rochester, Rochester, Minnesota, United States",WO-2005085178-A1,C07C229/36,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.4,213.18900000000002,124.01,6.0,5.0,1.0,19.85,50.29,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(C)C(=O)Oc1ccc[n+](C)c1,ORTHOSTATIC HYPOTENSION,_PYRIDOSTIGMINE,NCT01370512,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mayo Clinic in Rochester, Rochester, Minnesota, United States",3931205,C07D491/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,29.635105443643603,905.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.1,181.2117,33.42,1.0,0.0,1.0,19.38,49.66,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-],ORTHOSTATIC HYPOTENSION,_PYRIDOSTIGMINE_BROMIDE,NCT01370512,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mayo Clinic in Rochester, Rochester, Minnesota, United States",5298504,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,22.505595597445502,96.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,HEART FAILURE WITH PRESERVED EJECTION FRACTION,_DAPAGLIFLOZIN,NCT03619213,Phase 3,Recruiting,All,"40 Years to 130 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Fairhope, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Sheffield, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Beverly Hills, California, United States|Research Site, Loma Linda, California, United States|Research Site, Los Angeles, California, United States|Research Site, Stamford, Connecticut, United States|Research Site, Clearwater, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Augustine, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Gurnee, Illinois, United States|Research Site, Munster, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Hammond, Louisiana, United States|Research Site, Houma, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Bay City, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Rochester, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Morganton, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Beaumont, Texas, United States|Research Site, Humble, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sherman, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Falls Church, Virginia, United States|Research Site, Leesburg, Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Catamarca, Argentina|Research Site, Ciudad Autonoma de Buenos Aire, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Rosario, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Nicolás, Argentina|Research Site, Santa Fe, Argentina|Research Site, Aalst, Belgium|Research Site, Brasschaat, Belgium|Research Site, Bruxelles, Belgium|Research Site, Huy, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Blumenau, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Campinas, Brazil|Research Site, Curitiba, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo Andre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Votuporanga, Brazil|Research Site, Dimitrovgrad, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Winnipeg, Manitoba, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Port Perry, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Stoney Creek, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, York, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saint-Jerome, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Baotou, China|Research Site, Beijing, China|Research Site, Cangzhou, China|Research Site, Changchun, China|Research Site, Changchun, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Haerbin, China|Research Site, Jinan, China|Research Site, Nanchang, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Yinchuan, China|Research Site, Zhuhai, China|Research Site, Benesov, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Ceske Budejovice, Czechia|Research Site, Jaromer, Czechia|Research Site, Kladno, Czechia|Research Site, Louny, Czechia|Research Site, Nachod, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Pardubice, Czechia|Research Site, Prachatice, Czechia|Research Site, Praha 2, Czechia|Research Site, Bayonne, France|Research Site, Dijon, France|Research Site, La Tronche, France|Research Site, Lille, France|Research Site, Marseille Cedex 20, France|Research Site, Montpellier, France|Research Site, Paris, France|Research Site, Rennes Cedex 9, France|Research Site, Saint Brieuc, France|Research Site, Toulon, France|Research Site, Toulouse Cedex 9, France|Research Site, TOURCOING cedex, France|Research Site, Valenciennes, France|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Győr, Hungary|Research Site, Kecskemét, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Szekszárd, Hungary|Research Site, Szentes, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Adachi-ku, Japan|Research Site, Asahi-shi, Japan|Research Site, Azumino-shi, Japan|Research Site, Beppu-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hamada-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Higashiohmi-shi, Japan|Research Site, Ichinomiya-shi, Japan|Research Site, Iizuka-shi, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kasugai-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Kuki-shi, Japan|Research Site, Kure-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Mito-shi, Japan|Research Site, Miura-gun, Japan|Research Site, Nakagami-gun, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Takasago-shi, Japan|Research Site, Toride-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Tsuchiura-shi, Japan|Research Site, Ueda-shi, Japan|Research Site, Ureshino-shi, Japan|Research Site, Utsunomiya-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Aguascalientes, Mexico|Research Site, Culiacán, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mazatlán, Mexico|Research Site, Mexico, Mexico|Research Site, Monclova, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, Querétaro, Mexico|Research Site, Tijuana, Mexico|Research Site, Veracruz, Mexico|Research Site, Veracruz, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Groningen, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Leiderdorp, Netherlands|Research Site, Meppel, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Uden, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Bellavista, Peru|Research Site, Callao, Peru|Research Site, Chancay, Peru|Research Site, Chorrillos, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Urb. El Chipe, Peru|Research Site, Białystok, Poland|Research Site, Bochnia, Poland|Research Site, Chojnice, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Jasło, Poland|Research Site, Katowice, Poland|Research Site, Lublin, Poland|Research Site, Opole, Poland|Research Site, Oława, Poland|Research Site, Płock, Poland|Research Site, Rzeszów, Poland|Research Site, Torun, Poland|Research Site, Wierzchosławice, Poland|Research Site, Wroclaw, Poland|Research Site, Łódź, Poland|Research Site, Brasov, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Sibiu, Romania|Research Site, Targu Mures, Romania|Research Site, Tg Mures, Romania|Research Site, Chelyabinsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Dammam, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, A Coruña, Spain|Research Site, Barcelona, Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Sanlúcar De Barrameda (Cádiz), Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Villamartín (Cádiz), Spain|Research Site, Hsinchu, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam",6956026,A61K47/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,"HEART FAILURE, DIASTOLIC",_DAPAGLIFLOZIN,NCT04475042,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OLVG, Amsterdam, Noord-Holland, Netherlands",6956026,A61K47/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,ACUTE ISCHEMIC STROKE,_EXENATIDE,NCT03287076,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|St John of God Midland Public & Private Hospital, Midland, Western Australia, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Helsinki University Hospital, Helsinki, Finland|CDHB Christchurch Hospital, Christchurch, New Zealand",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,ISCHAEMIC STROKE,_APIXABAN,NCT03148457,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medizinische Universität Graz, Graz, Austria|Kepler Universitätsklinikum, Klinik für Neurologie 2, Linz, Austria|Universitätsklinikum St. Pölten, St.Pölten, Austria|Universitätsklinikum Tulln, Tulln, Austria|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Antwerp University Hospital, Edegem, Belgium|University Hospital Gent, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHC - Saint Joseph, Liège, Belgium|Cliniques de l'Europe - Site Ste-Elisabeth, Uccle, Belgium|Helsinki University Hospital, Helsinki, Finland|Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany|St. Josef-Hospital Bochum, Bochum, Germany|Klinik und Poliklinik für Neurologie Köln, Cologne, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Neurologische Universitätsklinik Heidelberg, Heidelberg, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Germany|Dept. of Medicine, University of Thessaly, Larissa, Thessaly, Greece|Mater Misericordiae University Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|Shaare Zedek Medical Center, Jerusalem, Israel|National Cerebral and Cardiovascular Center, Osaka, Japan|Oslo University Hospital, Ullevål, Oslo, Norway|Dept. of Neurology, Kantonsspital Aarau, Aarau, Aargau, Switzerland|Dept. of Neurology, Universitätsspital Basel, Basel, Basel Stadt, Switzerland|Dept. of Neurology, Kantonsspital Chur, Chur, Graubünden, Switzerland|Dept. of Neurology, Universitätsspital Lausanne, Lausanne, Waadt, Switzerland|Dept. of Neurology, Hôpital de Zone de Nyon, Nyon, Waadt, Switzerland|Dept. of Neurology, Kantonsspital Sion, Sion, Wallis, Switzerland|Dept. of Neurology, Bern University Hospital, Bern, Switzerland|Dept. of Neurology, Kantonsspital Fribourg, Fribourg, Switzerland|Dept. of Neurology, Universitätsspital Genf, Geneve, Switzerland|Ospedale Regionale di Lugano (EOC), Lugano, Switzerland|Dept. of Neurology, Kantonsspital Luzern, Luzern, Switzerland|Kantonsspital Münsterlingen, Münsterlingen, Switzerland|Hôpital neuchâtelois, Neuchâtel, Switzerland|Dept. of Neurology, Kantonsspital St.Gallen, St.Gallen, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Dept. of Neurology, Universitätsspital Zürich, Zurich, Switzerland|St George's University Hospitals NHS Foundation Trust, Tooting, London, United Kingdom|University Hospital Monklands, Airdrie, United Kingdom|Royal United Hospitals Bath, Bath, United Kingdom|Southmead Hospital Bristol, Bristol, United Kingdom|Countess of Chester Hospital, Chester, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Morriston Hospital, Morriston, United Kingdom|Perth Royal Infirmary, Perth, United Kingdom|Glan Clwyd Hospital, Rhyl, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom|Weston General Hospital, Weston-super-Mare, United Kingdom|Wirral University Teaching Hospital, Wirral, United Kingdom",6413980,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,ISCHAEMIC STROKE,_RIVAROXABAN,NCT03148457,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medizinische Universität Graz, Graz, Austria|Kepler Universitätsklinikum, Klinik für Neurologie 2, Linz, Austria|Universitätsklinikum St. Pölten, St.Pölten, Austria|Universitätsklinikum Tulln, Tulln, Austria|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Antwerp University Hospital, Edegem, Belgium|University Hospital Gent, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHC - Saint Joseph, Liège, Belgium|Cliniques de l'Europe - Site Ste-Elisabeth, Uccle, Belgium|Helsinki University Hospital, Helsinki, Finland|Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany|St. Josef-Hospital Bochum, Bochum, Germany|Klinik und Poliklinik für Neurologie Köln, Cologne, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Neurologische Universitätsklinik Heidelberg, Heidelberg, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Germany|Dept. of Medicine, University of Thessaly, Larissa, Thessaly, Greece|Mater Misericordiae University Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|Shaare Zedek Medical Center, Jerusalem, Israel|National Cerebral and Cardiovascular Center, Osaka, Japan|Oslo University Hospital, Ullevål, Oslo, Norway|Dept. of Neurology, Kantonsspital Aarau, Aarau, Aargau, Switzerland|Dept. of Neurology, Universitätsspital Basel, Basel, Basel Stadt, Switzerland|Dept. of Neurology, Kantonsspital Chur, Chur, Graubünden, Switzerland|Dept. of Neurology, Universitätsspital Lausanne, Lausanne, Waadt, Switzerland|Dept. of Neurology, Hôpital de Zone de Nyon, Nyon, Waadt, Switzerland|Dept. of Neurology, Kantonsspital Sion, Sion, Wallis, Switzerland|Dept. of Neurology, Bern University Hospital, Bern, Switzerland|Dept. of Neurology, Kantonsspital Fribourg, Fribourg, Switzerland|Dept. of Neurology, Universitätsspital Genf, Geneve, Switzerland|Ospedale Regionale di Lugano (EOC), Lugano, Switzerland|Dept. of Neurology, Kantonsspital Luzern, Luzern, Switzerland|Kantonsspital Münsterlingen, Münsterlingen, Switzerland|Hôpital neuchâtelois, Neuchâtel, Switzerland|Dept. of Neurology, Kantonsspital St.Gallen, St.Gallen, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Dept. of Neurology, Universitätsspital Zürich, Zurich, Switzerland|St George's University Hospitals NHS Foundation Trust, Tooting, London, United Kingdom|University Hospital Monklands, Airdrie, United Kingdom|Royal United Hospitals Bath, Bath, United Kingdom|Southmead Hospital Bristol, Bristol, United Kingdom|Countess of Chester Hospital, Chester, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Morriston Hospital, Morriston, United Kingdom|Perth Royal Infirmary, Perth, United Kingdom|Glan Clwyd Hospital, Rhyl, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom|Weston General Hospital, Weston-super-Mare, United Kingdom|Wirral University Teaching Hospital, Wirral, United Kingdom",7157456,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,ISCHAEMIC STROKE,_EDOXABAN,NCT03148457,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medizinische Universität Graz, Graz, Austria|Kepler Universitätsklinikum, Klinik für Neurologie 2, Linz, Austria|Universitätsklinikum St. Pölten, St.Pölten, Austria|Universitätsklinikum Tulln, Tulln, Austria|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Antwerp University Hospital, Edegem, Belgium|University Hospital Gent, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHC - Saint Joseph, Liège, Belgium|Cliniques de l'Europe - Site Ste-Elisabeth, Uccle, Belgium|Helsinki University Hospital, Helsinki, Finland|Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany|St. Josef-Hospital Bochum, Bochum, Germany|Klinik und Poliklinik für Neurologie Köln, Cologne, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Neurologische Universitätsklinik Heidelberg, Heidelberg, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Germany|Dept. of Medicine, University of Thessaly, Larissa, Thessaly, Greece|Mater Misericordiae University Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|Shaare Zedek Medical Center, Jerusalem, Israel|National Cerebral and Cardiovascular Center, Osaka, Japan|Oslo University Hospital, Ullevål, Oslo, Norway|Dept. of Neurology, Kantonsspital Aarau, Aarau, Aargau, Switzerland|Dept. of Neurology, Universitätsspital Basel, Basel, Basel Stadt, Switzerland|Dept. of Neurology, Kantonsspital Chur, Chur, Graubünden, Switzerland|Dept. of Neurology, Universitätsspital Lausanne, Lausanne, Waadt, Switzerland|Dept. of Neurology, Hôpital de Zone de Nyon, Nyon, Waadt, Switzerland|Dept. of Neurology, Kantonsspital Sion, Sion, Wallis, Switzerland|Dept. of Neurology, Bern University Hospital, Bern, Switzerland|Dept. of Neurology, Kantonsspital Fribourg, Fribourg, Switzerland|Dept. of Neurology, Universitätsspital Genf, Geneve, Switzerland|Ospedale Regionale di Lugano (EOC), Lugano, Switzerland|Dept. of Neurology, Kantonsspital Luzern, Luzern, Switzerland|Kantonsspital Münsterlingen, Münsterlingen, Switzerland|Hôpital neuchâtelois, Neuchâtel, Switzerland|Dept. of Neurology, Kantonsspital St.Gallen, St.Gallen, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Dept. of Neurology, Universitätsspital Zürich, Zurich, Switzerland|St George's University Hospitals NHS Foundation Trust, Tooting, London, United Kingdom|University Hospital Monklands, Airdrie, United Kingdom|Royal United Hospitals Bath, Bath, United Kingdom|Southmead Hospital Bristol, Bristol, United Kingdom|Countess of Chester Hospital, Chester, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Morriston Hospital, Morriston, United Kingdom|Perth Royal Infirmary, Perth, United Kingdom|Glan Clwyd Hospital, Rhyl, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom|Weston General Hospital, Weston-super-Mare, United Kingdom|Wirral University Teaching Hospital, Wirral, United Kingdom",7365205,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,73.33210127518021,31.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.61,548.06,136.63,7.0,3.0,4.0,56.31,140.14,6.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,ISCHAEMIC STROKE,_DABIGATRAN,NCT03148457,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medizinische Universität Graz, Graz, Austria|Kepler Universitätsklinikum, Klinik für Neurologie 2, Linz, Austria|Universitätsklinikum St. Pölten, St.Pölten, Austria|Universitätsklinikum Tulln, Tulln, Austria|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Antwerp University Hospital, Edegem, Belgium|University Hospital Gent, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHC - Saint Joseph, Liège, Belgium|Cliniques de l'Europe - Site Ste-Elisabeth, Uccle, Belgium|Helsinki University Hospital, Helsinki, Finland|Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany|St. Josef-Hospital Bochum, Bochum, Germany|Klinik und Poliklinik für Neurologie Köln, Cologne, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Neurologische Universitätsklinik Heidelberg, Heidelberg, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Germany|Dept. of Medicine, University of Thessaly, Larissa, Thessaly, Greece|Mater Misericordiae University Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|Shaare Zedek Medical Center, Jerusalem, Israel|National Cerebral and Cardiovascular Center, Osaka, Japan|Oslo University Hospital, Ullevål, Oslo, Norway|Dept. of Neurology, Kantonsspital Aarau, Aarau, Aargau, Switzerland|Dept. of Neurology, Universitätsspital Basel, Basel, Basel Stadt, Switzerland|Dept. of Neurology, Kantonsspital Chur, Chur, Graubünden, Switzerland|Dept. of Neurology, Universitätsspital Lausanne, Lausanne, Waadt, Switzerland|Dept. of Neurology, Hôpital de Zone de Nyon, Nyon, Waadt, Switzerland|Dept. of Neurology, Kantonsspital Sion, Sion, Wallis, Switzerland|Dept. of Neurology, Bern University Hospital, Bern, Switzerland|Dept. of Neurology, Kantonsspital Fribourg, Fribourg, Switzerland|Dept. of Neurology, Universitätsspital Genf, Geneve, Switzerland|Ospedale Regionale di Lugano (EOC), Lugano, Switzerland|Dept. of Neurology, Kantonsspital Luzern, Luzern, Switzerland|Kantonsspital Münsterlingen, Münsterlingen, Switzerland|Hôpital neuchâtelois, Neuchâtel, Switzerland|Dept. of Neurology, Kantonsspital St.Gallen, St.Gallen, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Dept. of Neurology, Universitätsspital Zürich, Zurich, Switzerland|St George's University Hospitals NHS Foundation Trust, Tooting, London, United Kingdom|University Hospital Monklands, Airdrie, United Kingdom|Royal United Hospitals Bath, Bath, United Kingdom|Southmead Hospital Bristol, Bristol, United Kingdom|Countess of Chester Hospital, Chester, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Morriston Hospital, Morriston, United Kingdom|Perth Royal Infirmary, Perth, United Kingdom|Glan Clwyd Hospital, Rhyl, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom|Weston General Hospital, Weston-super-Mare, United Kingdom|Wirral University Teaching Hospital, Wirral, United Kingdom",6087380,C07D277/64,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,28.715168689295396,108.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.37,471.52099999999996,150.22,8.0,4.0,4.0,50.96,143.26,9.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,THROMBOSIS,_APIXABAN,NCT02981472,Phase 2,Recruiting,All,up to 17 Years   (Child),Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children'S Hospital, Phoenix, Arizona, United States|University Of California San Diego, La Jolla, California, United States|Children'S Hospital Colorado, Aurora, Colorado, United States|Local Institution, Wilmington, Delaware, United States|Childrens Healthcare Of Atlanta, Atlanta, Georgia, United States|Riley Hospital For Children, Indianapolis, Indiana, United States|Boston Childrens Hospital, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|Childrens Mercy Hospital, Kansas City, Missouri, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Texas Children'S Hospital, Houston, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Seattle Childrens Hospital, Seattle, Washington, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Westmead, New South Wales, Australia|Local Institution, Parkville, Victoria, Australia|Medical University Of Vienna, Vienna, Austria|Local Institution, Brasilia, Distrito Federal, Brazil|Hospital Pequeno Principe, Curitiba, Parana, Brazil|Local Institution, Passo Fundo, Rio Grande Do Sul, Brazil|Instituto De Cardiologia Do Rio Grande Do Sul, Porto Alegre, RIO Grande DO SUL, Brazil|Instituto de Pesquisa Clinica de Campinas, Campinas, SAO Paulo, Brazil|Instituto de Pesquisa PENSI, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Universidade Federal De Sao Paulo, Sao Paulo, Brazil|Local Institution, Toronto, Ontario, Canada|Local Institution, Helsinki, Finland|Local Institution, Marseille, France|Local Institution, Montpellier, France|Local Institution, Paris, France|Local Institution, Pessac, France|Universitatsklinikum Freiburg Kinderklinik, Freiburg, Germany|Uni Hamburg-Eppendorf, Hamburg, Germany|Deutsches Herzzentrum Munchen Des Freistaates Bayern, Muenchen, Germany|Local Institution, Petach Tikva, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Bologna, Italy|Policlinico San Donato, Milano, Italy|Ospedale Bambino Gesu', Roma, Italy|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Morales Vargas Centro de Investigacion, S.C., Leon, Guanajuato, Mexico|Local Institution, Ekaterinburg, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Kemerovo, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Leicester, Leicestershire, United Kingdom|Local Institution, Bristol, Somerset, United Kingdom|Local Institution, Manchester, United Kingdom",6413980,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,0.0,0.0,1.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
[Cl-].[Na+],HEART FAILURE WITH PRESERVED EJECTION FRACTION,_SODIUM_CHLORIDE,NCT03837470,Early Phase 1,Recruiting,All,"21 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Utah, Salt Lake City, Utah, United States",6248726,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,HEART FAILURE WITH PRESERVED EJECTION FRACTION,_FUROSEMIDE,NCT03837470,Early Phase 1,Recruiting,All,"21 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Utah, Salt Lake City, Utah, United States",3939713,G01N30/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,11.8606131542742,1299.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,330.744,122.63,5.0,3.0,2.0,30.55,77.47,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1,"HYPERTROPHY, LEFT VENTRICULAR",_MIRABEGRON,NCT02599480,Phase 2,Enrolling by invitation,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cliniques universitaires Saint-Luc, Brussels, Belgium|Nantes university hospital (CHU Nantes), Nantes, France|Center for Cardiovascular Research Berlin (CCR/Charité), Berlin, Germany|University Medical Center Göttingen (UMG-GOE), Göttingen, Germany|Athens University Medical School (NKUA), Athens, Greece|Hospital ""Papa Giovanni XXIII"" (HPG23), Bergamo, Italy|Department of Heart Diseases at Wroclaw Medical University (UMW), Wroclaw, Poland|Association for Research and Development of the Faculty of Medicine (AIDFM), Lisbon, Portugal|University of Oxford - Division of Cardiovascular Medicine (UOXF), Oxford, United Kingdom",6346532,C07D233/26,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,22.2099016406907,16.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.2,396.506,100.27,5.0,4.0,3.0,44.2,113.23,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,NON-VALVULAR ATRIAL FIBRILLATION,_RIVAROXABAN,NCT04174859,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Observational Model: Cohort|Time Perspective: Prospective,"Many locations, Multiple Locations, Italy",7157456,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,DEEP VEIN THROMBOSIS,_RIVAROXABAN,NCT02722447,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ospedale di Faenza, Faenza, Italy|Ospedale di Padova, Padua, Italy|Ospedale di Pieve di Soligo, Pieve di Soligo, Italy|Ospedale di Reggio Emilia, Reggio Emilia, Italy|University of Siena, Siena, Italy|Ospedale di Circolo, Varese, Italy|University Of Insubria, Varese, Italy",7157456,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1,HEART FAILURE|CARDIOMYOPATHY,_MILRINONE,NCT02077010,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Kansas Medical Center, Kansas City, Kansas, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",4313951.0,C07D213/75,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,15.4417955194151,576.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.04,211.2194,65.78,3.0,1.0,2.0,21.46,61.14,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,ATRIAL FIBRILLATION|STROKE,_COLCHICINE,NCT02282098,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hamilton General Hospital, Hamilton, Ontario, Canada",7619004,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,ESSENTIAL HYPERTENSION,_COLCHICINE,NCT04303689,Not Applicable,Recruiting,Male,"40 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,"Department of Nutrition, Exercise and Sports, UCopenhagen, Copenhagen, Denmark",7619004,1,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,HEART FAILURE WITH PRESERVED EJECTION FRACTION,_SPIRONOLACTONE,NCT02901184,Phase 3,Recruiting,All,"50 Years to 99 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Advanced Cardiovascular LLC, Alexander City, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner - University Medical Group, Tucson, Arizona, United States|MedStar Cardiovascular Research Network, Washington, District of Columbia, United States|Howard University Hospital, Washington, District of Columbia, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Wellstar Health System, Inc., Marietta, Georgia, United States|Queens Medical Center, Honolulu, Hawaii, United States|Fox Valley Clinical Research Center, LLC, Aurora, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|St. Vincent Medical Group, Indianapolis, Indiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Shady Grove Adventist Hospital, Rockville, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Pentucket Medical Associates, Haverhill, Massachusetts, United States|Charles River Medical Associates, Natick, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Ascension Genesys Hospital, Grand Blanc, Michigan, United States|The Heart House Haddon Heights, Haddon Heights, New Jersey, United States|Rutgers University - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, United States|University at Buffalo, Buffalo, New York, United States|Northwell Health - Manhasset, Manhasset, New York, United States|Mount Sinai Medical Cente, New York, New York, United States|Mid Carolina Cardiology Research, Charlotte, North Carolina, United States|Duke University, Durham, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Stern Cardiovascular Center, Germantown, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Miami Hospital, Miami, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Angereds närsjukhus, Angered, Sweden|Avesta lasarett, Avesta, Sweden|Falu lasarett, Falun, Sweden|Närsjukvården i Finspång, Finspång, Sweden|Vårdcentralen Centrum i Flen, Flen, Sweden|Sahgrenska University Hospital Östra, Göteborg, Sweden|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Hemse Vårdcentral, Hemse, Sweden|Karolinska University Hospital, Huddinge, Sweden|Öbackakliniken, Härnösand, Sweden|Länssjukhuset Ryhov, Jönköping, Sweden|Blekingesjukhuset, Karlskrona, Sweden|Hjärtmottagningen, Centralsjukhuset, Karlstad, Sweden|Centralsjukhuset Kristianstad, Kristianstad, Sweden|Västmanlands sjukhus Köping, Köping, Sweden|Lasarettet i Landskrona, Landskrona, Sweden|Skaraborgs sjukhus i Lidköping, Lidköping, Sweden|Linköpings Universitetssjukhus, Linköping, Sweden|VO Akut- och internmedicin, Skånes Universitetssjukhus, Lund, Sweden|Capio Citykliniken, Lund, Sweden|FO Kranskärl/Svikt, Skånes Universitetssjukhus, Lund, Sweden|Hjärtavdelningen, Skånes Universitetssjukhus, Malmö, Sweden|Kliniska forskningsenheten Skånes Universitetssjukhus, Malmö, Sweden|Mariefreds Vårdcentral, Mariefred, Sweden|Sahgrenska University Hospital Mölndal, Mölndal, Sweden|Kardiologikliniken, Vrinnevisjukhuset, Norrköping, Sweden|Skellefteå lasarett, Skellefteå, Sweden|Karolinska University Hospital, Solna, Sweden|VO Kardiologi, Södersjukhuset AB, Stockholm, Sweden|Capio S:t Görans sjukhus AB, Stockholm, Sweden|Danderyds sjukhus AB, Stockholm, Sweden|Stockholm Heart Center, Stockholm, Sweden|Länssjukhuset Sundsvall-Härnösand, Sundsvall, Sweden|Sundsvalls Vårdcentral, Sundsvall, Sweden|Södertälje sjukhus, Södertälje, Sweden|Norrlands Universitetssjukhus, Umeå, Sweden|Uppsala University Hospital, Cardiology dept, Uppsala, Sweden|Uppsala University Hospital, Internal Medicine dept, Uppsala, Sweden|Medicinkliniken, Hallands sjukhus, Varberg, Sweden|Västerviks sjukhus, Västervik, Sweden|Västmanlands sjukhus Västerås, Västerås, Sweden|Hälsostaden Ängelholms sjukhus, Ängelholm, Sweden|Örebro University Hospital, Örebro, Sweden",9757394.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Oc1ncnc2[nH]ncc12,HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF),_ALLOPURINOL,NCT04327024,Phase 2,Recruiting,All,"40 Years to 130 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Torrance, California, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario, Argentina|Research Site, Bedford Park, Australia|Research Site, Chermside, Australia|Research Site, Geelong, Australia|Research Site, Milton, Australia|Research Site, New Lambton Heights, Australia|Research Site, Graz, Austria|Research Site, Wien, Austria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Bad Oeynhausen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Goettingen, Germany|Research Site, Regensburg, Germany|Research Site, Würzburg, Germany|Research Site, Cheongju-si, Korea, Republic of|Research Site, Gangwon-do, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Bydgoszcz, Poland|Research Site, Chojnice, Poland|Research Site, Warszawa, Poland|Research Site, Aramil, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Brezno, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Presov, Slovakia|Research Site, Svidnik, Slovakia",8084483.0,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,ACUTE ISCHEMIC STROKE,_ARGATROBAN,NCT03735979,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama Hospital, Birmingham, Alabama, United States|Community Regional Medical Center of Fresno, Fresno, California, United States|UCSD Health La Jolla, La Jolla, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCSD Medical Center - Hillcrest Hospital, San Diego, California, United States|San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Harbor UCLA Medical Center, Torrance, California, United States|Swedish Medical Center, Englewood, Colorado, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|UF Health Shands Hospital, Gainesville, Florida, United States|Mayo Clinic Hospital, Jacksonville, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Central DuPage Hospital, Winfield, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Kansas Hospital, Kansas City, Kansas, United States|St. Elizabeth Medical Center South, Edgewood, Kentucky, United States|St. Elizabeth Hospital, Florence, Kentucky, United States|St. Elizabeth Hospital Fort Thomas, Fort Thomas, Kentucky, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|UMASS Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|McLaren Flint, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|University of Minnesota Medical Center Hospital, Minneapolis, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Hospital, Kansas City, Missouri, United States|St. Louis University Hospital, Saint Louis, Missouri, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|North Shore University Hospital, Manhasset, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|The Mount Sinai Hospital, New York, New York, United States|NYP Columbia University Medical Center, New York, New York, United States|NYP Weill Cornell Medical Center, New York, New York, United States|SUNY Upstate University Hospital, Syracuse, New York, United States|Forsyth Medical Center, Winston-Salem, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Akron General Medical Center, Akron, Ohio, United States|Mercy Health West Hospital, Cincinnati, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|The Jewish Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|Mercy Hospital Anderson, Cincinnati, Ohio, United States|OSU Wexner Medical Center, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|St. John Medical Center, Tulsa, Oklahoma, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|St. Luke's University Hospital, Bethlehem, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC Mercy Hospital, Pittsburgh, Pennsylvania, United States|WellSpan York Hospital, York, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Greenville Hospital System, Greenville, South Carolina, United States|Vanderbilt University Hospital, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|DHR Health, Edinburg, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Memorial Hermann-Texas Medical Center, Houston, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|UVA Medical Center, Charlottesville, Virginia, United States|WVU Healthcare Ruby Memorial Hospital, Morgantown, West Virginia, United States|University of Wisconsin University Hospital, Madison, Wisconsin, United States",5214052.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,4.0,14.390439228731502,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.04,508.64,177.71,9.0,6.0,3.0,53.77,143.83,8.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0
N=C(N)NCCCC[C@@H]1NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O,ACUTE ISCHEMIC STROKE,_EPTIFIBATIDE,NCT03735979,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama Hospital, Birmingham, Alabama, United States|Community Regional Medical Center of Fresno, Fresno, California, United States|UCSD Health La Jolla, La Jolla, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCSD Medical Center - Hillcrest Hospital, San Diego, California, United States|San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Harbor UCLA Medical Center, Torrance, California, United States|Swedish Medical Center, Englewood, Colorado, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|UF Health Shands Hospital, Gainesville, Florida, United States|Mayo Clinic Hospital, Jacksonville, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Central DuPage Hospital, Winfield, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Kansas Hospital, Kansas City, Kansas, United States|St. Elizabeth Medical Center South, Edgewood, Kentucky, United States|St. Elizabeth Hospital, Florence, Kentucky, United States|St. Elizabeth Hospital Fort Thomas, Fort Thomas, Kentucky, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|UMASS Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|McLaren Flint, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|University of Minnesota Medical Center Hospital, Minneapolis, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Hospital, Kansas City, Missouri, United States|St. Louis University Hospital, Saint Louis, Missouri, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|North Shore University Hospital, Manhasset, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|The Mount Sinai Hospital, New York, New York, United States|NYP Columbia University Medical Center, New York, New York, United States|NYP Weill Cornell Medical Center, New York, New York, United States|SUNY Upstate University Hospital, Syracuse, New York, United States|Forsyth Medical Center, Winston-Salem, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Akron General Medical Center, Akron, Ohio, United States|Mercy Health West Hospital, Cincinnati, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|The Jewish Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|Mercy Hospital Anderson, Cincinnati, Ohio, United States|OSU Wexner Medical Center, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|St. John Medical Center, Tulsa, Oklahoma, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|St. Luke's University Hospital, Bethlehem, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC Mercy Hospital, Pittsburgh, Pennsylvania, United States|WellSpan York Hospital, York, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Greenville Hospital System, Greenville, South Carolina, United States|Vanderbilt University Hospital, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|DHR Health, Edinburg, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Memorial Hermann-Texas Medical Center, Houston, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|UVA Medical Center, Charlottesville, Virginia, United States|WVU Healthcare Ruby Memorial Hospital, Morgantown, West Virginia, United States|University of Wisconsin University Hospital, Madison, Wisconsin, United States",WO-1999046283-A1,A61K47/64,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,51.0,32.7488,269.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0
FCOC(C(F)(F)F)C(F)(F)F,HEART DISEASE,_SEVOFLURANE,NCT03569085,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States",5990176,0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
FC(F)OC(Cl)C(F)(F)F,HEART DISEASE,_ISOFLURANE,NCT03569085,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.3,184.49200000000002,9.23,1.0,0.0,0.0,9.73,23.04,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
NC[C@H]1CC[C@H](C(=O)O)CC1,"HEMATOMA, SUBDURAL, CHRONIC",_TRANEXAMIC_ACID,NCT03582293,Phase 3,Recruiting,All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Academic Medical Center, Amsterdam, Netherlands",8273795.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,ACUTE MYOCARDIAL INFARCTION,_EMPAGLIFLOZIN,NCT03087773,Phase 3,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Barmherzige Brüder Eisenstadt, Eisenstadt, Burgenland, Austria|Klinikum Klagenfurt am Wörthersee, Klagenfurt, Kärnten, Austria|Universitätsklinikum St. Pölten, St.Pölten, Niederösterreich, Austria|Barmherzige Brüder Linz, Linz, Oberösterreich, Austria|Kepler Universitätsklinikum Linz, Linz, Oberösterreich, Austria|Kardinal schwarzenberg Klinikum Schwarzach, Schwarzach Im Pongau, Salzburg, Austria|VIVIT Institut am akademischen Lehrkrankenhaus Feldkirch, Feldkirch, Vorarlberg, Austria|Landeskrankenhaus Graz II Standort West, Graz, Austria|Medical University of Graz, Graz, Austria|Uniklinikum Salzburg, Salzburg, Austria|Krankenanstalt Rudolfstiftung, Vienna, Austria|AKH Vienna, Vienna, Austria",6303661,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O,DIABETIC FOOT ULCER,_TREPROSTINIL,NCT03654989,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CHU Grenoble Alpes, Grenoble, France",5153222.0,3,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,15.770344360253803,26.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.53,390.5131,86.99,5.0,3.0,3.0,45.74,108.0,10.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,ISCHEMIA REPERFUSION INJURY,_ESTROGEN,NCT03663543,Phase 1|Phase 2,Recruiting,Female,"21 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,NON-VALVULAR ATRIAL FIBRILLATION,_EDOXABAN,NCT04519944,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Observational Model: Cohort|Time Perspective: Prospective,"Zentralklinik Bad Berka, Bad Berka, Germany|SLK-Kliniken Heilbronn GmbH Klinikum am Plattenwald, Bad Friedrichshall, Germany|Kerckhoff-Klinik GmbH, Bad Nauheim, Germany|Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany|Schüchtermann-Schiller'sche Kliniken Bad Rothenfelde GmbH & Co. KG, Bad Rothenfelde, Germany|Charité - Campus Benjamin Franklin, Berlin, Germany|Deutsches Herzzentrum Berlin, Berlin, Germany|GFO-Kliniken, Standort St.-Marienhospital Bonn, Bonn, Germany|StädtischesKlinikum Brandenburg, Brandenburg, Germany|Klinikum Braunschweig, Braunschweig, Germany|Klinikum Chemnitz, Chemnitz, Germany|REGIOMED-KLINIKEN GmbH, Klinikum Coburg, Coburg, Germany|Kreiskrankenhaus Demmin GmbH, Demmin, Germany|Klinikum Lippe Detmold, Detmold, Germany|St. Johannes-Hospital Dortmund, Dortmund, Germany|Herzzentrum Dresden GmbH Universitätsklinik an der Technischen Universität Dresden, Dresden, Germany|Universitätsklinikum Essen, Essen, Germany|Klinikum Frankfurt Höchst GmbH, Frankfurt am Main, Germany|CCB Cardioangiologisches Centrum Bethanien, Frankfurt, Germany|Universitäts Herzzentrum Freiburg Bad Krozingen, Freiburg, Germany|Klinikum Fürth, Fürth, Germany|Universitätsklinikum Greifswald, Greifswald, Germany|Klinikum Gütersloh, Gutersloh, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|SLK-Kliniken Heilbronn, Heilbronn, Germany|Klinikum Nordfriesland, Husum, Germany|Universitätsklinikum Jena, Jena, Germany|SRH Klinikum Karlsbad-Langensteinbach GmbH, Karlsbad, Germany|Universitätsklinikum Schleswig-Holstein - Campus Kiel, Kiel, Germany|Gemeinschaftsklinikum Mittelrhein gGmbH, Ev. Stift St. Martin, Koblenz, Germany|Krankenhaus der Augustinerinnen Köln, Köln, Germany|St. Vinzenz-Hospital Köln, Köln, Germany|Universitätsklinikum Köln, Köln, Germany|Evangelisches Krankenhaus Kalk gGmbH, Köln, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany|UKSH Lübeck, Lübeck, Germany|Technische Universität München, Klinikum rechts der Isar, München, Germany|München Klinik gGmbH, Klinik Neuperlach, München, Germany|St. Franziskus-Hospital GmbH, Münster, Germany|Klinikum Oldenburg AöR, Universitätsklinik für Innere Medizin - Kardiologie, Oldenburg, Germany|St. Vincenz Krankenhaus, Paderborn, Germany|Harzklinikum Dorothea Christiane Erxleben GmbH, Quedlinburg, Germany|Universitätsmedizin Rostock, Rostock, Germany|Herz-Kreislauf-Zentrum Rotenburg, Rotenburg An Der Fulda, Germany|Leopoldina, Schweinfurt, Germany|Klinikum Westmünsterland GmbH, Stadtlohn, Germany|Robert-Bosch-Krankenhaus GmbH, Stuttgart, Germany|SRH Zentralklinikum Suhl, Innere Medizin I, Suhl, Germany|Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Universitätsklinikum Ulm, Ulm, Germany|Herzzentrum Saar, Volklingen, Germany|Kliniken Nordoberpfalz AG, Weiden, Germany|GRN-Klinik Weinheim, Weinheim, Germany|Klinikum Wilhelmshaven gGmbH, Wilhelmshaven, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Heinrich-Braun-Klinikum Zwickau, Zwickau, Germany",7365205,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,6.0,73.33210127518021,31.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.61,548.06,136.63,7.0,3.0,4.0,56.31,140.14,6.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,CARDIAC DISEASE,_EDOXABAN,NCT03395639,Phase 3,Recruiting,All,up to 17 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Cardon Childrens Medical Center, Mesa, Arizona, United States|Cedars Sinai Medical Center (ECG), Los Angeles, California, United States|University of California-San Francisco Department of Pediatrics - Hematology/Oncology, San Francisco, California, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Novant Health Heart and Vascular institute, Charlotte, North Carolina, United States|East Carolina Heart Institute @ ECU, Greenville, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|OU Health Sciences Center, Oklahoma City, Oklahoma, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Seattle Children's Research Institute, Seattle, Washington, United States|Kepler Universitätsklinikum Med Campus IV, Linz, Austria|McMaster Children's Hospital, Hamilton, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada|McGill University Health Centre/Glen Site/Montreal Children's Hospital, Pierrefonds, Quebec, Canada|University Hospital Center Zagreb, Zagreb, Croatia|Zagazig University Hospital, Zagazig, Al Sharkeya, Egypt|Alexandria Clinical Research Center, Faculty of Medicine, Alexandria, Egypt|Kasr Elainy School of Medicine, Abo Elreesh Hospital (Japanese Hospital), Ali Basha Ibrahim ST Faculty of Medicine Cairo University, Cairo, Egypt|Ain Shams University Hospital, Cairo, Egypt|Suez Canal University Hospital, Ismailia, Egypt|Hôpital Des Enfants, Bâtiment Modulaire, Toulouse cedex 9, Haute Garonne, France|Pediatric and Congenital Cardiology and Pulmonology Department; Arnaud De Villeneuve University Hospital, Montpellier, Herault, France|Pediatric Cardiology Department, Hospital Necker Enfants Malades, APHP, Université Paris Descartes, Paris, Paris Cedex 15, France|Gottsegen Gyorgy Orszagos Kardiologiai Intezet, Budapest, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, Hungary|Nirmal Hospital Private Limited, Sūrat, Gujarat, India|Institute of Child Health, Mitra, Monjiri, Kolkata, India|Soroka University Medical Center, Be'er Sheva, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, Israel|Sheba Medical Center, Ramat Gan, Israel|Children's Heart Centre at the American University of Beirut Medical Center, Beirut, Lebanon|Hotel Dieu de France Hospital, Beirut, Lebanon|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Erciyes University Medical Faculty, Department of Children Hospital, Edirne, Kayseri, Turkey|Hacettepe University Medical Faculty, Ankara, Turkey|Istanbul University Istanbul Medical Faculty, Istanbul, Turkey|Ege University Faculty of Medicine Department of Child Health and Diseases, İzmir, Turkey|Izmir-Dr. Behçet Uz. Pediatric Diseases and Surgery Training and Research Hospital- Izmir Dr. Behcet Uz Cocuk Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi, İzmir, Turkey|Communal Institution Dnipropetrovsk Regional Pediatric Clinical Hospital of Dnipropetrovsk Regional Council, State Institution Dnipropetrovsk Medical Academy of MoH of Ukraine, Dnipro, Ukraine|Communal Healthcare Institution Regional Pediatric Clinical Hospital, Kharkiv National Medical University, Kharkiv, Ukraine|Vynnitsa Regional Children Clinical Hospital Policlinic Dept, Vinnytsia, Ukraine|Royal Brompton Hospital, London, Greater London, United Kingdom|Glenfield Hospital, Leicester, Leicestershire, United Kingdom|Ward 2B, Royal Hospital for Children, Glasgow, Strathclyde, United Kingdom",7365205,4,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,73.33210127518021,31.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.61,548.06,136.63,7.0,3.0,4.0,56.31,140.14,6.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,AORTIC VALVE STENOSIS,_EDOXABAN,NCT04171726,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erasmus MC, Rotterdam, Netherlands",7365205,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,6.0,73.33210127518021,31.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.61,548.06,136.63,7.0,3.0,4.0,56.31,140.14,6.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,ATRIAL FIBRILLATION AND FLUTTER,_EDOXABAN,NCT03488420,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Observational Model: Cohort|Time Perspective: Prospective,"Montreal Heart Institute, Montréal, Quebec, Canada",7365205,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,6.0,73.33210127518021,31.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.61,548.06,136.63,7.0,3.0,4.0,56.31,140.14,6.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,DEEP VEIN THROMBOSIS|VENOUS THROMBOEMBOLISM,_EDOXABAN,NCT02303431,Phase 1,Recruiting,All,"up to 18 Years   (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of California, Los Angeles (UCLA), Los Angeles, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|University of Colorado Denver, Denver, Colorado, United States|Nemours Childrens Clinic, Jacksonville, Florida, United States|Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States|University of Louisville ; Kosair Charities Pediatric Clincial Research Unit, Louisville, Kentucky, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Duke University Medical Center (DUMC), Durham, North Carolina, United States|University Hospitals Case Medical Center - Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Hasbro Children's Hospital, Providence, Rhode Island, United States|St. Jude Children's Research Hospital, Inc., Memphis, Tennessee, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|McMaster Children's Hospital, Hamilton, Ontario, Canada|Childrens Hospital of Eastern Ontario, Ottawa, Canada|Hopital Arnaud de Villeneuve, Montpellier, France|CHU Bordeaux - Hopital Haut-Leveque, Pessac, France|Nirmal Hospital Pvt. Ltd, Gujarat, India|Christian Medical College and Hospital, Punjab, India|Institute of Child Health, West Bengal, India|Istituto Giannina Gaslini - UOSD Emostasi e Trombosi, Genova, Italy|A O Universita degli Studi di Padova ; Dipartimento di Salute della Donna e del Bambino-Universita di Padova, Padova, Italy|Bambino Gesu Hospital, Rome, Italy|King Abdullah University Hospital, Irbid, Jordan|Hotel Dieu De France, Beirut, Lebanon|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Araba, Vitoria Gasteiz, Spain|Ege University Medical Faculty - Department of Pediatric Hematology, Izmir, Turkey|Leeds General Infirmary, Leeds, United Kingdom|Glenfield Hospital, Leicester, United Kingdom|Guy's and St Thomas Hospital NHS Trust, London, United Kingdom|Royal Brompton Hospital, London, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",7365205,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,73.33210127518021,31.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.61,548.06,136.63,7.0,3.0,4.0,56.31,140.14,6.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,SYSTOLIC HEART FAILURE,_RIFAXIMIN,NCT02637167,Phase 2,Recruiting,All,"18 Years to 74 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oslo University Hospital - Rikshospitalet, Oslo, Norway",6861053,6,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,66.6625598061561,159.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,4.94,785.8785,198.38,11.0,5.0,6.0,82.26,216.69,3.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],PULMONARY EMBOLISM,_FERUMOXYTOL,NCT03173066,Phase 1,Enrolling by invitation,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Brigham and Women's Hospital, Boston, Massachusetts, United States",6599498,B82Y5/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,ANEURYSMAL SUBARACHNOID HEMORRHAGE,_NICARDIPINE,NCT04269408,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Universitätsklinik Innsbruck, Universitätsklinik für Neurochirurgie, Innsbruck, Austria|Kepler Universitätsklinikum, Universitätsklinik für Neurochirurgie, Linz, Austria|Medizinische Universität Wien, Universitätsklinik für Neurochirurgie, Vienna, Austria|Charité Universitätsmedizin Berlin, Klinik für Neurochirurgie mit Arbeitsbereich pädiatrische Neurochirurgie, Berlin, Germany|Universitätsklinikum Göttingen, Neurochirurgische Klinik, Göttingen, Germany|Klinikum Rechts der Isar, Neurochirurgische Klinik und Poliklinik, Munich, Germany",5164405,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,9.0,24.871147251483606,1273.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.34,479.525,113.69,6.0,1.0,3.0,49.95,134.8,11.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,ACUTE STROKE,_ADENOSINE,NCT03720522,,Recruiting,All,"18 Years to 86 Years   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Bern University Hospital - Inselspital, Bern, BE, Switzerland",5731296,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,60.2887122938869,1415.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.2,267.2413,139.54,8.0,4.0,3.0,25.28,63.2,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,CORONARY ARTERY STENOSIS,_ADENOSINE,NCT04401657,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Asan Medical Center, Seoul, Korea, Republic of",5731296,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,60.2887122938869,1415.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.2,267.2413,139.54,8.0,4.0,3.0,25.28,63.2,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,PAROXYSMAL ATRIAL FIBRILLATION,_ADENOSINE,NCT01672346,Phase 3,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. david's Medical Center, Austin, Texas, United States|Texas Cardiac arrhythmia Institute, St. David's Hospital, Austin, Texas, United States",5731296,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,60.2887122938869,1415.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.2,267.2413,139.54,8.0,4.0,3.0,25.28,63.2,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21,RETINAL VEIN OCCLUSION|MACULAR EDEMA,_FLUORESCEIN,NCT04140448,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Renmin Hospital of Wuhan University, Wuhan, Hubei, China",10293047,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,18.135896014291802,9013.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.64,332.3063,75.99,3.0,2.0,5.0,33.14,91.22,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)O,REPERFUSION INJURY,_RIP,NCT03068689,Not Applicable,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University Hospital Basel, Clinic of Urology, Basel, Switzerland",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,PERIPHERAL ARTERY DISEASE,_ALPROSTADIL,NCT04197323,Phase 2,Recruiting,All,"40 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Xuanwu Hospital Capital Medical University, Beijing, Beijing, China",5886039,2,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,APHASIA|STROKE,_DONEPEZIL,NCT04134416,Phase 3,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Centro de Investigaciones Medico-Sanitarias. University of Malaga, Málaga, Spain",4895841,C07D405/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,19.1215425368077,230.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,379.49199999999996,38.77,4.0,0.0,4.0,44.34,112.11,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,CAROTID ARTERY STENOSIS,_TERAZOSIN,NCT03195673,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Beijing Anzhen Hospital, Beijing, Beijing, China|The Luhe Teaching Hospital of the Capital Medical University, Beijing, Beijing, China",5212176,C07D405/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,34.629047824390604,855.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.12,387.4329,103.04,8.0,1.0,4.0,41.26,105.18,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,ESSENTIAL HYPERTENSION,_FIMASARTAN,NCT03991442,Phase 3,Recruiting,All,"19 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Boryung Pharmaceutical Co., Ltd, Seoul, Korea, Republic of",EP-0991627-B1,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,12.0,50.2022628801412,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.09,501.65,90.37,5.0,1.0,4.0,54.86,161.24,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0
COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,HEART FAILURE WITH REDUCED EJECTION FRACTION,_OMECAMTIV_MECARBIL,NCT03759392,Phase 3,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alaska Heart and Vascular Institute, Anchorage, Alaska, United States|Arkansas Cardiology Clinic, Little Rock, Arkansas, United States|Harbor-UCLA Medical Center, Torrance, California, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Hartford Hospital-University of Connecticut School of Medicine, Hartford, Connecticut, United States|Holy Cross Hospital - Fort Lauderdale, Fort Lauderdale, Florida, United States|Broward Research Center - Pembroke Pines, Pembroke Pines, Florida, United States|Emory University, Atlanta, Georgia, United States|Community Hospital South, Inc., Indianapolis, Indiana, United States|Saint Vincent Medical Group Inc., Indianapolis, Indiana, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital (MGH) - Cardiac Unit Associates, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Heart & Vascular Institute, Detroit, Michigan, United States|McLaren Health Care Corporation, Petoskey, Michigan, United States|Michigan Heart, Ypsilanti, Michigan, United States|Glacier View Research Institute, Cardiology, Kalispell, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cardiovascular Associates Of The Delaware Valley (Cadv), P.A. - Elmer Physicians Care Center - Elmer, Elmer, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|NYU Langone Medical Center, New York, New York, United States|Queens Heart Institute, Rosedale, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Med Health and Hospital, Raleigh, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|St. John Clinical Research Institute, Tulsa, Oklahoma, United States|Oregon Health, Portland, Oregon, United States|Capital Area Research, LLC, Camp Hill, Pennsylvania, United States|Penn State Hershey Children's Hospital, Hershey, Pennsylvania, United States|Lancaster Heart And Stroke Foundation, Lancaster, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|University of Texas - Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott and White Heart and Vascular Hospital, Dallas, Texas, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Mcgill University Health Centre (MUHC)-The Montreal General Hospital (MGH), Montreal, Quebec, Canada|Centre Hospitalier De La Cote Basque, Bayonne cedex, France|Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France|Universite De Nantes - L'Institut Du Thorax, Nantes CEDEX 1, France|Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Lariboisiere, Paris, France|Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital Rangueil, Toulouse Cedex 9, France|Universitaetsklinik Heidelberg, Heidelberg, Baden-wurttemberg, Germany|Universitatsklinikum Magdeburg, Magdeburg, Saxony-Anhalt, Germany|Universitaetsklinikum Jena, Jena, Thueringen, Germany|Kerckhoff-Klinik- Bad Nauheim, Bad Nauheim, Germany|Praxisklinik Dresden, Dresden, Germany|Universitaetsklinikum Des Saarlandes Und Medizinische Fakultaet Der Universitaet Des Saarlandes, Homburg, Germany|Balatonfuredi Allami Szivkorhaz, Balatonfured, Hungary|Semmelweis University Heart and Vascular Center, Budapest, Hungary|Pecsi Tudomanyegyetem (PTE) Altalanos Orvostudomanyi Kar (AOK) (University of Pecs Medical School), Pecs, Hungary|Centro Cardiologico Monzino IRCCS, Milano, Lombardia, Italy|Azienda Ospedaliera S.Orsola Malpighi, Bologna, Province Of Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia, Brescia, Province Of Brescia, Italy|Erasmus MC - Universitair Medisch Centrum Rotterdam, Rotterdam, South Holland, Netherlands|Jeroen Bosch Ziekenhuis, 'S-Hertogenbosch, Netherlands|Onze Lieve Vrouwe Gasthuis (OLVG) Locatie West, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leids Universitair Medisch Centrum (LUMC), Leiden, Netherlands|Universitair Medisch Centrum Utrecht - Wilhelmina Kinderziekenhuis, Utrecht, Netherlands|Maxima Medisch Centrum Veldhoven, Veldhoven, Netherlands|Centrum Medyczne Medyk Sp z o.o. Sp. k., Rzeszow, Podkarpackie, Poland|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Oddzial Kliniczny Choroby Wiencowej i Niewydolnosci Serca z Pododdzialem Intensywnego Nadzoru Kardiologicznego, Krakow, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika, Oddzial Kardiologiczny, Lodz, Poland|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Enhet Klinisk forskning, hjartmedicin, Skanes Universitet Sjukhus, Lund, Sweden",US-20060014761-A1,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,61.0,45.2411753834781,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.05,401.44199999999995,86.8,4.0,2.0,3.0,40.95,109.19,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
O=N[O-],OUT-OF-HOSPITAL CARDIAC ARREST,_NITRITE,NCT03452917,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Harborview Medical Center, Seattle, Washington, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.17,46.0055,52.49,3.0,0.0,0.0,2.44,7.6,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=N[O-].[Na+],OUT-OF-HOSPITAL CARDIAC ARREST,_SODIUM_NITRITE,NCT03452917,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Harborview Medical Center, Seattle, Washington, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCCCC1OC(=O)c2ccccc21,CEREBRAL SMALL VESSEL DISEASE,_BUTYLPHTHALIDE,NCT04078204,Not Applicable,Recruiting,All,"50 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking Union Medical College Hospital, Beijing, China",WO-1995000157-A1,A61K36/23 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,22.0,32.7488,72.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,190.2384,26.3,1.0,0.0,2.0,21.29,54.78,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
CCCCC1OC(=O)c2ccccc21,VASCULAR DEMENTIA,_BUTYLPHTHALIDE,NCT03804229,Phase 3,Recruiting,All,"50 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China",WO-1995000157-A1,A61K36/23 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,22.0,32.7488,72.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,190.2384,26.3,1.0,0.0,2.0,21.29,54.78,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
CN1C(=O)c2c(nn(Cc3ccc(-c4cccc(F)n4)cc3)c2Nc2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12,"HEART FAILURE, SYSTOLIC",_ITI-214,NCT03387215,Phase 1|Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Johns Hopkins University, Baltimore, Maryland, United States|Duke Clinical Research Institute, Durham, North Carolina, United States",US-20120238589-A1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,19.0,27.2695537896055,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.04,507.57300000000004,78.65,6.0,1.0,7.0,54.23,154.78,5.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0
NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,RESISTANT HYPERTENSION,_APROCITENTAN,NCT03541174,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Advanced Cardiovascular, LLC, Alexander City, Alabama, United States|University of Alabama at Birmingham Vascular Biology and Hypertension Program, Birmingham, Alabama, United States|Chrishard Medical Group, Inglewood, California, United States|Clinical Trials Research, Lincoln, California, United States|Academic Medical Research Institute, Los Angeles, California, United States|Entertainment Medical Group, Inc., Los Angeles, California, United States|Amicis Research Center, Northridge, California, United States|Empire Clinical Research, Pomona, California, United States|North America Research Institute, San Dimas, California, United States|Orange County Research Center, Tustin, California, United States|Alfieri Cardiology, Wilmington, Delaware, United States|Bay Area Cardiology Associates, P.A., Brandon, Florida, United States|West Broward Research, Coral Springs, Florida, United States|Century Clinical Research, Inc, Daytona Beach, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Canvas Clinical Research, LLC, Lake Worth, Florida, United States|Southwest Florida Research, LLC., Naples, Florida, United States|East Coast Institute for Research, Saint Augustine, Florida, United States|Premier Medical Associates, The Villages, Florida, United States|Northwest Heart Clinical Research, LLC., Arlington Heights, Illinois, United States|SIU School of Medicine Center for Clinical Research, Springfield, Illinois, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Cardiovascular Research of Northwest Indiana, L.L.C., Munster, Indiana, United States|Reid Physician Associates, Richmond, Indiana, United States|Alexandria Cardiology Clinic, Alexandria, Louisiana, United States|Grace Research, LLC, Bossier City, Louisiana, United States|Horizon Research Group of Opelousas, LLC, Eunice, Louisiana, United States|DelRicht Research, Gretna, Louisiana, United States|Capital Nephrology, Greenbelt, Maryland, United States|MedStar Health Research Institute, Hyattsville, Maryland, United States|Washington Nephrology Associates, Takoma Park, Maryland, United States|St Clair Nephrology Research, Roseville, Michigan, United States|Clinical Research Consultants, LLC, Kansas City, Missouri, United States|Hypertension and Nephrology Association PA, Eatontown, New Jersey, United States|Renal Medicine Associates, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|Scott Research Inc, Laurelton, New York, United States|Great Lakes Medical Research LLC, Westfield, New York, United States|Metrolina Internal Medicine/Internal Medicine Research, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Physician's East Endocrinology, Greenville, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Sterling Research Group, Ltd, Cincinnati, Ohio, United States|Sentral Clinical Research Services, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center - Neurological Institute, Cleveland, Ohio, United States|Aventiv Research Inc., Columbus, Ohio, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Doylestown Health Cardiology, Doylestown, Pennsylvania, United States|Aventiv Research, Inc, Erie, Pennsylvania, United States|Allegheny Valley Hospital, Natrona Heights, Pennsylvania, United States|Drexel University Dept of Nephrology, Philadelphia, Pennsylvania, United States|TLM Medical Services LLC, Columbia, South Carolina, United States|DeGarmo Institute of Medical Research, Greer, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Stern Cardiovascular Foundation, Inc, Germantown, Tennessee, United States|The University of Tennessee, Memphis, Tennessee, United States|LifeDOC Research PLLC, Memphis, Tennessee, United States|Amarillo Heart Clinical Research Institute, Inc., Amarillo, Texas, United States|LinQ Research, LLC, Pearland, Texas, United States|San Antonio Kidney Disease Center, PLLC, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Mercury Clinical Research, Webster, Texas, United States|St. George Kidney Care, Saint George, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Salem Veterans Affairs Medical Center, Salem, Virginia, United States|Milwaukee Nephrologists, SC, Wauwatosa, Wisconsin, United States|Central Coast Local Health District, Gosford, New South Wales, Australia|Renal Research, Gosford, New South Wales, Australia|St. George Hospital, Dept. Renal Medicine, Kogarah, New South Wales, Australia|Western Sydney Local Health District, Westmead, New South Wales, Australia|Sunshine Coast University Private Hospital, Birtinya, Queensland, Australia|Core Research Group Pty Ltd, Milton, Queensland, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|CCRE Clinical Trial Centre, SPHPM, Monash University, Caulfield, Victoria, Australia|St Vincent's Hospital (Melbourne), Fitzroy, Victoria, Australia|Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia|Curtin University, Faculty of Health Sciences, School of Public Health, Bentley, Western Australia, Australia|Royal Perth Hospital Unit - The University of Western Australia, Perth, Western Australia, Australia|Grand Hôpital de Charleroi, Site St-Joseph, Gilly, Charleroi, Belgium|Hospital Erasme _Cardiology department, Brussels, Belgium|UZ Brussel, Brussels, Belgium|Clinique Universitaires de Saint Luc, Departement cardio-vasculaires intensives, Brussels, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier Universitaire du Sart-Tilman, Liège, Belgium|Clinical Research Solutions Inc., Kitchener, Ontario, Canada|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|Lakeridge Health, Oshawa, Ontario, Canada|The Ottawa Hospital, Renal Hypertension Program, Ottawa, Ontario, Canada|Manna Research (Stoney Creek), Stoney Creek, Ontario, Canada|Canadian Phase Onward Inc., Toronto, Ontario, Canada|Stephen S. Chow Medicine Professional Corporation, Toronto, Ontario, Canada|Jewish General Hospital - Cardiovascular Prevention Center, Montreal, Quebec, Canada|Hopital MaisonNeuve-Rosemont, Montréal, Quebec, Canada|Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada|The First Affiliated Hospital of Baotou Medical College of Inner Mongolia, Baotou, China|The Third Xiangya Hospital of Central South University, Changsha, China|Guangdong General Hospital, Guangzhou, China|Zhejiang Province People's Hospital, Hangzhou, China|Lanzhou University Second Hospital, Lanzhou, China|Hainan NO.3 Provincial people's Hospital, Sanya, China|Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|FN U Sv.Anny Brno, kardiologická klinika, Brno, Czechia|Krajska zdravotni, a.s. - Nemocnice Decin, o.z., Děčín, Czechia|Fakultní nemocnice Plzeň, Pilsen, Czechia|Všeobecní fakultní nemocnice Praha, Prague, Czechia|Nefromed s.r.o., Prague, Czechia|Fakultní nemocnice Královské Vinohrady, Praha 10, Czechia|Thomayerova nemocnice, Praha 4, Czechia|Kardio Václavík s.r.o, Přerov, Czechia|Aalborg University Hospital Cardiology, Aalborg, Denmark|Regional Hospital Holstebro Department of Medicine University Clinic in Nephrology and Hypertension at Holstebro, Holstebro, Denmark|University of Oulu, Medical Research Center, Oulu, Finland|TAYS RDI center (Tampere University Hospital,Specialist Internal Medicine, Rare Diseases), Tampere, Finland|Turku University Central Hospital - Turun yliopistollinen keskussairaala Sisätautien klinikka, Turku, Finland|Centre de Recherche Clinique, Bobigny, France|Hôpital Saint-André - Service de Cardiologie et Hypertension Artérielle, Bordeaux cedex, France|CHU Grenoble - Alpes, Grenoble cedex 9, France|Institut Cœur Poumon CHRU LILLE, Lille Cedex, France|Hôpital de la Croix-Rousse - Rhône, Lyon, France|GHRMSA - Hôpital Emile Muller, Mulhouse, France|Hôpital Européen Georges Pompidou- Centre d' Investigation Clinique, Paris, France|Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, Toulon, France|Medic Trials STUG, Berlin, Germany|Universitätsklinikum Düsseldorf Klinik für Nephrologie, Düsseldorf, Germany|Universitätsklinikum Erlangen Klinische Forschungsstation (CRC), Erlangen, Germany|University Medical Centre Goettingen - Universitätsmedizin Göttingen Klinik für Nephrologie und Rheumatologie, Göttingen, Germany|Clinical Trial Center North GmbH & Co. KG, Hamburg, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Germany|Herzzentrum der Uniklinik Köln, Köln, Germany|Herzzentrum Leipzig Universitätsklinik für Kardiologie, Leipzig, Germany|Sana Kliniken Lüebeck, Cardiology, Lübeck, Germany|Universitätsklinikum Nürnberg Süd, Nürnberg, Germany|Euroclinic Athens, Athens, Greece|General Hospital of Athens, Ippokrateio, Athens, Greece|National and Kapodistrian University of Athens, School of Medicine Third Department of Medicine, Sotiria Hospital, Athens, Greece|General Hospital of Athens Georgios Gennimatas, Athens, Greece|University Hospital of Heraklion, Heraklion, Greece|General Hospital Konstantopouleio -Patision, Nea Ionia, Greece|AHEPA University Hospital, Thessaloniki, Greece|Asklepeion General Hospital, Voula, Greece|Principal SMO Kft., Baja, Hungary|DRC Gyógyszervizsgáló Központ Kft., Balatonfüred, Hungary|Gottsegen György Országos Kardiológiai Intézet, Budapest, Hungary|Debreceni Egyetem - Klinikai Központ, Debrecen, Hungary|Pest Megyei Flór Ferenc Kórház, Kistarcsa, Hungary|Pécsi Tudományegyetem Klinikai Központ, Pécs, Hungary|University of Szeged, 1st Dept. of Medicine, Szeged, Hungary|Markusovszky Egyetemi Oktatókórház, Szombathely, Hungary|HaEmek M.C, Afula, Israel|Assuta Medical Center Ashdod, Ashdod, Israel|Cardiovascular Institute, Ashkelon, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Galilee Medical Center, Nahariya, Israel|Sheba Medical Center, Tel HaShomer, Israel|University Brescia Department Clinical and Experimental Science, Brescia, Italy|Division of Internal Medicine & Nephrology University of L'Aquila - San Salvatore Hospital V.le San Salvatore, L'Aquila, Italy|Ospedale San Gerardo, Clinica Medica, Monza, Italy|Azienda Ospedaliera S. Andrea di Roma - Division of Cardiology and of Cardiothoracic and Vascular Science Department -, Pisa, Italy|Azienda Ospedaliero Universitaria PisanA - Department Clinical and Experimental Medicine, Pisa, Italy|SCU Medicina Interna e Centro Ipertensione arteriosa. Dipartimento di Scienze Mediche Università di Torino, Aou Citta' Salute E Scienza Torino, Torino, Italy|Veterans Health Service Medical Center Division of Cardiology - Dep. of Internal Medicine, Seoul, Gangdong-gu, Korea, Republic of|Gangnueng Asan Hospital University of Ulsan College of Medicine, Seoul, Gangwon-do, Korea, Republic of|Yonsei University Wonju Severance Christian Hospital Division of Cardiology - Dept. of Internal Medicine, Wonju, Ganwon-do, Korea, Republic of|Seoul National University Hospital Division of Cardiology, Department of Internal Medicine, Seoul, Korea, Republic of|Kaunas Clinical Hospital, Kaunas, Lithuania|JSC ""InMedica"", Kaunas, Lithuania|Clinic of Cardiology and Rehabilitation, Klaipeda, Lithuania|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|Academic Medical Center Amsterdam, Amsterdam, Netherlands|Zuyderland Medical Center, Geleen, Netherlands|Maastricht University Medical Center, Dept. of Medicine, Maastricht, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Haga Ziekenhuizen-Internal Medicine, The Hague, Netherlands|Klinika Nadciśnienia Tętniczego i Diabetologii, Gdańsk, Poland|Mazowieckie Centrum Badań Klinicznych, Grodzisk-Mazowiecki, Poland|Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mielęckiego Śląskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland|Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w, Kraków, Poland|Diamond Clinic, Kraków, Poland|Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1w Lublinie, Lublin, Poland|KO-MED. CentraKliniczne Sp. Z o.o. Ośrodek Badań Klinicznych w Lublinie II, Lublin, Poland|ETG Lublin, Lublin, Poland|Etyka Ośrodek Badań Klinicznych, Olsztyn, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|KO-MED. Centra Kliniczne Sp. Z o.o. Ośrodek Badań Klinicznych w Puławach, Puławy, Poland|ETG Skierniewice, Skierniewice, Poland|Medycyna Kliniczna, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Warszawa, Poland|ETG Warszawa, Warszawa, Poland|Instytut Kardiologii im. Prymasa Tysiąclecia Stefana Kardynała Wyszyńskiego, Warszawa, Poland|Samodzielny Publiczny Szpital Wojewódzki im. Papieża Jana Pawła II w Zamościu, Zamość, Poland|ETG Zgierz, Zgierz, Poland|State Budgetary Healthcare Institution of Arkhangelsk Region ""First City Clinical Hospital n.a. E.E. Volosevich"", Arkhangelsk, Russian Federation|Municipal Autonomous Healthcare Institution City Clinical Hospital #6, Gastroenterology Department, Chelyabinsk, Russian Federation|Federal State Autonomous Institution of Higher Education ""Kazan (Volga Region) Federal University"", Kazan, Russian Federation|Federal State Budget Scientific Institution ""Scientific Research Institute for Complex Issues of Cardiovascular Diseases"", Kemerovo, Russian Federation|Scientific Research Institute - Regional Clinical Hospital №1, Krasnodar, Russian Federation|Regional State Budget Healthcare Institution ""Krasnoyarsk Interdistrict Clinical Hospital for Emergency Medical Care n.a. N.S Karpovich"", Nephrology Department, Krasnoyarsk, Russian Federation|Regional Budget Healthcare Institution ""Kursk City Clinical Hospital for Emergency Medical Care"" of Healthcare Committee of Kursk Region/Therapeutic, Kursk, Russian Federation|National Medical Research Center for Preventive Medicine, Moscow, Russian Federation|SBHI of Moscow ""City clinical hospital #52"" of Moscow healthcare department / city nephrology center, Moscow, Russian Federation|State budget healthcare institution of Novosibirsk region ""City clinical hospital #34"", Novosibirsk, Russian Federation|Federal State Budget Scientific Institution ""Federal Research Center Institute of Cytology and Genetics of Siberian Department of Russian Academy of Sciences"", Novosibirsk, Russian Federation|International Medical Center ""SOGAZ"", LLC, Saint Petersburg, Russian Federation|Federal State Military Educational Institution of Higher Professional Education, Military Medical Academy named for S. M. Kirov of the Ministry of Defense of the Russian Federation, Saint Petersburg, Russian Federation|State Healthcare Institution ""Regional Clinical Cardiology Dispensary"", Saratov, Russian Federation|Federal State Budget Educational Institution of Higher Education ""Saratov State Medical University n.a. V.I. Razumovskiy"" of the Ministry of Healthcare of the Russian Federation, Saratov, Russian Federation|State Budgetary Educational Institution of Higher Professional Education Smolensk State Medical Academy, Smolensk, Russian Federation|Federal State Budget Institution ""National Medical Research Center n.a. V.A. Almazov"" of the Ministry of healthcare of the Russian Federation, St. Petersburg, Russian Federation|Federal State Budget Scientific Institution ""Tomsk National Research Medical Center of the Russian Academy of Sciences"", Tomsk, Russian Federation|Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen, Russian Federation|Hospital Universitari Germans Trias i Pujol de Badalona, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Fundació Puigvert, Barcelona, Spain|Hospital Vall d'Hebron de Barcelona, Barcelona, Spain|Hipertensión Clinic, Internal Medicine, Hospital Clinico, University of Barcelona, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Virgen de las Nieves - Internal Medicine Department, Granada, Spain|Hospital Clinico San Carlos - Istituto de Investigacion Sanitaria San Carlos (IdISSC), Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Virgen del Rocio Departamento de Medicina Interna, Sevilla, Spain|Hospital Clínic Universitari de València, Valencia, Spain|Hypertension Clinic, Internal Medicine, Hospital Clinico, University of Valencia, Valencia, Valencia, Spain|Municipal non-profit enterprise ""Clinical hospital of emergency medicine"" of the Dniрro city council, Dnipro, Ukraine|State Institution ""L.T. Malaya Therapy National Institute of the NAMS of Ukraine"", Kharkiv, Ukraine|Municipal non-profit enterprise ""Clinical Hospital # 8""of Kharkiv City Council, Kharkiv, Ukraine|Kyiv City Clinical Hospital # 1, Kyiv, Ukraine|Kyiv Municipal Clinical Emergency Hospital, Kyiv, Ukraine|State Institution ""National Scientific Center ""M.D. Strazhesko Institute of Cardiology"" of the National Academy of Medical Sciences of Ukraine"", Kyiv, Ukraine|State Institution ""D.F. Chebotarev Institute of Gerontology, National Academy of Medical Science of Ukraine"", Kyiv, Ukraine|State Institution ""Institute of Gerontology named after D.F. Chebotarev of National Academy of Medical Sciences of Ukraine"", Kyiv, Ukraine|Municipal Enterprise ""Lutsk City Clinical Hospital"", Volyn Regional Center for Cardiovascular Pathology, Lutsk, Ukraine|Municipal Noncommercial Enterprise ""Lviv City Clinical Hospital #5"", Lviv, Ukraine|Communal Non-profit Enterprise ""Vinnytsya regional Clinical Hospital named after. N.I. Pirogov Vinnytsia Regional Council""/ National Pirogov Memorial Medical University, Vinnytsya, Vinnytsya, Ukraine|Municipal non-profit enterprise ""Regional Clinical Hospital named after AF Gerbachevsky"" of Zhytomyr Regional Council, Zhytomyr, Ukraine|James Paget University Hospitals Foundation Trust, Great Yarmouth, Norfolk, United Kingdom|Aberdeen Royal Infirmary, Clinical Pharmacology Unit, Aberdeen, United Kingdom|Clinical Research Centre The University of Edinburgh Centre for Cardiovascul, Edinburgh, United Kingdom|Glasgow Clinical Research Facility (CRF), Glasgow, United Kingdom|University Hospitals of Leicester NHS Trust Dept of Chemical Pathology and Metabolic Diseases, Leicester, United Kingdom|Altnagelvin Area Hospital, Londonderry, United Kingdom|Queen Mary University of London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.85,546.19,142.21,9.0,2.0,3.0,44.36,112.81,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
O=[Se]([O-])[O-].[Na+].[Na+],HEART DISEASE,_SODIUM_SELENITE,NCT02002247,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hamilton General Hospital, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Institut de cardiologie de Montreal, Montreal, Quebec, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Sacre Coeur, Montreal, Quebec, Canada|IUCPQ, Quebec City, Quebec, Canada|Centre de recherche CIUSSS de l'Estrie CHUS, Sherbrooke, Quebec, Canada|RWTH Aachen University Hospital, Aachen, Germany|Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin Universitätsklinikum Bonn, Bonn, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Klinik für Her- und Gefäßchirurgie Universitäts-Herzzentrum Freiburg, Freiburg, Germany|Klinik für Herz-, Kinderherz- und Gefäßchirurgie UKGM Giessen, Gießen, Germany|University Medical Center Schleswig-Holstein, Kiel, Germany|Klinik und Poliklinik für Herz- und Thoraxchirurgie Uniklinik Köln, Koln, Germany|Klinik für Anästhesiologie Universitätsmedizin Mainz, Mainz, Germany|Klinik für Anästhesiologie Klinikum der Universität München, München, Germany|Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie Universitätsmedizin Münster, Zentralklinikum, Münster, Germany|Klinikum Oldenburg gGmbH Universitätsklinik für Anästhesiologie / Intensivmedizin / Notfallmedizin / Schmerztherapie, Oldenburg, Germany|Klinik und Poliklinik für Anästhesiologie und Intensivtherapie Universitätsmedizin Rostock, Rostock, Germany",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0
CCCCCCCC(=O)OC[C@H](NC(=O)CNC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)O,PERIPHERAL ARTERY DISEASE,_GHRELIN,NCT04377126,Phase 2,Recruiting,All,"55 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0
CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O,ACUTE STROKE,_TIROFIBAN,NCT04491695,Phase 2|Phase 3,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China|Beijing Luhe Hospital, Capital Medical University, Beijing, Beijing, China|The first Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|Hunan Provincial People's Hospital, Changsha, Hunan, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|The Third People's Hospital of Hubei Province, Wuhan, Jinan, China|Shandong Provincial Hospital, Jinan, Shandong, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Beichen Hospital of Traditional Chinese Medicine, Tianjin, Tianjin, China|TEDA Hospital, Tianjin, Tianjin, China|The General Hospital of Tianjin Medical University, Tianjin, Tianjin, China",5658929,C07C311/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,24.969711903735103,371.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.78,440.597,104.73,6.0,3.0,2.0,49.27,117.48,13.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(/C=C/C=C(\C)C(=O)O)=C\C=C\C=C(C)\C=C\C=C(/C)C(=O)O,"STROKE, ACUTE",_CROCETIN,NCT03763929,Phase 2,Recruiting,All,"40 Years to 85 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, Los Angeles, Los Angeles, California, United States|University of Virginia, Charlottesville, Virginia, United States",3965261,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,5.0,13.799051315222002,98.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,4.54,328.408,74.6,4.0,2.0,0.0,38.07,103.8,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,COVID-19,_DAPAGLIFLOZIN,NCT04350593,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Heart Group of the Eastern Shore, Fairhope, Alabama, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Loyola University, Maywood, Illinois, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Jacobi Medical Center, Bronx, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Sentara Healthcare, Norfolk, Virginia, United States|Centro de Pesquisa Dr. Marco Mota, Maceió, Alagoas, Brazil|Hospital Cárdio Pulmonar, Salvador, Bahia, Brazil|Hospital de Messejana dr Carlos Alberto Studart Gomes, Fortaleza, Ceará, Brazil|Hospital Coração do Brasil, Brasília, Distrito Federal, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, Espírito Santo, Brazil|Santa Casa de Misericórdia de Passos, Passos, Minas Gerais, Brazil|PROCAPE, Recife, Pernambuco, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, Rio Grande Do Sul, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Centro de Pesquisa Clínica do Coração, Aracaju, Sergipe, Brazil|Faculdade de Medicina de Botucatu, UNESP, Botucatu, São Paulo, Brazil|Instituto de Pesquisa Clínica de Campinas, Campinas, São Paulo, Brazil|Centro Integrado de Pesquisas, São José do Rio Preto, São Paulo, Brazil|Fundação Pio XII, Barretos, Brazil|Hospital Moriah, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil",6956026,A61K47/12,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
CCCCC(CC)CCC(CC(C)C)OS(=O)(=O)[O-].[Na+],VENOUS INSUFFICIENCY,_SODIUM_TETRADECYL_SULFATE,NCT03311269,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The Vascular Experts, Darien, Connecticut, United States|Capitol Vein and Laser Centers, Frederick, Maryland, United States|Southeastern Surgical Associates, Hyannis, Massachusetts, United States|Englegwood Hospital and Medical Center, Englewood, New Jersey, United States|Lake Washington Vascular, PLLC, Bellevue, Washington, United States",4701223,A61K8/042,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,20.0,17.7416374052855,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.97,316.43,66.43,3.0,0.0,0.0,33.26,76.65,11.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
